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Abstract 
Increasing evidence supports the existence of intratumour heterogeneity in many solid 
and haematological tumour types, with potential clinical implications for both cancer 
diagnosis and treatment. Multi-region whole-exome sequencing of surgically resected 
non-small cell lung cancer (NSCLC) tumours demonstrated intratumour spatial and 
temporal heterogeneity in the mutational burden, copy number aberrations, and 
mutational signatures identified in these tumours. Furthermore, heterogeneity of 
mutations, including driver mutations, was also demonstrated in pre-invasive lung 
adenocarcinoma in situ lesions, suggesting that clonal evolution may be a feature of 
the early stages of cancer development. Whilst deciphering the clonal landscape of 
tumours may rely on multi-region and repeated tissue sampling, this remains 
challenging outside the context of clinical studies, and is not routine clinical practice. A 
non-invasive alternative may be the use of circulating biomarkers, such as circulating 
cell-free tumour DNA (cfDNA). Truncal and branch mutations were identified in cfDNA 
from patients with early stage NSCLC using different approaches. The detection of low 
frequency branch mutations, which are predicted to be subclonal in origin and may be 
potentially involved in the emergence of therapeutic resistance and tumour progression, 
were difficult to identify in cfDNA. Further studies are required to develop effective 
strategies for clonal and subclonal mutation detection in cfDNA, and to determine the 
utility of such biomarkers in representing the tumour genomic landscape, and in 
tracking tumour evolution in time.  
 
Chromosomal instability (CIN), describes an increased rate of numerical and structural 
chromosome aberrations, and is a known driver of intercellular genetic tumour 
heterogeneity. CIN has been shown to be associated with drug resistance and poor 
clinical outcome in several cancer types. However, in oestrogen receptor (ER)-negative 
breast cancer it has previously been shown that extreme CIN is associated with 
improved clinical outcome, consistent with a negative impact of CIN on cellular fitness 
and growth. This paradoxical relationship was further validated in a large breast cancer 
cohort study, in which extreme CIN was associated with improved outcome in patients 
with ER-negative cancer (p trend = 0.03). A similar relationship was seen in ER-
negative/human epidermal growth factor receptor (HER2)-negative cancers (p trend = 
0.007). Identifying such patients may help distinguish good from poor prognostic 
groups, and therefore support treatment and risk stratification. 
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We are yet to uncover the true extent of intratumour heterogeneity and CIN in different 
cancer types, their relevance to clinical outcome, and how we may be able to 
overcome or exploit these features for the therapeutic gain and benefit of patients with 
cancer. Longitudinal studies employing serial tissue and circulating biomarker sampling 
have the potential to address these questions, and to truly define the breadth of genetic 
diversity in different tumour types and its relevance to patient outcome.    
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1 Introduction 
The existence of distinct subpopulations of cancer cells within a tumour harbouring 
different behavioural phenotypes, including tumourigenicity, ability to metastasise and 
to develop resistance to treatment, has been recognised for many years (Heppner & 
Miller 1983). Recent advances in massively parallel sequencing technologies have 
enabled the analysis of the clonal architecture of both primary and metastatic tumours 
(Russnes et al. 2011). These genomic studies have demonstrated the complex and 
heterogeneous landscape in cancer (Lawrence et al. 2014; Lawrence et al. 2013), and 
its potential implications for treatment response and prognosis (Lawrence et al. 2013; 
Kandoth et al. 2014; Alexandrov, Nik-Zainal, Wedge, Aparicio, et al. 2013). Using 
whole-genome sequencing (WGS) or whole-exome sequencing (WES), these studies 
have demonstrated that tumours consist of somatic events, defined by mutations and 
copy number alterations, which can occur early in tumour evolution (events present in 
all cancer cells), or can occur later in tumour evolution (events present in some, but not 
all cancer cells) (Swanton 2014). In addition, these studies have shown spatial 
heterogeneity, branched evolution and mutational patterns that can vary over time (Nik-
Zainal et al. 2012; de Bruin et al. 2014), as well as in response to cancer therapies 
(Walter et al. 2012; Boeckx et al. 2014; Diaz et al. 2012). Chromosomal instability 
(CIN), which describes an increased rate of change in chromosome number and 
structure, is also a potential mechanism generating intratumour heterogeneity 
(Gisselsson et al. 2000; McGranahan et al. 2012). CIN can create significant cell-to-cell 
heterogeneity, such that chromosomally unstable tumours may promote tumour 
evolution under selection pressures, such as chemotherapy, resulting in drug 
resistance and poor prognosis (Duesberg et al. 2000; Lee et al. 2011; McGranahan et 
al. 2012; McClelland et al. 2009; Swanton et al. 2009). Given the existence of such 
heterogeneity in tumours, the efficacy of therapies targeting somatic driver events, 
even in combination, may be limited in terms of achieving disease cure.  
 
1.1 Intratumour heterogeneity in cancer 
Intratumour heterogeneity, describes the existence of distinct cellular populations with 
specific phenotypic features within tumours and has long been recognised (Bloom & 
Richardson 1957; Heppner & Miller 1983). This has been described in several adult 
solid tumours, including lung (de Bruin et al. 2014; Zhang et al. 2014), breast (Nik-
Zainal et al. 2012; Shah et al. 2012; Navin et al. 2012; Yates et al. 2015), ovarian 
Chapter 1 Introduction 
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(Bashashati et al. 2013; R. F. Schwarz et al. 2015; Tone et al. 2014), pancreatic 
(Campbell et al. 2010; Yachida et al. 2010), kidney (Gerlinger et al. 2012; Gerlinger et 
al. 2014), colorectal (Thirlwell et al. 2010; Sottoriva et al. 2015), brain (Snuderl et al. 
2011; Sottoriva et al. 2013; Suzuki et al. 2015; A. Kumar et al. 2014), thyroid (Le 
Pennec et al. 2015), oropharyngeal (Zhang et al. 2013), phaeochromocytoma (Flynn et 
al. 2015), and prostate cancers (Carreira et al. 2014; Haffner et al. 2013; Cooper et al. 
2015), as well as hematological malignancies, such as chronic lymphoblastic leukemia 
(CLL) (Landau et al. 2013; Ojha et al. 2015), and acute lymphoblastic leukemia 
(Anderson et al. 2011). Other types of genetic heterogeneity have also been described 
in cancer biology. The most well known is inter-patient tumour heterogeneity, whereby 
no two patients with the same subtype of tumour behave the same clinically, with or 
without treatment. This may be related to host factors, such as tumour 
microenvironment, germ line mutations influencing treatment response, and the unique 
somatic mutations that can occur within the tumour of each individual patient 
(Vogelstein et al. 2013). Metastatic lesions at different secondary sites can arise from 
different cellular populations within a primary tumour, resulting in heterogeneity among 
metastases, known as intermetastatic heterogeneity (Vogelstein et al. 2013). In 
addition, since metastatic lesions can acquire new mutations and evolve independently 
with each cell division, heterogeneity within a metastasis can also exist, known as 
intrametastatic heterogeneity (Vogelstein et al. 2013) (Figure 1 A-D).  
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Figure 1 Types of intratumour heterogeneity 
Reproduced from (Jamal-Hanjani, Quezada, et al. 2015). Inter-patient heterogeneity: the 
presence of unique subclones in the tumour of each patient (A), intratumour heterogeneity: the 
presence of multiple subclones within a primary tumour resulting in heterogeneity among 
tumour cells (B), intermetastatic heterogeneity: the presence of different subclones in different 
metastatic lesions of the same patient; some subclones may have been derived from the 
primary tumour and some may have emerged as a result of acquired alterations within each 
metastatic lesion (C), and intrametastatic heterogeneity: the presence of multiple subclones 
within a single metastatic lesion (D). 
 
Patient 1 Patient 2
Brain
Liver
Intermetastatic heterogeneity
Interpatient tumor heterogeneity
Intrametastatic heterogeneity
A B
C D
Intratumor heterogeneity
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1.2 Intratumour heterogeneity and clonal evolution 
Phenotypic heterogeneity observed in tumours results from both genetic and non-
genetic causes. Spontaneous tumours can arise through Darwinian-like clonal 
evolution involving the acquisition of ‘driver’ events, such as genetic mutations or copy 
number aberrations, which are believed to affect cancer cell proliferation or survival, 
along with ‘passenger’ events, which are assumed to be phenotypically silent and 
without a selective fitness advantage (Abramyuk et al. 2010). Non-genetic causes of 
heterogeneity include epigenetic changes (Dick 2008), differentiation hierarchies as a 
result of cancer stem cells (Shipitsin et al. 2007), stochastic biochemical processes 
within individual cells and heterogeneous tumour microenvironments (Marusyk et al. 
2012). Processes of genetic diversification promote tumour progression through clonal 
evolution so that tumours appear to be composed of evolved cell populations 
(McGranahan & Swanton 2015). The linear model of somatic tumour evolution is that 
of clonal succession, where a series of clonal expansions are triggered by the 
acquisition of driver events conferring fitness gain, outcompeting and outgrowing other 
clones (Nowell 1976). This model implies that tumours are homogenous for functionally 
significant mutations, and whilst some tumours are found to evolve through linear steps 
(Anderson et al. 2011), there is also increasing evidence for the existence of 
genetically distinct clonal subpopulations with substantial genetic divergence coexisting 
within different regions of the same primary tumour, between primary and secondary 
tumours, and within metastases (Navin et al. 2010).  
 
1.3 Intratumour heterogeneity and cancer progression 
Intratumour heterogeneity is not simply a tumour characteristic, it may also have the 
potential to forecast risk of tumour progression and therapeutic outcome (Swanton 
2012). Using WES and copy number analysis to identify clonal and subclonal driver 
mutations, Landau and colleagues found that the presence of a subclonal driver was 
an independent risk factor for disease progression (Landau et al. 2013). Patients 
treated with cytotoxic chemotherapy were more likely to undergo clonal evolution, such 
that the extent of heterogeneity evolved during treatment. Using whole-genome 
genotyping single-nucleotide polymorphism (SNP) array analysis, Mengelbier and 
colleagues demonstrated intratumour diversity in a cohort of seven chemotherapy-
treated childhood cancers, including nephroblastoma, neuroblastoma and rhabdoid 
tumours (Mengelbier et al. 2015). By analyzing metastatic samples, they found that this 
Chapter 1 Introduction 
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diversity provided a substrate for further clonal evolution in the metastases. In a larger 
cohort of 44 patients with pre-operatively treated nephroblastoma, they found that 
intratumour diversity was more prevalent in high risk histological subtypes, and high 
stage disease. Furthermore, it was an independent predictor for poor cancer-specific 
survival (Mengelbier et al. 2015). Studies like these indicate the likely relevance of 
tumour heterogeneity in predicting adverse outcomes, and the evolution of tumour 
subclonal composition during treatment. It may not always be the case that the 
dominant clone dictates tumour growth and malignant potential. Using a mouse 
xenograft model, Marusyk and colleagues demonstrated that subclones, without a 
known fitness advantage, could drive tumour growth in a non-cell-autonomous manner 
by inducing tumour-promoting changes in the microenvironment (Marusyk et al. 2014). 
Furthermore, non-cell-autonomous subclones could be outcompeted by other 
subclones with greater proliferative potential resulting in tumour collapse. Observations 
where minority subclones influence progression of the tumour mass suggest 
challenges for predictive and prognostic biomarker discovery efforts, that have 
traditionally focused on identifying genomic alterations in the dominant clone. The 
mechanisms, by which subclonal alterations can impact tumour biology and phenotype, 
are yet to be determined and will require further functional genomic studies. Such 
studies will need to investigate the interactions, both synergistic and antagonistic, 
between subclones during tumour evolution. In addition, these studies should 
specifically assess how these relationships may promote or impede cancer progression, 
and contribute to therapeutic failure and drug resistance (Kleppe & Levine 2014). 
Heterogeneity in the tumour microenvironment may also influence the evolution and 
progression of tumours. Interactions between tumour and stromal cells, changes in the 
level of hypoxia or acidity, increased or decreased inflammatory cell infiltrate, and 
remodeling of the extracellular matrix may act as selection pressures and lead to 
increased phenotypic heterogeneity, potentially influencing treatment response, and 
therefore tumour evolution (Marusyk et al. 2012). 
 
1.4 Intratumour heterogeneity and biomarker detection 
Intratumour heterogeneity for both genetic and phenotypic biomarkers has been shown 
in several tumour types. This can complicate the detection of clinical biomarkers, such 
as those predictive of therapeutic response, due to sampling bias (Yap et al. 2012). 
Heterogeneous amplification of the HER2 (human epidermal growth factor receptor 2) 
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gene in primary tumours has been shown in breast (Davila & Amazon 2010; Seol et al. 
2012), mucinous ovarian (Anglesio et al. 2013), and oesophageal (Yoon et al. 2012) 
cancers. In primary gastric cancers, heterogeneous HER2 amplification and HER2 
expression has been shown within the same tumour, and between diagnostic biopsies 
and resected tumours (Yang et al. 2012). Glioblastomas (GBMs) have been shown to 
have mosaic patterns of EGFR (epidermal growth factor receptor) and PDGFRA 
(platelet-derived growth factor receptor, alpha polypeptide) amplification (Snuderl et al. 
2011; Szerlip et al. 2012). In these tumours therapeutic response to single agent 
inhibitor therapy can be poor and may be associated with the heterogeneous 
amplification of such genes (Paulsson et al. 2011; Hegi et al. 2011; Stommel et al. 
2007). In another GBM study, Sottoriva and colleagues demonstrated extensive 
intratumour heterogeneity at the copy number level, including heterogeneous copy 
number aberrations involving putative drivers of disease such as PDGFRA, MDM4 
(Mdm2-Like P53-Binding Protein) and AKT3 (v-akt murine thymoma viral oncogene 
homolog 3) amplification, and PTEN (phosphatase and tensin homolog) deletion 
(Sottoriva et al. 2013).  
 
Significant biomarker discordance between primary and metastatic tumours in the 
same patient has been demonstrated in several tumour types, presumed to be the 
result of independent tumour growth associated with different phenotypes (Stoecklein 
& Klein 2010; Goswami et al. 2015). In breast cancer, discordance between single 
biopsies taken from primary and metastatic tumours has been shown for HER2 
expression (Niikura et al. 2012), HER2 amplification (Gancberg et al. 2002; Cottu et al. 
2008), and oestrogen receptor (ER), progesterone receptor (PR) and HER2 status 
(Lindström et al. 2012). In colorectal cancer, mutational concordance in the genes 
KRAS (Kirsten rat sarcoma viral oncogene homolog), NRAS (neuroblastoma RAS viral 
(v-ras) oncogene homolog), BRAF (v-raf murine sarcoma viral oncogene homolog B), 
PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha), and 
TP53 (tumor protein p53) has been demonstrated using single biopsies from primary 
and metastatic tumours (Vakiani et al. 2012). However, in patients with a history of 
more than one primary tumour who had received treatment, there was evidence for 
discordance in TP53. In a similar colorectal cancer study, a concordance rate of 78% 
was found for known recurrent mutations between primary and metastatic tumours 
(Vignot et al. 2015). In a study by Baldus and colleagues, by comparing two biopsies 
taken from the same primary tumour, a discordance rate of 8%, 5%, and 1% was 
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identified in activating mutations for KRAS, BRAF, and PIK3CA, respectively (Baldus et 
al. 2010). Mutational discordance was also identified between primary tumours and 
lymph node metastases in 31% (KRAS), 4% (BRAF), and 13% (PIK3CA) of cases. In 
non-small cell lung cancer (NSCLC), discordance for the EGFR mutation has also 
been demonstrated between primary and metastatic tumours (Gomez-Roca et al. 
2009; Kalikaki et al. 2008). These studies demonstrate the sampling bias associated 
with single tumour biopsies, and the potential difficulties in identifying therapeutically 
relevant lesions (Yap et al. 2012). Furthermore, distinct subclonal populations appear 
to be unequally distributed over space and time, indicating that existing biomarkers are 
subject to change during disease progression (Greaves & Maley 2012). This may pose 
a challenge for therapeutic strategies if treatment allocation is based only on an 
archival primary tumour biopsy. 
 
1.5 Intratumour heterogeneity, therapeutic resistance and 
alternative approaches 
Heterogeneous tumours are composed of multiple subclones, some of which may be 
either intrinsically resistant to certain therapeutic interventions, or may acquire 
resistance under selection pressures, such as chemotherapy. Such selection 
processes allow these subclones to dominate a tumour mass and potentially drive 
disease progression (Misale et al. 2012; Engelman & Settleman 2008) (Figure 2). The 
selection of resistant subclonal populations, as a result of therapy leading to treatment 
resistance, has been shown in several solid tumour types including lung (Kosaka et al. 
2006; Turke et al. 2010), colorectal (Diaz et al. 2012), gastrointestinal (Liegl et al. 
2008) and brain (B. E. Johnson et al. 2014), as well as haematological cancers, such 
as chronic myeloid leukemia (Shah et al. 2002). In patients with EGFR-mutant NSCLC, 
the presence of the gatekeeper T790M resistance mutation pre-treatment has been 
associated with acquired resistance to the tyrosine kinase inhibitor (TKI) gefitinib as a 
result of the positive selection of cells harbouring the resistance mutation (Kosaka et al. 
2006). The presence of subclones with MET (met proto-oncogene) amplification pre-
treatment has also been associated with subsequent EGFR TKI resistance (Turke et 
al. 2010). In addition, a shorter progression-free survival has been demonstrated in 
patients with low frequency T790M mutant subclones before the onset of treatment (Su 
et al. 2012). In colorectal cancer, wild-type KRAS predicts sensitivity to anti-EGFR 
antibody therapies such as panitumumab. Diaz and colleagues showed that by 
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monitoring circulating tumour DNA in patients treated with panitumumab for initially 
KRAS wild-type tumours, the emergence of mutations in KRAS could be detected 
during the course of therapy resulting in acquired resistance (Diaz et al. 2012). They 
concluded that subclonal populations harbouring KRAS mutations existed pre-
treatment, and that under the selection pressure of anti-EGFR therapy, resistant 
subclones can rapidly expand and repopulate the tumour. In chronic myeloid 
leukaemia and gastrointestinal tumours, resistance to imatinib due to mutations in the 
BCR-ABL (breakpoint cluster region-c-abl oncogene 1) fusion protein (Shah et al. 
2002) and KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) 
(Liegl et al. 2008), respectively, has also been demonstrated in the context of clonal 
evolution. It should be noted that not all cases of therapeutic resistance arise from 
genetic heterogeneity; non-genetic causes, such as stochastic epigenetic 
heterogeneity, may also play a role in the emergence of resistant clones under 
selection pressures (Jänne et al. 2009). These examples demonstrate that relapsed 
clones in metastatic tumours can often be traced back to pre-treatment low frequency 
subclones, suggesting that the extent of intratumour heterogeneity is a likely important 
determinant of therapeutic outcome. In addition, the presence of different subclones in 
the primary tumour lends itself to the development of multiple mechanisms of 
resistance in the same patient under selection pressures, such as targeted therapy in 
EGFR-mutant NSCLC (Sequist et al. 2011), anaplastic lymphoma receptor tyrosine 
kinase (ALK)-rearranged NSCLC (Katayama et al. 2012) or BRAF-mutant melanoma 
(Romano et al. 2013).  
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Figure 2 Intratumour heterogeneity and cancer progression 
Adapted from (Jamal-Hanjani, Quezada, et al. 2015). Primary tumours consisting of different 
subclones may be subjected to various selection pressures, including chemotherapy and 
microenvironmental factors such as hypoxia, infiltrating stromal, and immune cells. Under the 
influence of such selection pressures, subclones with intrinsic resistance (green subclone) can 
outgrow a tumour mass, potentially leading to disease progression, and/or subclones can 
acquire somatic alterations (purple subclone), promoting cell survival, proliferation, and 
metastatic tumour formation. The outgrowth of some subclones (red subclone) may be 
constrained by selection pressures that they are sensitive to, for example, targeted therapy 
against a tumour subclone with a somatic alteration sensitive to therapy. Tumour infiltrating 
lymphocytes (TILs) may recognise neo-antigens presented on the surface of tumour cells as 
non-self, promoting enhanced T-cell activation and immune cell tumour infiltration. 
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Alternative therapeutic strategies may have the potential to overcome the challenges 
posed by clonal heterogeneity. Gillies and colleagues (Gillies et al. 2012) argue that 
subclonal populations that respond to initial therapy pass through an evolutionary 
bottleneck rendering them highly susceptible to a second therapy (Gerlinger & 
Swanton 2010), and that drug resistance in this instance, and the choice of a 
subsequent second therapy, could be anticipated. For example, combined therapy in 
EGFR-mutant NSCLC with an EGFR TKI and EGFR-specific antibody could prevent 
resistance associated with the expansion of a subclone harbouring a T790M mutation 
(Yelena et al. 2014). Approaches like this would require the development of biomarkers 
predicting likely resistance mechanisms in different patients, and such mechanisms 
could be targeted either in combination, or alternating, with standard treatment 
regimens (Komarova & Wodarz 2005). Treatment dosing schedules could also be 
adapted to prolong the suppression of resistant subpopulations, for example, drug 
holidays in androgen-dependent prostate cancer (Abrahamsson 2010) and melanoma 
(Thakur et al. 2013). Other adaptive approaches could involve combining standard 
treatment regimens with drugs targeting phenotypes known to contribute to tumour 
heterogeneity, such as altered tumour vasculature or altered glucose metabolism 
(Gillies et al. 2012).  
 
Gatenby and colleagues have proposed the concept of adaptive therapy, whereby 
cancer treatment is continuously adjusted in order to maintain a fixed population of 
drug-sensitive cells, which can in turn suppress the growth of drug-resistant cells, 
allowing overall tumour burden to remain stable (Gatenby et al. 2009). Knowledge of 
the existence of low-frequency resistant subclones at diagnosis may indicate the use of 
combined therapeutic regimens targeting mechanisms of resistance. Evidence for 
phenotypic convergence within and across tumour types, suggests that genetic events 
driving resistance and disease progression may focus on either one or several 
signaling pathways that may be therapeutically targetable (Swanton 2014; Gerlinger et 
al. 2012; Gerlinger et al. 2014; Bolli et al. 2014; B. E. Johnson et al. 2014). In addition, 
parallel evolution of subclones during tumour progression suggests that there exist 
constraints to tumour growth, which may be potentially exploitable. By predicting the 
likely next step in the evolution of a tumour, preventative measures could be taken to 
potentially delay the onset of cancer progression (Swanton 2014). Such tactics will 
require a good evidence base from genomic studies in different tumour types involving 
longitudinal tissue sampling, and therapeutic trial designs will need to take into account 
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alternative approaches, such as adaptive therapy. The ultimate aim would be to 
develop predictive tools or evolutionary ‘rule books’ of tumour progression, so that 
tumour-specific treatment strategies can be initiated in advance of significant disease 
progression.
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1.6 Evidence for intratumour heterogeneity in NSCLC 
1.6.1 Spatial heterogeneity and branched evolution in NSCLC 
Previous efforts to characterise the cancer genome in NSCLC have involved the 
analysis of copy number alterations (Weir et al. 2007; Tanaka et al. 2007), targeted 
sequencing of candidate cancer genes (Ding et al. 2008; Kan et al. 2010) and next-
generation sequencing (NGS) of genomes and/or exomes (Liu et al. 2012; Lee et al. 
2010; Govindan et al. 2012; Imielinski et al. 2012). By interrogating the mutational 
spectrum of tumours, these studies have demonstrated the complex and 
heterogeneous genomic landscape from point mutations to large structural variants, 
and the high mutational burden of smoking-related NSCLC. However, few studies in 
NSCLC have investigated the clonal and subclonal architecture of lung cancer tumours, 
and their evolution through disease progression. Furthermore, whilst it is known that 
different mutational processes, with specific mutation signatures, can contribute to the 
mutational burden in lung cancer, such as smoking (Pfeifer & Hainaut 2003; Lee et al. 
2010; Pleasance et al. 2010) and the upregulation of APOBEC (apolipoprotein B 
mRNA editing enzyme, catalytic polypeptide-like) cytidine deaminases (Burns et al. 
2013; Roberts et al. 2013; Alexandrov, Nik-Zainal, Wedge, Aparicio, et al. 2013), the 
temporal heterogeneity of such processes, and their potential contribution to the 
different stages of tumour evolution is unknown.  
 
Recent work from our laboratory has demonstrated extensive intratumour 
heterogeneity in NSCLC, in terms of mutations and copy number alterations (de Bruin 
et al. 2014).  By sequencing multiple regions sampled from resected primary NSCLC 
tumours, branched tumour evolution and intratumour heterogeneity in potential NSCLC 
driver mutations was demonstrated in a cohort of 7 NSCLC current or ex-smoker 
patients (5 adenoncarcinoma, 1 adeno-squamous cell carcinoma, and 1 squamous cell 
carcinoma). Mutational signatures were also investigated. Smoking-related mutations 
were found to decrease in late tumour evolution in all patients, accompanied by an 
increase in APOBEC-associated mutations in patients with lung adenocarcinoma. 
Intratumour heterogeneity in translocations, copy number alterations, and mutations 
associated with APOBEC cytidine deaminase activity was also demonstrated.  
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1.6.2 The lung TRACERx study 
Each patient’s cancer has a unique genomic landscape, comprised of populations of 
genetically distinct separated subclones, with the potential to undergo dynamic 
evolutionary processes throughout the disease course (Landau et al. 2013; Stratton et 
al. 2009). One of the major challenges in achieving the goal of precision medicine 
relies on obtaining an accurate view of this genomic landscape, in order to choose the 
appropriate therapeutic regimen (Yates & Campbell 2012). Intratumour heterogeneity 
poses a challenge in that a single tumour biopsy may not fully capture the current or 
future landscape of a tumour, and merely represents a ‘snapshot’ of the disease in 
space and time. Understanding how tumour clonal heterogeneity impacts upon clinical 
outcome, and how cancer subclones compete, adapt and evolve throughout the 
disease course and in relation to therapy, is an area of unmet clinical and scientific 
need. Lung TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a 
prospective multi-centre study in the United Kingdom aiming to recruit 842 patients with 
primary NSCLC, across stages I-IIIA over an accrual period of 4 years with a total 5-
year follow-up per patient. Surgically resected primary NSCLC tumours and associated 
lymph nodes, surplus to diagnostic requirements, will be subjected to multi-region 
sampling and subsequent WES and/or WGS. In patients who develop recurrent 
disease, consent is obtained for a further biopsy, to assess how the tumour clonal 
structure has changed in response to therapy and after disease progression. The 
objectives of the TRACERx study are outlined below: 
 
Primary objectives 
• To determine the relationship between intratumour heterogeneity and clinical 
outcome, in terms of disease-free survival (DFS) and overall survival (OS) 
• To determine the impact of adjuvant platinum-containing chemotherapy 
regimens on intratumour heterogeneity in relapsed disease 
 
Secondary objectives 
• To develop and validate an index of intratumour heterogeneity, which may be a 
predictive and/or prognostic biomarker in terms of DFS and OS 
• To identify potential drivers of disease progression and drug resistance by 
tracking the tumour clonal dynamics throughout the disease course  
• To define clonally dominant drivers of disease and to determine their role in 
targeted therapeutic response 
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• To determine the extent to which circulating biomarkers, such as circulating free 
DNA (cfDNA) and circulating tumour cells (CTCs), can represent the underlying 
mutational landscape of the primary and/or metastatic tumour 
• To determine if cfDNA and CTCs can be used to track actionable mutations to 
guide therapeutic intervention, monitor residual disease and predict tumour 
recurrence 
• To define the impact of intratumour heterogeneity on the tumour neo-antigen 
repertoire 
• To determine the impact of distinct drivers of intratumour heterogeneity on 
tumour immune cell infiltration and function throughout the disease course 
• To determine the correlation between measures of heterogeneity using clinical 
imaging and sequencing data. 
 
I wrote and developed the protocol for this study under the guidance of my supervisor 
during the production of this thesis, with the input of the TRACERx consortium and the 
support of the UCL Cancer Trials Centre (Alan Hackshaw, Yentig Ngai, and Natasha 
Iles). This study started recruitment in April 2014, and is currently open in London, 
Manchester, Leicester, Birmingham, Aberdeen, and Cardiff.  
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1.7 Circulating biomarkers in cancer  
Increasing disease burden and tumour size in patients with cancer is associated with 
increased cellular turnover and number of apoptotic and necrotic cells (Jahr et al. 2001; 
Stroun et al. 2001). Within a tumour mass, the process of phagocytic clearance of such 
cells is not as efficient as it is under normal physiological conditions, resulting in the 
accumulation of cellular debris, including tumour cells and tumour DNA, which can be 
released into the circulation. These circulating tumour cells and DNA may act as 
potential circulating biomarkers with predictive and prognostic value in cancer. Serial 
tumour sampling to track cancer progression, and to identify new targetable drivers of 
disease is practically challenging, and is currently not part of standard clinical practice. 
An alternative approach may be the use of circulating biomarkers, such as circulating 
cell-free tumour DNA (cfDNA) or circulating tumour cells (CTCs), which can be 
analysed in the peripheral blood of patients with cancer. Such sampling may offer a 
relatively simple and non-invasive method for the analysis of primary and metastatic 
tumours (Pantel et al. 2013), allowing the detection of therapeutic biomarkers to guide 
treatment stratification, the monitoring of residual disease, and detection of the 
emergence of molecular resistance (Diaz & Bardelli 2014).  
 
1.7.1 Methods of detection in cfDNA 
The detection of cfDNA derived from tumours has been challenging for several reasons, 
including the accurate quantification of mutant DNA fragments in a sample, 
distinguishing tumour cfDNA from normal circulating DNA, and identifying low levels of 
cfDNA in a sample. Standard sequencing technologies, such as Sanger sequencing 
(Jänne et al. 2006) or pyrosequencing (Ogino et al. 2005), rely on high levels of cfDNA, 
and are therefore able to accurately detect mutations in the tumour cfDNA of patients 
with significant disease burden. Advanced techniques, such as digital polymerase 
chain reaction (PCR) (Vogelstein & Kinzler 1999; Dawson et al. 2013; Yung et al. 
2009), targeted NGS (Forshew et al. 2012) or WGS (Chan et al. 2013; Leary et al. 
2012; Heitzer, Ulz, et al. 2013), pyrophosphorolysis-activated polymerisation (PAP) 
(Liu & Sommer 2000), beads, emulsion, amplification, and magnetics (BEAMing) 
(Dressman et al. 2003; Li et al. 2006; Diehl et al. 2008), mass spectrometry genotyping 
assay-mutant-enriched PCR (Brevet et al. 2011), and tagged-amplicon deep 
sequencing (TAm-Seq) (Forshew et al. 2012; Murtaza et al. 2014), have enabled the 
detection of mutations in cfDNA. In addition, the combination of PCR-based digital 
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approaches with NGS, has enabled the detection of rare mutations (Forshew et al. 
2012; Kinde et al. 2011; Leary et al. 2010; Taly et al. 2013). Aside from single point 
mutations, amplifications, rearrangements, and aneuploidy have also been shown to 
be detected in cfDNA (Leary et al. 2012; Dawson et al. 2013; Murtaza et al. 2014; 
Schütz et al. 2015). Several studies have demonstrated the detection of genetic 
aberrations in the cfDNA of patients with cancer (Table 1). 
 
 
Tumour type Stage Number of patients 
Tumour-
specific 
aberration 
Technique Reference 
Colorectal 
cancer 
Early to 
advanced 33 APC BEAMing 
(Diehl et al. 
2005) 
 Advanced 18 
APC, KRAS, 
PIK3CA, TP53 BEAMing 
(Diehl et al. 
2008) 
 
Early to 
advanced 104 
APC, KRAS, 
TP53 PCR-SSCP 
(J.Y. Wang 
et al. 2004) 
 
Early to 
advanced 70 KRAS ME-PCR 
(Frattini et 
al. 2008) 
Breast cancer Early to advanced 72 PIK3CA 
ARMS-
Scorpion 
PCR 
(Board et 
al. 2010) 
 
Early to 
advanced 
34 
(retrospective) 
and 51 
(prospective) 
PIK3CA BEAMing (Higgins et al. 2012) 
 Advanced 30 
PIK3CA, TP53, 
structural 
variation 
TAm-Seq and 
digital PCR 
(Dawson et 
al. 2013) 
Ovarian cancer Advanced 38 
TP53, PTEN, 
EGFR, BRAF, 
KRAS 
TAm-Seq 
Digital PCR 
(Forshew et 
al. 2012) 
 
Early to 
advanced 63 PIK3CA 
Fluorescent- 
PCR 
(Kuhlmann 
et al. 2012) 
Hepatocellular 
carcinoma Early 4 SNV WGS 
(Chan et al. 
2013) 
Pancreatic 
cancer 
Early to 
advanced 21 KRAS MASA PCR 
(Yamada et 
al. 1998) 
 
Early to 
advanced 44 KRAS RFLP-PCR 
(Castells et 
al. 1999) 
Oral squamous-
cell carcinoma 
Early to 
advanced 64 
Microsatellite 
loci PCR 
(Hamana et 
al. 2005) 
 
Early to 
advanced 20 
Microsatellite 
loci PCR 
(Kakimoto 
et al. 2008) 
NSCLC Advanced 246 KRAS ARMS-qPCR (Nygaard et al. 2013) 
Breast and 
osteosarcoma Advanced 3 
Genomic 
alterations 
Nested-real 
time PCR 
(McBride et 
al. 2010) 
Colorectal and 
breast cancer Advanced 10 
Chromosomal 
alterations WGS 
(Leary et al. 
2012) 
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Table 1 Detection of genetic aberrations in cfDNA 
Adapted from (Crowley et al. 2013). Studies in which genetic aberrations have been detected in 
the cfDNA using different techniques. Abbreviations: ARMS, amplification refractory mutation 
system; BEAMing, beads, emulsion, amplification, magnetics; MASA, mutant allele specific 
amplification; ME-PCR, mutant enriched PCR; PCR-SSCP, single-strand conformation 
polymorphism PCR; qPCR, quantitative PCR; RFLP-PCR, restriction fragment length 
polymorphism PCR; SNV, single nucleotide variants; WGS, and whole-genome sequencing.  
 
1.7.2 Insight into intratumour heterogeneity and clonal evolution using 
circulating biomarkers 
Several studies have demonstrated that genetic aberrations present in tumours can be 
detected in cfDNA, and that these can be used to track tumour evolution, as well as the 
mutational burden, in patients over time (Murtaza et al. 2014; Diehl et al. 2008; Diehl et 
al. 2005; Dawson et al. 2013; Diaz et al. 2012; Carreira et al. 2014; Siravegna et al. 
2015). Murtaza and colleagues performed serial sampling and exome-sequencing of 
plasma in six patients with advanced-stage breast, ovarian and lung cancer, during 
several lines of therapy (Murtaza et al. 2014). By quantifying the mutation allele 
frequencies in the plasma, they were able to correlate emerging therapeutic resistance 
with increased representation of mutant alleles. These included a T790M mutation 
following gefitinib therapy, a truncating mutation in MED1 (mediator complex subunit 1) 
following tamoxifen and trastuzumab therapy, and a truncating mutation in RB1 
(retinoblastoma 1) following cisplatin chemotherapy. Bettegowda and colleagues 
detected cfDNA in a cohort of 640 patients covering a broad spectrum of both early- 
and late-stage cancers (Bettegowda et al. 2014; Diaz et al. 2012). Forty-seven percent 
of patients with stage I cancers of any type had detectable levels of cfDNA, supporting 
the potential use of cfDNA in the early detection of cancer. In a subset of patients with 
colorectal cancer, who subsequently relapsed after receiving anti-EGFR antibody 
therapy, they detected the emergence of several mutations in genes involved in the 
MAPK (mitogen-activated protein kinase) pathway, and therefore potential 
mechanisms of resistance. Diehl and colleagues used cfDNA to track changes in the 
plasma of colorectal cancer patients on therapy (Diehl et al. 2008). Fluctuations in 
cfDNA after surgery corresponded with the extent of surgical resection, and in patients 
with detectable post-operative tumour-derived cfDNA, the likelihood of relapse within 1 
year was increased. Compared with the standard biomarker CEA (carcinoembryonic 
antigen), cfDNA was found to be more reliable as a predictor of tumor burden and 
outcome. Similarly, Dawson and colleagues showed that cfDNA was a more reliable 
indicator of tumour burden compared with the standard biomarker CA 15-3 (carcinoma 
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antigen 15-3) in patients with breast cancer (Dawson et al. 2013). Siravegna and 
colleagues used cfDNA to genotype tumours and track clonal evolution in a cohort of 
100 colorectal cancer patients whilst on treatment with the anti-EGFR antibodies 
cetuximab and panitumumab (Siravegna et al. 2015). In patients with primary or 
acquired resistance to therapy, they showed an emergence and rise in KRAS-mutant 
clones. Upon treatment withdrawal, the number of KRAS-mutant clones declined, with 
an associated increase in drug sensitivity. This study eloquently demonstrated the 
dynamic nature of tumours under a treatment selection pressure, and how tumours 
adapt in response to intermittent drug dosing providing an explanation for the efficacy 
of targeted drug re-challenges in different tumour types (Hata, Katakami, Fujita, et al. 
2013; Hata, Katakami, Kaji, et al. 2013; Seghers et al. 2012; Thakur et al. 2013), and a 
rationale for adaptive therapy strategies.  
 
Concordance between the molecular landscape in the plasma and tumour has been 
previously shown. In a study by Rothé and colleagues, matched primary and 
metastatic tumours and cfDNA, were analysed using a targeted gene panel in a cohort 
of 17 breast cancer patients (Rothe et al. 2014). In 76% (13/17) cases, mutations found 
in cfDNA were concordant with those found in the tumour. In the study by Siravegna 
and colleagues discussed above, matched tumour and cfDNA samples were analysed 
for the mutational status of KRAS, BRAF and NRAS using droplet digital PCR 
(Siravegna et al. 2015). In 97/100 (97%) cases, the mutational status in the plasma 
was concordant with the tumour. Interestingly, in 8/100 (8%) cases there were 
mutations identified in the plasma that were not found in the tumour, suggesting that 
the plasma may be a more comprehensive representation of the molecular landscape 
of a heterogeneous tumour compared with a single tumour biopsy (Siravegna et al. 
2015).  
 
Similar to the studies in cfDNA, CTCs have also been used to study mutations and 
somatic copy number aberrations (SCNAs), and have been shown to correlate with 
clinical outcome (Antonarakis et al. 2014; Ni et al. 2013; Heitzer, Auer, et al. 2013; 
Hodgkinson et al. 2014; Lohr et al. 2014). In a large prospective study by Rack and 
colleagues, CTC enumeration in breast cancer patients was found to be an 
independent prognostic marker for disease-free survival (DFS) and overall survival 
(OS) (Rack et al. 2014). The worst prognosis was seen in patients with at least 5 CTCs 
per 30ml blood sample, and the presence of CTCs after chemotherapy was associated 
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with a poorer DFS and OS. One of the advantages of studying CTCs is that NGS can 
be used to study heterogeneity in driver events with single-cell resolution. This has 
been shown for EGFR expression and KRAS/PIK3CA mutation status in colorectal 
cancer patients (Gasch et al. 2013), and for ROS1 translocations in NSCLC patients 
(Pailler et al. 2015). Another advantage is the ability to study CTCs in the context of 
patient-derived mouse models. In a study by Hodgkinson and colleagues, CTCs were 
found to be tumourigenic in immune-compromised mice (Hodgkinson et al. 2014).  
CTCs derived from patients with small-cell lung cancer were implanted into mice 
resulting in CTC-derived explants (CDXs) (Hodgkinson et al. 2014). The genomic 
profiles of CTCs derived from patients and CDXs showed considerable similarity. 
Interestingly, CDXs reflected the donor patient’s response to platinum and etoposide 
chemotherapy, suggesting that such mouse models could be used for therapy testing, 
and therefore potentially increase our understanding of potential resistance 
mechanisms.  
 
In summary, the analysis of circulating biomarkers in blood samples obtained before 
and after therapy, and at points of disease progression, can provide a dynamic picture 
of the genomic landscape of each patient’s tumour (Diaz & Bardelli 2014). Tracking this 
landscape at serial time points can improve our understanding of tumour evolution in 
response to therapy, and shed light on the mechanisms of acquired resistance at the 
molecular level.  
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1.8 Chromosomal instability in cancer 
Chromosomal instability (CIN) is characterised by an increased rate of gain or loss of 
whole or fractions of chromosomes, and is a known driver of intercellular and 
intratumour heterogeneity (Gisselsson et al. 2000; McGranahan et al. 2012). It 
represents genomic instability at the karyotypic level, and the aberrant chromosomal 
characteristics that result from CIN include aneuploidy (an abnormal chromosomal 
number) and gross chromosomal rearrangements, which are hallmarks of solid 
tumours. CIN can be classified into structural and/or numeral CIN (Figure 3). Structural 
CIN, such as duplications, deletions and gene amplifications, may be precipitated by 
telomeric dysfunction (Stewénius et al. 2005; Perera et al. 2008; Bailey & Murnane 
2006) or DNA replication stress (Stewénius et al. 2005; Gisselsson et al. 2001; Burrell 
et al. 2013; Dereli-Öz et al. 2011). Numerical CIN, a gain or loss of whole 
chromosomes, may be precipitated by defects in the mitotic checkpoint (Grabsch et al. 
2003; Wang et al. 2002), the attachment of chromosomes to the mitotic spindle 
(Gregan et al. 2011), centromere amplification (Ganem et al. 2009), aberrant sister 
chromatid cohesion (Barber et al. 2008; Meyer et al. 2009; Zhang et al. 2008) and 
cytokinetic failure (Gisselsson et al. 2010). Increasingly it is recognised that structural 
CIN can precipitate numerical CIN and vice versa (Janssen et al. 2011; Crasta et al. 
2012). Figure 4 demonstrates the mitotic mechanisms of CIN. 
 
 
Figure 3 Numerical and structural CIN 
Reproduced from (McGranahan et al. 2012). Schematic showing whole chromosome gains and 
losses (numerical CIN) and sub-chromosomal gains, losses, inversions and translocations 
(structural CIN).  
Numerical CIN
Structural CIN
Chapter 1 Introduction 
 33 
 
 
Figure 4 Mitotic mechanisms of CIN 
Reproduced from (A'Hern et al. 2013). Normal cell division resulting in identical daughter cells 
(A), pre-mitotic defects resulting in acentric chromosomes and anaphase bridges (B), defects in 
mitotic checkpoint signaling (C), defects in sister chromatid cohesion (D), centrosome 
amplification resulting in a multipolar mitotic spindle (E), and abnormal attachment of 
chromosomes to the mitotic spindle resulting in merotelic attachments, which can involve 
cytokinesis-induced DNA damage to give rise to micronuclei (F). 
 
1.8.1 Measuring CIN in tumour samples 
Although aneuploidy is not always associated with the dynamic process of CIN, its 
measurement in tumour samples is the most reliable method in identifying likely 
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chromosomally unstable tumours. Determining the CIN status of a tumour has proven 
challenging given that karyotypic heterogeneity varies during the different stages of 
cancer progression (Roschke & Kirsch 2010), from one tumour region to another and, 
possibly, within different regions of the same tumour (Bergers et al. 1996; Gerlinger et 
al. 2012). Techniques employed to measure both the presence and the extent of CIN 
rely on determining cell-to-cell numeric chromosomal variability, such as fluorescence 
in situ hybridisation (FISH) using centromere-specific probes ((Roylance et al. 2011; 
Lingle et al. 2002; Farabegoli et al. 2001). Previous studies have demonstrated that 
using centromeric FISH for two chromosomes is sufficient enough to segregate diploid 
from aneuploid tumours (Fiegl et al. 2000; Takami et al. 2001), allowing the 
differentiation between unstable aneuploidy or CIN (aneuploid tumours with high clonal 
heterogeneity) and stable aneuploidy (aneuploid tumours with low clonal 
heterogeneity) (Lingle et al. 2002).  Although these measurements are reasonable 
indicators of CIN, they are time consuming, labour intensive, and cannot measure the 
rate of change of ongoing chromosomal numerical and structural alterations (Geigl et al. 
2008). A relationship between CIN and aberrations in the regulators of mitosis has also 
been shown before (Cahill et al. 1998; Wang et al. 2004; Sen et al. 1997; Diaz-
Rodríguez et al. 2008; Yuan et al. 2006). Work within our laboratory has previously 
shown a significant association between direct centromeric CIN and the protein 
expression of the mitotic regulators AURKA (Aurora Kinase A) and SURVIVIN in breast 
cancer (Roylance et al. 2014). Such markers may also be of use as a proxy for CIN in 
breast cancer samples in the absence of more advanced molecular measurements. 
Alternative cell population-based methods involve the quantification of DNA content 
using DNA image and flow cytometry (Darzynkiewicz et al. 2010; Kronenwett et al. 
2006; Habermann et al. 2009). Other techniques involve the assessment of combined 
populations of cells rather than individual cells, such as the measurement of CIN-
associated gene expression signatures and copy number based scores (Habermann et 
al. 2009; Birkbak et al. 2011), which have been shown to correlate well with direct 
measures of CIN (Birkbak et al. 2011), and to be of prognostic value (Carter et al. 
2006; Birkbak et al. 2011; Mettu et al. 2010; Chin et al. 2007; Smid et al. 2010).  
 
1.8.2 CIN and response to taxane therapy 
Microtubule-stabilising drugs, such as taxanes, initiate prolonged activation of the 
spindle assembly checkpoint, mitotic arrest and, in sensitive cells, promote cell death in 
mitosis or death preceded by multi-nucleation (Weaver & Cleveland 2005). Dominant 
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negative mutations or RNA interference of genes that regulate mitosis (such as BUBR1, 
BUB1, TTK/ MPS1, MAD2 and AURKB can augment the formation of aneuploid cells, 
compromise apoptotic death or promote mitotic exit in the presence of mitotic inhibitors 
such as paclitaxel (Cahill et al. 1998; Sudo et al. 2004; Anand et al. 2003; Nakayama 
et al. 2009; Inaba et al. 2005; Swanton et al. 2006; Swanton et al. 2007). These 
observations are consistent with taxane resistance observed in vivo in colorectal 
cancer, a tumour type in which CIN is highly prevalent, and in which taxanes have 
failed to demonstrate therapeutic benefit (Swanton et al. 2006). Work within our 
laboratory has previously shown in a cohort of 44 patients with ovarian cancer, that 
chromosomally unstable tumours (defined by their expression of the CIN70 signature, 
which reflects tumour aneuploidy status) (Carter et al. 2006) are relatively resistant to 
paclitaxel in vivo compared with tumours with lower expression of the CIN70 signature 
(Swanton et al. 2009). Furthermore, dysregulation of mitotic regulators, which results in 
aneuploidy and taxane resistance in vitro (Swanton et al. 2007) can predict failure to 
achieve a pathological complete response to paclitaxel combination chemotherapy in 
patients with breast cancer (Juul et al. 2010). These data indicate overlap between 
pathways involved in the maintenance of chromosomal stability and taxane sensitivity. 
Conversely, the molecular pathways that mediate tolerance of CIN might also result in 
relative taxane resistance (McClelland et al. 2009; Bouchet et al. 2007).  
 
Several potential biomarkers have been reported to predict clinical response to taxane-
based therapies, which are known to improve survival in women with both primary 
(Nowak et al. 2004) and metastatic (Ghersi et al. 2005) breast cancer. For example, 
the over expression or amplification of HER2 has been reported to predict sensitivity to 
taxane therapy (Konecny et al. 2004; Hayes et al. 2007), as has antigen Ki-67 
expression in ER-positive breast cancers (Penault-Llorca et al. 2009). Paradiso and 
colleagues have shown that class III β-tubulin might be a predictive biomarker for 
taxane resistance (Paradiso et al. 2005). Other biomarkers, such as p53 and 
angiogenic-related markers, such as VEGF (vascular endothelial growth factor), have 
also been suggested, but the results have been inconsistent (Van Poznak et al. 2002; 
Khan & Wahl 1998; Lissoni et al. 2000; Grant et al. 2003). Predicting drug sensitivity 
can be challenging due to the polygenic nature of drug-resistance mechanisms, which 
although may be the result of multiple genetic and epigenetic aberrations, can still be 
perceived as a convergent phenotype (Burrell & Swanton 2014). For example, taxane 
resistance can be mediated in vitro by alterations in the expression of a number of 
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distinct genes, many of which have roles in transition through mitosis. A unifying 
mechanism of taxane sensitivity and resistance may help identify additional patient 
cohorts who will benefit from taxane-based therapies, and tumour CIN status might 
represent one such unifying predictor of taxane benefit. 
 
1.8.3 CIN and clinical outcome in cancer 
CIN has been shown to be associated with poor prognosis in several solid tumours, 
including lung (H. Nakamura et al. 2003; Carter et al. 2006; Choi et al. 2009; Mettu et 
al. 2010), breast (Kronenwett et al. 2004; Takami et al. 2001; Habermann et al. 2009; 
Smid et al. 2010), colorectal (Mettu et al. 2010; Walther et al. 2008), ovarian (Mettu et 
al. 2010), endometrial (Murayama-Hosokawa et al. 2010), endocrine pancreatic 
tumours (Jonkers et al. 2005), as well as diffuse large B-cell lymphoma (Bakhoum et al. 
2011). This association may be a consequence of increased intratumour heterogeneity 
and cellular diversity allowing tumours to adapt to various microenvironmental selection 
pressures, such as chemotherapy (Gerlinger & Swanton 2010; Cahill et al. 1999), 
leading to drug resistance (Swanton et al. 2009; Duesberg et al. 2000; Li et al. 2005), 
and therefore disease progression (Takami et al. 2001; Jonkers et al. 2005). In keeping 
with this hypothesis, in vitro models have shown that CIN-positive cell lines develop 
multi-drug resistance at a higher rate compared with chromosomally stable cell lines 
(Duesberg et al. 2000), and in vivo models have suggested that CIN can promote early 
tumour relapse (Sotillo et al. 2010). Work within our laboratory has also shown that 
CIN-positive cell lines are intrinsically multi-drug resistant compared with 
chromosomally stable cell lines in colorectal cancer (Lee et al. 2011). In addition, 
chromosomally unstable tumours may also provide a substrate for the selection of copy 
number aberrations involving chromosomal segments containing genes associated 
with tumour proliferation, conferring a selective advantage, and therefore increased 
cellular fitness for tumour progression (Endesfelder et al. 2014). However, evidence is 
emerging that CIN may also have a negative impact on tumour fitness and growth. In 
yeast and mouse experimental studies, aneuploidy has been shown to result in 
decreased proliferation and cellular fitness (Torres et al. 2007; Williams et al. 2008). 
This may be related to the continuous gross numerical and structural chromosomal 
changes seen in CIN tumours resulting in the accumulation of deleterious genomic 
events affecting cancer cell survival (Loeb 2001). It therefore follows that a threshold of 
CIN may exist, such that up to a certain level of instability, tumour growth, adaptation 
and progression may be enhanced, but that beyond this level cancer cell survival may 
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be disadvantageous for tumour growth (Gerlinger & Swanton 2010; Komarova & 
Wodarz 2004). We have previously applied the CIN70 expression signature (Carter et 
al. 2006) to the gene expression profile of 265 patients with ER-negative breast cancer, 
and demonstrated that tumours with extreme CIN (upper quartile of CIN70 expression) 
were associated with improved prognosis relative to the other three quartiles (Birkbak 
et al. 2011). This paradoxical relationship between increasing CIN and improved 
prognosis was also seen in gastric, ovarian and non-small cell lung cancers (Birkbak et 
al. 2011). We further validated these findings in a small discovery cohort study of 246 
patients with primary breast cancer using dual centromeric FISH as a surrogate 
measurement of CIN (Roylance et al. 2011). Whilst increasing CIN in ER-positive 
breast cancer was associated with worsening prognosis, in patients with ER-negative 
breast cancer, extreme CIN was paradoxically associated with improved prognosis.  
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1.9 Conclusion 
This thesis explores the prevalence of intratumour heterogeneity in NSCLC using multi-
region sequencing validation. It builds on previous data from our laboratory (de Bruin et 
al. 2014) using a much larger patient cohort representing both adenocarcinoma and 
squamous cell carcinoma histological subtypes, different tobacco smoke exposure 
histories, metastatic tumours and with clinical outcome follow-up data. Sequencing 
data were used to construct phylogenetic trees mapping the evolutionary history of 
each tumour. Spatial and temporal heterogeneity was seen in both mutations and copy 
number aberrations, such that branched evolution occurred in each tumour, with the 
presence of both early and late predicted drivers of disease. In a subset of NSCLC 
patients, cfDNA was analysed using three different approaches involving mass 
spectrometry, and a combination of multiplex PCR with NGS, to determine the extent 
to which cfDNA could represent the underlying genomic landscape of each tumour. A 
combination of multiplex PCR and NGS was the most promising method. Finally, 
having previously shown in our laboratory that extreme levels of CIN are associated 
with improved prognosis in ER-negative breast cancers (Roylance et al. 2011), this 
finding was further validated using direct centromeric FISH in a large prospective 
validation cohort of breast cancer patients (Jamal-Hanjani, A'Hern, et al. 2015).
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2 Materials and Methods 
2.1 Patient selection 
2.1.1 NSCLC pilot cohort 
Patients with NSCLC primary tumours eligible for curative surgical resection were 
identified by screening the surgical theatre lists for operations performed at the Heart 
Hospital, University College London Hospitals (UCLH) NHS Foundation Trust. These 
tumour samples were collected as part of the UCL/UCLH Biobank for Studying Health 
and Disease (UCLHRTB 10/H1306/42), and all study procedures were performed in 
accordance with Good Clinical Practice and national clinical research guidelines. This 
cohort consisted of eleven patients from whom follow-up data was also collected.  
2.1.2 TRACERx cohort 
The lung TRACERx study (Jamal-Hanjani et al. 2014) was approved in early 2014 by 
the Camden and Islington Research Ethics Committee (13/LO/1546, NIH study trial 
registration number NCT01888601; clintrials.gov), the Research and Development 
department at UCLH, and Cancer Research UK (C11496/A17786). This cohort 
consisted of 16 patients who were selected using the following eligibility criteria: 
Inclusion criteria: 
• Written Informed consent 
• Patients ≥18-years of age, with early stage I-IIIA disease eligible for primary 
surgery  
• Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung 
imaging necessitating surgery (e.g. diagnosis determined from frozen section in 
theatre) 
• Primary surgery in keeping with NICE guidelines planned 
• Agreement to be followed up in a specialist centre 
• Performance status 0 or 1  
Exclusion criteria: 
• Any other current malignancy or malignancy diagnosed or relapsed within the 
past 5-years (other than non-melanomatous skin cancer and in situ cervical 
cancer) 
• Psychological condition that would preclude informed consent 
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• Treatment with neo-adjuvant chemotherapy deemed necessary 
• Adjuvant chemotherapy regimen other than platinum-based chemotherapy (if a 
patient is deemed suitable for adjuvant chemotherapy) 
• Known human immunodeficiency virus, hepatitis B virus, hepatitis C virus or 
syphilis infection 
• Sufficient tissue is unlikely to be obtained for the study based on pre-operative 
imaging. 
 
2.1.3 TransTACT cohort and tissue microarray 
The TACT trial (CRUK01/001) was a multi-centre open label phase III clinical study 
investigating the potential benefit of the addition of a taxane to adjuvant treatment in 
early breast cancer (Ellis et al. 2009). Patients in the study had either node-positive or 
high-risk node negative operable early breast cancer, and were randomly assigned to 
receive either FEC-T chemotherapy (fluorouracil 600 mg/m2, epirubicin 60 mg/m2, 
cyclophosphamide 600 mg/m2 at 3-weekly intervals followed by docetaxel 100 mg/m2 
at 3-weekly intervals), or the control regimen, which consisted of either FEC for 8 
cycles or epirubicin (100 mg/m2 at 3-weekly intervals) for 4 cycles followed by CMF 
(cyclophosphamide 600 mg/m2, methotrexare 40 mg/m2, and fluorouracil 600 mg/m2 at 
4-weekly intervals) for 4 cycles. Accrual occurred between February 2001 and June 
2003; 4162 patients were randomised into the TACT trial, 4124 patients were from 
centres within the UK and were approached for consent to collect tissue for research in 
a prospectively planned programme for translational biomarker evaluation within the 
TACT trial called the ‘TransTACT’ cohort. Archival paraffin-embedded breast cancer 
tissue blocks were used to create tissue microarrays (TMAs) containing cores, 0.6 mm 
in diameter and 4 mm in thickness, selected from representative tumour areas as 
determined by a consultant breast histopathologist from hematoxylin and eosin–stained 
sections.  
 
2.2 Tumour sample processing 
Tumour samples collected in theatre were marked with surgical clips to aid orientation 
of the anterior, superior and lateral aspects of the sample. Samples were transported 
on wet ice in a dry container without formalin fixative, to the UCLH pathology 
department. 
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2.2.1 Multi-region sampling of tumour tissue 
All tumour samples were cut fresh in a class 2 cabinet. Each tumour sample was 
examined macroscopically by a pathologist to assess whether there was enough tissue 
surplus to diagnostic requirements, without compromising the bronchial or pleural 
resection margins. The sample was then dissected with new sterile scalpel blades on a 
clean surface to avoid DNA contamination. A cut (or more than one cut for tumours 
larger than 3-4cm) that fully bisected the tumour without compromising the integrity of 
the whole specimen was made. Multiple tumour regions, representing the macroscopic 
heterogeneity of the primary tumour, were excised from the newly exposed tumour 
surface. A fresh blade for every region sampled to avoid DNA carryover, and regions 
from the tumour, separated by 0.5-1cm, were collected as shown in Figure 5. Samples 
were then wrapped in foil and snap-frozen by immersion in liquid nitrogen for 30 
seconds. Areas that were obviously necrotic, fibrosed or haemorrhagic were avoided to 
maximise viable tumour cellularity. Where possible, regions sampled reflected the 
macroscopic morphological heterogeneity of the tumour. The size of the tumours 
determined how many regions were collected, and on average the volume of each 
region was 10mm3. Where possible, regions were also collected from lymph nodes with 
either obvious macroscopic or suspected tumour involvement.  
 
 
Figure 5 Primary lung tumour sample 
Lung tumour after surgical resection in its entirety (A), and incised tumour with marked regions 
for multi-region sampling (B).  
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2.3 Plasma extraction from whole blood 
Peripheral blood samples were collected from patients in standard phlebotomy tubes 
containing the anticoagulant ethylenediaminetetraacetic acid (EDTA). These samples 
were transported on wet ice between the surgical theatre and the laboratory, and 
processed within 1 hour of collection. The tubes were spun in a centrifuge at 1000g for 
10 minutes at 4˚C, separating the plasma, buffy coat (leucocytes and platelets) and 
erythrocytes. The supernatant (plasma) was then removed using a disposable pipette, 
and further spun at 1000g for 10 minutes at 4oC. The resulting supernatant was 
removed leaving behind any cellular debris, and stored at -80˚C in 1ml aliquots. 
 
2.4 DNA extraction 
2.4.1 Extraction from fresh frozen tissue 
From each frozen tumour region stored at -80˚C, 30 mg was excised for DNA 
extraction. A 700µl mixture of β-mercaptoethanol (βME) and RLT Plus buffer (10µl 
βME per 1ml RLT Plus buffer) was added to each tissue sample prior to tissue 
homogenization using the TissueRuptor homogenizer (Qiagen). The resulting lysate 
was used to extract genomic DNA using the AllPrep DNA/RNA Mini kit (Qiagen), 
according to the manufacturer’s instructions. DNA quality and concentration was 
assessed using a Qubit® 2.0.  
 
2.4.2 Extraction from FFPE 
Hematoxylin and eosin slides made from FFPE tumour tissue blocks were reviewed in 
order to demarcate regions of tumour compared to normal tissue, as shown in Figure 6. 
Using manual blade macrodissection from 10-40µm unstained slides tumour-rich areas 
of tissue were removed guided by the demarcated areas, added to 1.5ml of fresh 
xylene in centrifuge tubes and then vortexed to deparaffinise the tissue. This was 
centrifuged at full speed for 3 minutes, followed by the removal of the supernatant and 
the addition of 1.5ml of 100% ethanol. The mixture was centrifuged again and the 
process repeated with subsequent additions of 100%, 70% and 50% ethanol. The 
remaining tube with pellet was incubated at 40oC using a heat block until no residual 
supernatant was present. Using the Qiagen DNeasy Blood and Tissue kit, 200µl of ATL 
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buffer and 20µl of proteinase were added to the tube with pellet, vortexed and 
centrifuged prior to incubation overnight at 56oC to aid tissue digestion. The following 
day, 200µl of AL buffer and 200µl of 100% ethanol were added to the pellet. The 
sample was vortexed and centrifuged briefly prior to transfer into a DNeasy spin 
column for centrifugation at 1000 rpm for 1 minute. This centrifugation was repeated 
with the addition of 650µl AW1 buffer to the column, and again with the addition of 
650µl AW2 buffer, prior to DNA elution. DNA quality and concentration was assessed 
using a Qubit 2.0.  
 
Figure 6 FFPE tumour blocks with corresponding H&E slides 
H&E slides from FFPE tumour blocks with demarcated areas of tumour to guide manual blade 
macrodissection from unstained slides.  
 
2.4.3 Extraction from whole blood 
Whole blood stored at -80˚C was thawed at room temperature, and 400µl was added to 
a centrifuge tube containing 40µl proteinase K and 4µl of RNase A (100 mg/ml) stock 
solution. An average of 12µg of total DNA was extracted from 400µl of whole blood 
using the QIAamp DNA Blood Mini Kit (Qiagen), according to the manufacturer’s 
instructions. DNA quality and concentration was assessed using a Qubit 2.0. 
2.4.4 Extraction from plasma 
Plasma samples were stored at -80˚C and thawed at room temperature prior to 
extraction. Each plasma sample (2ml) was added to a 50ml centrifuge tube containing 
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400µl of Proteinase K, and DNA was extracted using the QIAamp Circulating Nucleic 
Acid kit (Qiagen) and QIAvac 24 Plus vacuum manifold (Qiagen). To obtain higher 
concentrations, DNA was eluted in 20µl of elution buffer. DNA quality and 
concentration was assessed using a Qubit 2.0. 
 
2.5 Multi-region whole-exome sequencing 
Whole-exome sequencing (WES) was performed using DNA extracted from each 
tumour region and whole blood, where the latter was used for the germ line reference. 
For each tumour region and matched germ line, exome capture was performed on 1-
2µg of genomic DNA using the Agilent SureSelect Human All Exon V4 kit or the 
Illumina® Nextera XT Index kit according to the manufacturer’s protocol. Samples were 
paired-end multiplex sequenced on the Illumina® HiSeq platforms by Illumina, Inc. or 
the Illumina® Genome Analyzer II (GAII) and HiSeq 2500 platforms by the Advanced 
Sequencing Facility at the Francis Crick Institute. Genomic DNA was randomly 
fragmented by Covaris and run on a 2% agarose gel using a 100bp ladder at 110V for 
30 minutes.  A scalpol was used to excise fragments between 250 and 300 base pairs 
(bp) in length for purification using the Qiagen QIAquick® Gel Extraction kit. Adaptors 
were ligated to both ends of the fragments, adaptor-ligated templates were purified 
using Agencourt AMPure SPRI beads (Beckman Coulter), and fragments with an insert 
size of about 250bp were excised. Extracted DNA was amplified by ligation-mediated 
PCR, purified and hybridised to the SureSelect Biotinylated RNA Library (BAITS) for 
enrichment. Hybridised fragments were bound to streptavidin beads, whereas non-
hybridized fragments were washed out after 24 hours. For all samples, each captured 
library was loaded on the Illumina platform, and paired-end sequencing was performed 
with 200bp read length at a mean sequencing depth of 347x. Section 8.3 shows the 
detailed coverage per region for each tumour.  
 
2.5.1 Single nucleotide and indel variant calling from multi-region WES 
Raw paired end reads in FastQ format generated by the Illumina pipeline were aligned 
to the full hg19 genomic assembly (including unknown contigs) obtained from GATK 
bundle 2.8 (McKenna et al. 2010), using Burrows-Wheeler Aligner (bwa-0.7.7 (Li & 
Durbin 2009) with a seed length of 72bp for data sequenced on the GAII and 100bp for 
data sequenced on the HiSeq. Up to 3 or 4 mismatches were allowed per read for the 
GAII or HiSeq respectively, all other settings were left as default. Picard tools v1.107 
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was used to clean, sort, and merge files from the same patient region and to remove 
duplicate reads (http://broadinstitute.github.io/picard). Quality control metrics were 
obtained using a combination of Picard tools (1.107), GATK (2.8.1) and FastQC 
(0.10.1) (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). SAMtools mpileup 
(0.1.16) (Li et al. 2009) was used to locate non-reference positions in tumour and germ 
line samples. Bases with a phred score of <20 or reads with a mapping-quality <20 
were skipped. BAQ computation was disabled and the coefficient for downgrading 
mapping quality was set to 50. Somatic variants between tumour and matched germ 
line were determined using VarScan2 somatic (v2.3.6) (Koboldt et al. 2012) utilising the 
output from SAMtools mpileup. Default parameters were used with the exception of 
minimum coverage for the germ line sample that was set to 10, minimum variant allele 
frequency (VAF) was changed to 0.01 and tumour purity was set to 0.5. VarScan2 
processSomatic was used to extract the somatic variants. 
 
The resulting single nucleotide variant (SNV) calls were filtered for false positives using 
the associated fpfilter.pl script from Varscan2, having first run the data through bam-
readcount (0.5.1). Additionally, for those variants not subjected to Ion Torrent validation, 
further filtering was applied, whereby variants were only accepted if present in ≥ 5 
reads, ≥ 5% VAF and a somatic p-value (as determined by VarScan) of ≤ 0.01 in at 
least one tumour region with germ line VAF ≤ 1%. If a variant was found to meet these 
criteria in a single region, then the VAF threshold was reduced to ≥ 1% in order to 
detect low frequency variants. All indel calls classed as ‘high confidence‘ by VarScan2 
processSomatic underwent manual review prior to validation. All variants were 
annotated using ANNOVAR (Wang et al. 2010). Variants identified as non-silent 
mutations were manually reviewed using the Integrated Genomics Viewer (IGV) 
(Robinson et al. 2011), Thorvaldsdottir et al. 2013) and those showing an Illumina 
specific error profile (K. Nakamura et al. 2011) were removed from further analysis. 
 
2.5.2 Manual review of variants 
Exonic and/or splicing non-silent (non-synonymous, stop-gain or stop-loss) SNVs 
called using the above data platform were filtered prior to manual review using the 
following criteria: 
 
• A VAF ≥ 5% in at least one tumour region 
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• A minimum variant count ≥ 5 reads in at least one tumour region 
• A VAF ≤ 1% in the germ line  
 
A variant was considered to be present in a tumour region provided the VAF was ≥ 1%. 
In addition, variants were further filtered using a somatic p-value of ≤ 0.01, which was 
derived based on a cohort of tumours with variants that had been manually reviewed 
and validated using high-depth sequencing. Non-silent (frameshift or non-frameshift) 
indels were all manually reviewed. All identified variants were manually reviewed using 
IGV (Robinson et al. 2011; Thorvaldsdottir et al. 2013) in order to determine which 
variants were likely to be real and therefore put forward for validation. Variants only 
present in poorly aligned reads and those showing an Illumina-specific error profile (K. 
Nakamura et al. 2011) were removed. Recurrent C>A mutations with a variant count of 
4 and an average coverage of 60x, were found in the tumours prepared for WES using 
the Nextera XT Index kit. These mutations were subsequently deemed to be errors 
specific to the library preparation kit and were therefore excluded from further analyses.  
 
2.6 AmpliseqTM Ion Torrent sequencing  
2.6.1 Ion AmpliSeq custom validation 
Ion AmpliSeq custom panels (Life Technologies) were designed by entering the 
genomic positions of all variants called in at least one region using the online designer 
(www.ampliseq.com). Multiplex PCRs were performed with tumour-specific primer 
pools on DNA from each region of the relevant tumour to ensure that primer products 
of an appropriate size were present prior to sequencing. PCR was carried out in a total 
volume of 15µl with 2µl (12ng) of DNA template supplemented with 13µl of a master 
mix consisting of 3µl of 5X Ion AmpliSeq HiFi Mix (Life Technologies), 7.5µl of 2X Ion 
AmpliSeq primer pool (Life Technologies), and 2.5µl of nuclease-free water. Reactions 
were initially incubated at 99˚C for 2 minutes followed 22 cycles of PCR at 99˚C for 15 
seconds, 60˚C for 4 minutes. Presence of PCR products of the expected size were 
verified with 2µl of the PCR product (plus 8µl loading buffer) ran on a 2% agarose gel 
using a 100bp ladder at 110V for 30 minutes (Figure 7).  
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Figure 7 PCR amplification prior to validation 
Agarose gel (2%) with a 100bp ladder (left hand side) and visible PCR products using primer 
pools for respective tumour and gem line DNA for 3 separate patients.  
 
The Amplicon pools were used for the construction of barcoded sequencing libraries, 
and these were multiplex sequenced with 200bp read length on the Ion Torrent PGMTM 
sequencer (Life Technologies) at a mean sequencing depth of 1369x by the Advanced 
Sequencing Facility at the Francis Crick Institute. Section 8.3 shows the detailed 
coverage per region for each tumour. Sequence alignment to target regions from the 
hg19 genome was performed using the Ion Torrent SuiteTM software. VAFs for each 
variant position having a phred score >20 were identified. All variants were manually 
reviewed again using IGV; a variant was considered absent if the VAF was < 1% for 
SNVs or 2% for indels, while having a read coverage ≥ 50x, or considered a germ line 
variant if the VAF was > 1% in the germ line. Variants that were absent in all tumour 
regions or identified as germ line variants were excluded from further analysis. Variants 
with read coverage <50x were considered inconclusive and regional distribution was 
extracted from exome or genome sequencing data. Some variants failed amplification, 
either because the AmpliSeqTM Designer could not generate suitable primers or 
because primer pairs failed in PCR, and these were also excluded from further analysis. 
Taking these failed variants into account, the overall validation rate was > 90% and 
these SNVs and indels were taken forward as validated mutations.  
 
2.7 Intratumour heterogeneity index 
Robust and accurate measures of intratumour heterogeneity are yet to be determined, 
but one potential measure developed in our laboratory is the pairwise intratumor 
heterogeneity index. This was calculated by determining the mean proportion of 
heterogeneous (branch) mutations relative to the total number of mutations for each 
possible pairwise comparison of all tumour regions. However, including ubiquitous 
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(truncal) mutations can introduce a bias against tumours that arise in the context of 
tobacco smoke exposure, since these tumours will generally have a greater number of 
somatic mutations generated by exposure to tobacco smoking (Pfeifer & Hainaut 2003), 
and therefore a greater number of truncal mutations. One alternative is to calculate the 
index in the absence of the truncal mutations, such that the relative lengths of the 
branches are determined indicating the degree of evolution that has taken place after 
clonal diversification (branching of the tree). This was calculated as the mean of the 
branch length for each pairing of tumour regions, divided by the sequencing depth after 
it had been adjusted for tumour purity. This measure was used to calculate an 
intratumour heterogeneity index for each tumour. A two-sided Wilcoxon rank-sum test 
was used to test for statistically significant correlations between the intratumour 
heterogeneity index and patient clinical variables between two groups of patients. 
Spearman’s rank correlation coefficient was used to determine the strength and 
significance of the index with tumour stage and size. 
 
2.8 Phylogenetic tree analysis 
In the NSCLC pilot cohort, all non-silent mutations that were either validated or filtered 
were used for phylogenetic tree construction. In the TRACERx cohort, filtered 
synonymous and non-synonymous mutations were used for phylogenetic tree 
construction. Variants that were filtered met the following criteria: 
 
• A VAF ≥ 5% in at least one tumour region 
• A minimum variant count ≥ 5 reads in at least one tumour region 
• A somatic p-value of ≤ 0.01 
• A germ line VAF < 0.01 
• Not detected in a pre-defined artefact blacklist region of the human genome 
 
For each tumour, mutations that were present in all regions (ubiquitous) were 
considered to occur early in tumour evolution, and therefore present on the trunk of the 
phylogenetic tree. In contrast, mutations that were present in either one or some 
regions only (heterogeneous) were considered to occur later in tumour evolution, and 
therefore present on the branches of the phylogenetic tree (Figure 8). Trees were built 
using binary presence/absence matrices obtained from the regional distribution of 
variants within the tumour. The R Bioconductor package phangorn (1.99-7) (Schliep 
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2011) was used to generate unrooted trees using the parsimony ratchet method (Nixon 
1999). Branch lengths were determined using the acctran function. Phylogenetic trees 
were redrawn in Adobe Illustrator with trunk and branch lengths proportional to the 
average number of mutations. Angles between branches were chosen only for 
convenience of display. 
 
 
Figure 8 Phylogenetic tree construction 
Reproduced from (Jamal-Hanjani, Quezada, et al. 2015). Primary tumours consist of different 
subclones with shared and private somatic alterations. Alterations shared by all tumour cells (A) 
occur early in tumourigenesis, represented by the blue trunk of the phylogenetic tree; alterations 
shared by tumour cells present in some regions of the tumour but not all (B and C) occur later in 
tumourigenesis, represented by the yellow branches of the tree; and private alterations (D–F) 
present in only one region of the tumour also occur later in tumourigenesis, represented by the 
red branches of the tree. 
 
 
2.9 Identification and classification of predicted driver mutations 
All identified non-silent variants were compared against a list of 582 potential driver 
genes. The driver gene list was consisted of all genes identified in the Catalogue of 
Somatic Mutations in Cancer (COSMIC) cancer gene census (downloaded June 2014) 
(Futreal et al. 2004), and those identified in a large scale pan-cancer analysis (using q 
< 0.05 as a cut-off for statistical significance) (Lawrence et al. 2013) and previous 
NSCLC sequencing studies (Lawrence et al. 2014; Cancer Genome Atlas Research 
Network, 2015). Any variants that were located within one of these genes underwent 
categorisation based on pre-set criteria. The COSMIC database and review of the 
existing literature was used to determine whether genes were considered to be 
oncogenes (OGs) or tumour suppressor genes (TSGs). Functional prediction scores 
associated with non-silent mutations were derived using the software packages SIFT 
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(P. Kumar et al. 2009), Polyphen-2 (Adzhubei et al. 2010) and MutationTaster2 (J. M. 
Schwarz et al. 2014)). If a variant in a TSG was deemed to be deleterious (either a 
stop-gain or predicted deleterious in two of the three computational approaches, the 
specific variant was classified as a category 1 (high confidence) driver mutation. If it 
failed to reach these criteria, the proximity to mutations annotated in COSMIC (data 
obtained February 2015) was determined. If ≥ 3 COSMIC mutations were located 
within 15bp, the variant was classified as a category 2 (putative) driver mutation. If not, 
it was classified as a category 3 (low confidence) driver mutation. If a variant was found 
in an OG, COSMIC was reviewed for the exact match to the specific variant. If an exact 
match was found ≥3 times, the variant was classified as a category 1 driver mutation. If 
an exact match was not found, the same criteria as described for the TSGs above was 
applied to classify the variant as a category 2 or 3. Finally, if the driver gene had not 
been classified as either an OG or TSG, all tests described above were applied and if it 
passed, the variant was classified as a category 2, otherwise a category 3 driver 
mutation. All the remaining variants were classified as a category 4 or 5 driver mutation 
(determined by the maximum variant count and maximum VAF being greater than 5 
and 5%, respectively). These represented variants of unknown significance. In 
summary, the 5 driver categories were:  
 
• Category 1 - high confidence driver mutations containing all inactivating 
mutations in TSGs or activating mutations in OGs  
• Category 2 - putative driver mutations containing all mutations in driver genes 
located up to 15bp away from other mutations present in COSMIC or mutations 
meeting category 1 criteria but not annotated as a TSG or OG 
• Category 3 - low confidence driver mutations containing all other non-silent 
mutations in genes that were present in the lists of cancer-related genes  
• Category 4 and 5 – mutations of unknown significance  
 
2.10  Mutational spectra plots 
In the NSCLC pilot cohort, all non-synonymous mutations that were either validated or 
filtered, and all synonymous mutations that were filtered were used to create 
mutational spectra plots for each tumour. In the TRACERx cohort, filtered synonymous 
and non-synonymous mutations were used to create mutational spectra plots for each 
tumour. Variants with a VAF of ≥ 1% in all tumour regions were classified as truncal 
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mutations, and otherwise they were classified as branch mutations. Variants that were 
filtered met the following criteria: 
 
• A VAF ≥ 5% in at least one tumour region 
• A minimum variant count ≥ 5 reads in at least one tumour region 
• A somatic p-value of ≤ 0.01 
• A germ line VAF < 0.01 
• Not detected in a pre-defined artefact blacklist region of the human genome 
 
Chi-square tests were used to compare the mutation spectra of the six mutation types 
C>A, C>G, C>T, T>A, T>C, T>G (all substitutions are referred to by the pyrimidine of 
the mutated Watson-Crick base pair). A two-sided Fisher’s exact test was used to 
compare the relative frequency of each mutation type between early and late variants.  
 
2.10.1 Detecting a smoking signature pattern 
In lung cancer it is well known that a substantial number of somatic mutations are 
generated by exposure to tobacco smoking (Pfeifer & Hainaut 2003). A significant 
association between a signature rich in C>A transversions and either a history of 
smoking or cancers associated with tobacco smoking (lung adenocarcinoma, 
squamous and small cell carcinomas, head and neck squamous, and liver cancers) 
has been previously demonstrated (Alexandrov, Nik-Zainal, Wedge, Aparicio, et al. 
2013; Alexandrov, Nik-Zainal, Wedge, Campbell, et al. 2013). This pattern of mutation 
was investigated in all tumours.  
 
2.10.2 Detecting an APOBEC signature pattern 
To detect an APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like) mutation pattern, previously established methods were used (Roberts et al. 2013; 
de Bruin et al. 2014). In brief, the enrichment ETCW relating to the strength of 
mutagenesis at the TCW motif across the genome was calculated as follows:  
                                         
where mutationsTCW is the number of mutated cytosines (and guanines) falling in a 
TCW (or WGA) motif, mutationsCorG is the total number of mutated cytosines or 
ETCT =
mutationsTCW × contextCorG
mutationsCorG × contextTCW
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guanines, contextTCW is the total number of TCW (or WGA) motifs within a 41-
nucleotides region centered on the mutated cytosines (and guanines) and contextCorG is 
the total number of cytosines or guanines within the 41-nucleotides region centered on 
the mutated cytosines (or guanines). Only specific base substitutions were included 
(TCW to TTW or TGW, WGA to WAA or WCA, C to T or G, and G to A or C). Over-
representation of APOBEC signature mutations in each sample was determined using 
a two-sided Fisher's exact test comparing the ratio of the number of cytosine-to-
thymine or cytosine-to-guanine substitutions and guanine-to-adenine or guanine-to-
cytosine substitutions that occurred in and out of the APOBEC target motif (TCW or 
WGA) to an analogous ratio for all cytosines and guanines that reside inside and 
outside of the TCW or WGA motif within 41-nucleotide region centered on the mutation 
cytosine (and guanine). P-values were corrected using Benjamin-Hochberg multiple 
testing correction, and a significance threshold of q < 0.05. For each sample, APOBEC 
mutation enrichment was determined for all mutations, early (truncal) mutations and 
late (branch) mutations separately. Comparisons between early and late APOBEC 
mutation enrichment was performed using a two-sided paired t-test.  
 
2.11  Copy number analysis 
All data analysis was performed using the R statistical package, version 3.0.2. 
Processed sample exome SNP and copy number data from paired tumour-normal was 
generated using VarScan2 (v2.3.6). Varscan2 copy number was run using default 
parameters with the exception of min-coverage (Robinson et al. 2011) and data-ratio. 
The data-ratio was calculated on a per sample basis as described in (Koboldt et al. 
2012). Output from Varscan were processed using the Sequenza R package 2.1.1 
(Favero et al. 2015) to provide segmented copy number data, and cellularity and ploidy 
estimates for all samples based on the WES data. The following settings were used: 
breaks.method = 'full', gamma = 40, kmin = 5, gamma.pcf = 200, kmin.pcf = 200. 
Manual verification was performed of the automatically selected models for ploidy and 
cellularity. Processed copy number data for each sample was divided by the sample 
mean ploidy, and log2 transformed. Gain and loss was defined as log2(2.5/2) and 
log2(1.5), respectively. Amplification was defined as log2(4/2). For calling copy number 
aberrations, segments smaller than 500kb or containing less than 5 SNPs were 
removed. A higher tumour purity was required for the copy number analysis pipelines 
compared with the variant calling, and therefore the following tumour regions were 
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excluded for the analysis: tumours LTX016 (R4, R5), LTX022 (R2, R3, R4, R6), 
LTX028 (R4, R8), LTX031 (R1, R2), LTX036 (R1, R2, R5, R7 and R8), and LTX038 
(R7). In addition, tumour LTX030 was excluded from the copy number loss analysis 
since data from only one region was available, but included in the copy number gain 
and/or amplification analysis where two regions were analysed. Heat maps were 
created showing the distribution of potential driver copy number amplifications and 
deletions for each tumour region, based on recurrent amplified and deleted 
chromosomal segments identified in The Cancer Genome Atlas (TCGA) LUAD and 
LUSC cancer data. For each region, copy number amplification was determined as ≥ 
2x ploidy, copy number gain was determined as ≥ 1 copy gain but less than the 
amplification threshold, and copy number loss was determined as ≤ 1 copy number 
relative to ploidy.  
 
2.12   cfDNA analyses 
2.12.1 Selection of mutations 
Non-silent mutations identified by WES and subsequently validated by Ion AmpliSeq 
sequencing were considered for detection in cfDNA. The majority of the mutations 
investigated were SNVs, but in some cases indels were tested and in one case an 
EML4-ALK translocation was tested (collaboration with Illumina). All approaches 
involved multiplex PCR and PCR primers were designed using the specified genomic 
coordinates for the selected mutations. In order to address the question as to whether 
the heterogeneous genetic landscape of a tumour could be explored using cfDNA, both 
truncal and branch mutations were selected. cfDNA analyses involved collaborations 
with companies outside of our laboratory (as described below), whereby cfDNA 
extracted at diagnosis from 2ml of plasma for each patient was sent to these 
companies along with specified mutations for detection. The results of these 
experiments were analysed in our laboratory. Significant associations between VAFs 
for selected mutations in these analyses were tested for using the Mann-Whitney U 
test.  
 
2.12.2 Multiplex PCR and MALDI-TOF mass spectrometry 
In collaboration with Agena Bioscience (Michael Mosko and Anders Nygren, San Diego, 
CA, USA), the presence of mutations in cfDNA was analysed using a novel minor 
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variant detection technique called UltraSEEK, which is able to process multiple 
informative variants within a single reaction, and involves standard multiplex PCR 
followed by a mutation specific single base extension reaction and characterisation 
using Matrix Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) mass 
spectrometry (Figure 9).  
 
 
Figure 9 The UltraSEEK technique 
The UltraSEEK technique consists of multiplex PCR followed by a mutation specific single base 
extension reaction.  The extension reaction utilizes a single mutation specific chain terminator 
labelled with a moiety for solid phase capture. Captured, washed, and eluted products are 
interrogated for mass and mutational genotypes are identified and characterised using MALDI-
TOF mass spectrometry. 
 
2.12.2.1  Assay design 
Each UltraSEEK assay consisted of three primers, two PCR primers and one single 
base extension primer. PCR primers were manually designed using the specified 
genomic coordinates of the selected mutations. Table 2 summarises the chosen 
variants and primer designs. All amplicons were under 150bp in length to ensure 
cfDNA amplification success and mass tags were added to the 5’ end of the primer to 
move unincorporated PCR primers out of the analytical mass window. Different 
extension probe lengths between 15 to 30 nucleotides long were used to ensure there 
were no conflicts between assays. Probe polarity was designed to ensure that the 
maximum number of assays shared the same variant nucleotide of extension. All 
oligonucleotides were obtained from Integrated DNA Technologies. The customised 
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UltraSEEK panel contained multiplex reactions consisting of assays for parallel 
detection of somatic mutations in selected genes. Control assays were also included to 
ensure functional biochemistry, a sufficient quality template, and the ability to 
distinguish between a wild type result and a failed assay.  In addition, five capture 
controls were also present in each multiplex to verify that the bead capture, cleaning, 
and elution steps were successful. 
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Pt Gene Type Genomic coordinates 
Primer sequences 
Probe sequence 
Forward Reverse  
L0
03
 
BRAF S chr7:140624415 
ACTCACCTCCTCCG
GAATG 
TCTGTTCAACGGG
GACATGG 
AGGCCGCGGCGC
CGGCG 
CTNNB1 S chr3:41266113 
CCTCAGGATTGCCT
TTACCA 
TTTGATGGAGTTG
GACATGG 
CTGTGGTAGTGG
CACCA 
EGFR S chr7:55259515 
CCTCCTTCTGCATG
GTATTC 
AAACACCGCAGCA
TGTCAAG 
CACCCAGCAGTTT
GGCC 
FOXP1 S chr3:71179760 
TTGCTGTAGATGGG
TTCTGG 
AAAGGGCAATGTT
CCAGTGT 
GCGGGGGTTGCC
GAGTG 
IL7R S chr5:35871172 
TTCCCGATAGACGA
CACTCA 
TTTCCTTGGCTGC
CCTTTAG 
CGACACTCAGGT
CAAAAG 
JAK1 S chr1:65313277 
GGGAAATATCCCTG
TGGCTG 
GATGGATTACAAG
GATGACG 
ATCACTTTTATCT
TCTTCTCTT 
MLL S chr11:118375108 
CCGCAGAGTCCACA
CAAGTA 
TGAAGGCAGGATA
TTCCCAC 
ATACTGAGCTCCT
GAAAT 
MUC1 S chr1:155159940 
CTGGTCTGTGTTCT
GGTTGC 
CATGGAGTGCCTT
CTACCG 
CTGGCCATTGTCT
ATCT 
L0
08
 
BRAF S chr7:140481402 
TACCATGCCACTTT
CCCTTG 
GACGGGACTCGA
GTGATGAT 
ATTGGATCTGGAT
CATTTG 
MAGI2 S chr7:77885584 
AGATATAACAGATC
GGCCGC 
ACATTGTCATCAT
GGACGGG 
GTGCCGTCTAGC
TGACCAT 
MLL2 S chr12:49420721 
CTGCTGCTGACCAT
CCAGAA 
ATGTCTCGCGGTA
CCTTGTC 
GCTGCTCCATAAA
CTCTG 
PIK3CA S chr3:178936082 
AAGAAAAAGAAACA
GAGAATCTCCA 
GCTAGAGACAATG
AATTAAGGGAAA 
CCTGCTCAGTGAT
TT 
RB1 S chr13:49039501 
TCAGAAGGTCTGCC
AACACC 
CCCCTCTCATTCT
TTACTAC 
AGAGAAAACACA
CACCTT 
TNK2 S chr3:195615444 
AGGCGGCAGAATGC
AGCCA 
TACTGTTGCAGCT
GCACCTC 
AGCTCCAGCAGC
CAGCCTGTGC 
TP53 S chr17:7578272 
CATCCAAATACTCC
ACACGC 
AGAGACGACAGG
GCTGGTT 
GTCTGGCCCCTC
CTCAG 
L0
11
 
BRAF S 
chr7:140453136 
CCACAAAATGGATC
CAGACA 
TCTTCATGAAGAC
CTCACAG 
CCACTCCATCGA
GATTTC 
CHD2 S chr15:93524686 
GAAGTGTCAACAAG
TGCAAC 
CAATGCTGAGAAC
TCTCTCC 
ACTTCTATCACAG
TTTA 
CSMD3 S chr8:113301756 
ACTTCTCGCCAGAC
AGGACT 
CATGCTGGTATAG
GTTGTTCG 
AGGAACGCCAGG
GTGTC 
GPX6 S chr6:28474130 
TGCAAGCACTCACT
TGAGAC 
ATTGTGTTGGCCT
TTCCCTG 
TGTTCCTGGTTCT
TGTTT 
HSP90AA
1 
S chr14:10255175
7 
CAGTTTGGTCTTCTT
TCAGGTG 
TGGCGTTGAGCAC
TAAATTG 
CTTGCAGGTGAA
CCTATG 
LGALSL S chr2:64683447 
TGGGATGATTTTCTT
TTCAGC 
CTTTGAGTTCGAT
TGCCACA 
TCAGCTTGACCTG
TGGG 
OR10Z1 S chr1:158577038 
TTATGGCTGTGCTT
CCTTCG 
GGGTCACTACAGT
ATAGGTC 
CAAAGCCAGCTA
GTCTCTTGAGAG 
TP53 S chr17:7577046 
TGCTTGCTTACCTC
GCTTAG 
ACAGAGGAAGAGA
ATCTCCG 
AAGGGGAGCCTC
ACCAC 
L0
13
 
EGFR S chr7:55241708 
AAAATTCCCGTCGC
TATCAA 
GAGAAAAGGTGG
GCCTGAG 
GCCAACAAGGAA
ATCCTC 
EGFR S chr7:55242511 
TCTCTTGAGGATCTT
GAAGG 
CCCCACCAGACCA
TGAGA 
ATTCAAAAAGATC
AAAGTGCTGG 
FBXO46 S chr19:46216357 
TTGGTGGGGTCAAG
ACAGC 
AGCTCCATGAAGG
TCAAGGG 
GATAGCTCCAAG
GCCAAG 
JAK2 S chr9:5022084 
AGATACACCTGAAG
AACTGG 
GAAATGGAGGGAA
CATCCAC 
TGGAAATGCCAAT
TCTATG 
KMT2C S chr7:151947008 
TGAACATACTGCTTA
CCAGCAA 
ACTCACAGCGGTT
CAAGTCC 
GACTTTCTGAGG
GATGACTC 
MSH2 S chr2:47693816 
TCTTCCTTACAGGTT
ACACG 
TGGAATACTTTTTC
TTTTCTTCTTGA 
GGACCCTGGCAA
ACA 
TP53 S chr17:7579509 
CTCTGGCATTCTGG
GAGCTT 
ATGATTTGATGCT
GTCCCCG 
TCACTGAAGACC
CAGGT 
L0
17
 BRCA2 S chr13:32914959 
TTGGTTCCTAATACC
AACTG 
TGTTGAAGGTGGT
TCTTCAG 
CTATTAAAGTTTC
TCCATATCTCT 
EIF2AK1 S chr7:6098705 TCTTCGCGCTTGCG ATCGGAGTGTGGC CGGCCGGCGATG
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GACCC AGTGCT CAGGGG 
KRAS S chr12:25398284 
CTGTATCGTCAAGG
CACTCT 
AGGCCTGCTGAAA
ATGACTG 
GTGGTAGTTGGA
GCTG 
NF1 S chr17:29653134 
ACACCAAGTATCAT
GAGCGG 
CAGCAGGTAGTTT
CTGTTGTTCA 
GCTCAGCCAGTT
GCCCAGGA 
NF1 S chr17:29528088 
TGTTGGGGTTTTTAT
AGAACCTG 
GCAAGAAACAAGG
CAGTCAA 
CCAAGTAAGCCAT
TCTCA 
PAX8 S chr2:113984793 
ATGGCAGAGGAGG
CATAGC 
CTGTATTTTTCCA
GGGCGAG 
GCCCGGATACCC
ACC 
TP53 S chr17:7577079 
TGGTGAGGCTCCCC
TTTCTT 
AGCTTTGAGGTGC
GTGTTTG 
CGGCGCACAGAG
GAA 
TP53 S chr17:7577610 
CCATGCAGGAACTG
TTACAC 
CTGCTTGCCACAG
GTCTCC 
GGCCTGTGTTATC
TCCT 
TRIM67 S chr1:231299607 
GTTCTCCATTTCATG
CTCGG 
GGCTGCAAGAGC
CCGGGAG 
GGGGGCAGCACG
GCC 
TRIP11 S chr14:92471631 
TGTTCCTTGATCGT
GTTCAG 
ACGACTCAGGGAA
GAGCAGA 
GTGTTACTGAACT
AGCATCT 
L0
19
 
AKAP9 S 
chr7:91674380 
GATCTATCTAGAATC
CCAAGGACA AGGTATGCACTCC
AGAAAGC 
TTTCTTGAACAGC
TGCTGTTG 
ARID5A S chr2:97215990 
GGTGCCCTTGCAGG
TGA 
CCGCCGTACCTCT
CGTAGT 
TTCCAGCGGCAG
ATCCC 
EML4-
ALK T 
Chr2:29447613-
29447682/Chr2:
42497966-
42498097 
GTGTTAGCTCCTATT
ATCCTGTCC 
TTTTTGAGATAGG
GTCTCACTGT 
CCAGGGTAGAAG
GGAGA 
KNTC1 S chr12:12302666
9 
GTAAATATTGCTGC
AAATC 
TGTATTACAAACC
TTCAGC 
AAAAATATAATGT
ATTACTTACCTTG
T 
LEPRE1 S chr1:43232537 
TTCCATGCTCAGGA
CCACC 
CCAAGCCGAGGT
CGAGTC 
GGGGCATGGTGA
CGCCT 
MYCN S chr2:16082899 
GCGGGTATTGCCGC
CCCAG 
TACTGAGGGCCTT
GTGGTC 
TAGCGGCCGCCT
GGG 
POU2AF1 S chr11:111228360 
GGTGTAAGGTGTCC
ATGGG 
TGTGTCTGCAGTG
ACAGAGG 
CCTGTGTGTCGG
CTGGCTCT 
XRRA1 S chr11:74644897 
GGGGCCTTAAGAGA
CAACTC 
TTGGAGAACTTCA
GGCCAC 
GAAGCACCACTG
TGTGAG 
Table 2 Primer designs (UltraSEEK) 
Genomic coordinates, forward and reverse primer sequences, and probe sequences for each 
mutation. Abbreviations: Pt, patient; S, SNV; T, translocation. 
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2.12.2.2  PCR amplification 
In order to identify 1% of mutant copies in 10ng of cfDNA, the UltraSEEK technique 
required 30 mutant copies per reaction. The amount of functional template DNA was 
quantified in several of the cfDNA samples using the TaqMan® Copy Number 
Reference Assay (Life Technologies) targeting the telomerase reverse transcriptase 
(TERT) gene, according to the manufacturer’s instructions. In L003, there were 
approximately a total of 25 copies/µl in 10µl, in L008 there were approximately a total 
10 copies/µl in 10µl, and in L011 there were approximately a total 150 copies/µl in 19µl. 
The PCR was carried out in a total volume of 20µl with 10µl of DNA template 
supplemented with 10µL of a master mix consisting of 1x PCR Buffer supplemented 
with 1mM MgCl2, 125µM dNTPs, 0.125U Uracil-DNA glycosylase (New England 
Biolabs), 4U Taq polymerase, and 100nM of each PCR primer. Reactions were initially 
incubated at 30˚C for 10 minutes followed by 94˚C for 2 minutes. 45 cycles of PCR 
were performed at 94˚C for 30 seconds, 56˚C for 30 seconds, and 72˚C for 1 minute. 
The PCR was completed with a final incubation of 5 minutes at 72˚C. 5µl of amplified 
products were conditioned with the addition of 2µl of 0.5U shrimp alkaline phosphatase 
(SAP) in 0.24X SAP buffer in a total volume of 7µl for 40 minutes at 37˚C followed by 
SAP enzyme denaturation for 10 minutes at 85˚C. All reagents used were obtained 
from Agena Bioscience. 
 
2.12.2.3  Single base extension  
Single base extension was performed by adding 2µl of a mastermix consisting of 0.2X 
extension buffer, 5.56µM extend mix, extension probes at various concentrations, and 
0.14U iPLEX® Pro enzyme. Single base extension reactions were performed in a total 
volume of 9µL. Reaction parameters included an initial incubation at 94˚C for 30 
seconds, followed by 40 cycles at 94˚C for 5 seconds with five nested cycles of 52˚C 
for 5 seconds then 80˚C for 5 seconds. The single base extension was completed with 
incubation at 72˚C for 3 minutes. 
2.12.2.4  Control assays 
The UltraSEEK panel contained two types of control assays as quality assurance 
metrics of the acquired data, so that only mutated alleles were detected. Without the 
presence of the wild-type allele, these controls differentiate a negative result from a 
failed reaction in the absence of a somatic mutation (Figure 10). To control for the 
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initial steps of the reaction including DNA addition, PCR and single base extension, a 
DNA-dependent control targeting Albumin (ALB), a housekeeping gene highly unlikely 
to be mutated in tumours, was included. A second set of controls was added at the 
post-PCR step to give an indication of the success of the capture process. The capture 
controls exist at constant concentration across all reactions and were used for data 
normalisation and mutation calling. The intensity of the capture ions were used to 
create a capture control fit, and the intensities of each assay were normalised to this fit 
using a linear least squares regression model (Figure 11). 
 
 
Figure 10 UltraSEEK controls 
MALDI-TOF results of the UltraSEEK reaction with controls: capture controls (green), DNA 
process control (purple), mutation-specific assay peaks (red). 
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Figure 11 UltraSEEK capture control fit 
Per-well capture control ion intensities (A), and linearity of the capture control response using a 
linear least squares regression model (B).  
 
2.12.2.5  Capture and data acquisition 
Prior to capture, the streptavidin coated magnetic beads were conditioned in binding 
and wash buffer. Two rounds of conditioning were performed on the beads and then 
they were re-suspended in the binding and wash buffer at a concentration of 1µg/µl. A 
total volume of 41µl of conditioned beads was added to 9µl reaction and capture was 
performed at room temperature for 30 minutes under constant rotation. Beads with 
captured products were pelleted using a magnet and the binding and wash solution 
was removed. The beads were washed once with 100µl of HPLC grade water, re-
suspended with 13µl of elution solution, and incubated at 95˚C for 5 min. Eluted 
products were conditioned with 5µl (3mg) of anion exchange resin slurry. Finally, the 
analyte was dispensed onto a Spectrochip® II solid support using an RS1000 
  
  
 
B 
A 
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Nanodispenser. Data was acquired via MALDI-TOF mass spectrometry using the 
MassARRAY® 4 instrument.  
 
2.12.2.6  Automated data analysis  
Data analysis was performed using the Typer Software (Agena Bioscience). The 
software acquired raw peak intensity data for all assay products and a linear least 
squares function was used to fit intensities of the capture control assays and determine 
the per-well data quality, and the normalisation factor. The intensity of each assay was 
normalised to the linear fit of the internal controls.  The average adjusted normalised 
intensity for each assay was calculated as the difference between the normalised 
intensity data point per assay and the average normalised intensity for all data points 
per assay. This did not change the relative distribution of the data for each assay. 
Mutations were detected using robust z-score (median absolute deviation (MAD)-
based z-score).  A robust z-score was calculated for each assay using the median and 
the MAD values previously established with known non-mutant samples. This data 
served as the historical baseline for the mutation detection and was used for each data 
analysis. Samples that exceeded the user-defined assay z-score cutoff (default of 10) 
and met the peak quality criteria (adjustable minimum peak intensity and the call 
probability of 0.8 and better) were labelled as containing the mutation by the analysis 
software and reported accordingly. 
 
2.12.3  Multiplex PCR and targeted MiSeqTM sequencing 
2.12.3.1  Assay design and PCR amplification 
In collaboration with Illumina (Claire Fielding and Mark Ross, Cambridge, UK), the 
presence of mutations in cfDNA was analysed using a multiplex PCR and NGS (MiSeq 
sequencing) approach. PCR primers were designed both manually and separately 
using the software package Primer3 version 4.0.0 (Koressaar & Remm 2007; 
Untergasser et al. 2012). Table 3 summarises the chosen variants and primer designs. 
Primers were tested and optimised individually beforehand using Promega control DNA 
(30ng input) and tumour DNA (30ng input). In general, the primers designed using 
Primer3 performed better with PCR amplification (Figure 12). Primers for the AKAP9 
and KNTC1 mutations failed PCR amplification, and were therefore not included in the 
multiplex PCR reaction. Primers for the EML4-ALK translocation were designed 
manually and tested on DNA from a patient in the NSCLC pilot cohort who was known 
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to have the translocation previously identified by the UCLH pathology department using 
a diagnostic FISH assay. DNA from lymph node region LN2 was used, and PCR 
amplification was performed using different DNA concentrations (neat: 30ng, 1:100 and 
1:10 dilutions) with Primer3 and manually designed primers, as well as an EML4-ALK 
primer set previously used by Illumina (Figure 12). The PCR products were analysed 
and quantified using the DNA 1000 kit (Agilent). The 1:10 dilution using the Primer3 
designed primers (circled red in Figure 12) was taken forward for the multiplex 
approach.  
 
Figure 12 Primer optimisation using Promega control DNA 
Electrophoresis gels showing PCR products using primers designed both manually and with 
Primer3 were tested on control DNA. Each well is labeled with the mutation gene name and 
amplicon size, and those labeled with ‘ManualDesign’ were for primers designed manually. PCR 
performed by Clare fielding, Illumina. 
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Figure 13 Testing the EML4-ALK translocation primers 
Gel electrophoresis using different EML4-ALK primers with DNA from patient L019. Primers 
designed for the mutation in ZNF1751 was used on DNA from patient L019 as a control sample. 
PCR performed by Clare fielding, Illumina. 
 
The total amount of available cfDNA in the case analysed was 4.5ng. Provided PCR 
products were present with individual primers, all primers were combined into one pool 
to allow a multiplex approach using cfDNA and tested using a titration of Promega DNA 
from 25ng to 1ng inputs within a larger 65ul reaction to account for the volume required 
of cfDNA for 4.5ng input. Using the cfDNA sample, two rounds of PCR were conducted 
to amplify the mutations using the designed primers. PCR1 was carried out in a total 
volume of 65µl with 25µl of DNA template (4.5ng) supplemented with a mastermix 
consisting of 32.5µl Phusion (2x) (New England Biolabs), 6.5µl primer pool (100µM) 
and 1µl nuclease-free water (Life Technologies). Reactions were initially incubated at 
98˚C for 1 minute followed by 30 cycles of 98˚C for 40 seconds, 64˚C for 20 seconds 
and 72˚C for 15 seconds. The PCR was completed with a final incubation of 5 minutes 
at 72˚C. PCR2 was performed using a 1:10 dilution of the PCR1 product (2µl PCR1 
product plus 18µl nuclease-free water) as the DNA template. PCR2 was carried out in 
a total volume of 25µl with 2.5µl of DNA template supplemented with a mastermix 
consisting of 12.5µl Phusion (2x) (New England Biolabs), 1µl primer PE1.0 (10µM), 1µl 
primer PE2.0 index (10µM), and 8µl nuclease-free water (Life Technologies). 
Reactions were initially incubated at 98˚C for 1 minute followed by 10 cycles of 98˚C 
for 40 seconds, 64˚C for 20 seconds and 72˚C for 15 seconds. The PCR was 
completed with a final incubation of 5 minutes at 72˚C.  
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2.12.3.2  Targeted sequencing using the MiSeq platform 
The amplified cfDNA from PCR2 was analysed and quantified using the Agilent 
DNA100 kit (Agilent). An initial concentration of 82.3nmol/l was diluted to 2nM, then 
denatured, and diluted again so that a final cfDNA concentration of 6pM was used for 
targeted multiplex sequencing on the MiSeq (Illumina) platform with a paired end 
151bp read length. Results were analysed using the FASTQ files generated.  
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Gene Type Design Genomic coordinates 
Amplicon 
size 
Primer sequences 
Forward Reverse 
ZNF175 Indel 
Primer3 Chr19:52084702-52084807 106 
TGGACCCTGCCCAGA
GATGC 
AGGATCCAGCCAA
GATTCCC 
Manual Chr19:52084742-52084784 43 
GGAGCTCTATAGCCA
TCTCT 
TCAGTTGTGCTCAC
CCACTG 
AKAP9 SNV 
Primer3 Chr7:91674338-91674457 120 
GCTAATAATAGACTTT
TGAAGATCC 
AGATGACTGGCTTT
TACTAGATCT 
Manual Chr7:91674359-91674401 43 
ATCCTCTTAGAAGTTG
TAAA 
TTTCTTCAACAGCT
GCTGTT 
DIS3L2 Indel 
Primer3 Chr2:233194568-233194690 123 
CAAGATCCACCGCGC
CTTCC 
GAGCTGAAGTCCAC
GGGCAG 
Manual Chr2:233194592-233194634 44 
GCAGGCCCTGCTGCG
CCGGC 
CATCCTTGTTTGGG
GCGGGG 
POU2AF1 SNV 
Primer3 
Chr11:111228
304-
111228417 
115 TGGAAGGTTCTGTGTCTGCA 
ACTCGGTGTAAGGT
GTCCAT 
Manual 
Chr11:111228
339-
111228381 
43 CCCTGTGTGCCGGCTGGCTC 
AGGGTGGCCGGGG
TGGGCTG 
KNTC1 SNV 
Primer3 
Chr12:123026
609-
123029724 
117 GCCGCCTCTGGAAGAACGTG 
CTAGTAAATATTGC
TGCAAATCA 
Manual 
Chr12:123026
646-
123026690 
45 GGGCAGCCCAGGCAGCACCA 
ATAATGTATTACTTA
CCTTG 
XRRA1 SNV 
Primer3 Chr11:74644852-74644972 121 
GATTAATTAAACTTTG
TAGGGGCC 
GAACTTCAGGCCAC
TCACATTAA 
Manual Chr11:74644876-74644923 48 
CCAGCGCTGAAGCAC
CACTGTGT 
GGTGCACAGATCTG
ATGGC 
LEPRE1 SNV 
Primer3 Chr1:43232505-43232628 124 
GTTGAAGCTGCTGAC
CACAC 
GTAGGCTGCGGTC
CCCTCGG 
Manual Chr1:43232516-43232558 43 
AGGATGGGGCATGGT
GACGCC 
TCCCCTCGGCGAA
GAGCAGA 
MYCN SNV 
Primer3 Chr2:16082856-16082975 120 
GGTATTGCCGCCCCA
GC 
TGAATCGCTCAGGG
TGTCC 
Manual Chr2:16082878-16082920 43 
CCCCGGGGGTCGCCC
CTCCG 
CTGGTCTGGCGGC
CGCCTGG 
ARID5A SNV 
Primer3 Chr2:97215935-97216035 101 
GCCGCCTCTGGAAGA
ACGTG 
CGCCCCGCCGTAC
CTCTCGT 
Manual Chr2:97215969-97216011 43 
GGGCAGCCCAGGCA
GCACCA 
GCGGCGCGTGCAC
GTGGCCG 
EML4-
ALK 
Tr
an
sl
oc
at
io
n 
Primer3 
F:Chr2:29447
613-29447634 
(ALK) 196 CCTATTATCCTGTCCCTTTGAG 
GGATAAACAGAAAG
GACGGAAGAC R:Chr2:42497
966-42497989 
(EML4) 
Manual 
F:Chr2:29447
656-29447675 
(ALK) 
105 CAGTGTGTGCTGCCATCTCC 
CTTAATTCTAAAAC
CTATGT R:Chr2:42498
016-42498035 
(EML4) 
Table 3 Primer designs (Illumina) 
Chosen variants in L019 and primer sequences designed manually and using Primer3.  
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2.12.4  Multiplex PCR and targeted HiSeq sequencing 
In collaboration with Natera (Robert Pelham, San Carlos, CA, USA), the presence of 
mutations in cfDNA was analysed using a combined multiplex PCR and NGS (HiSeq 
sequencing) approach.  
 
2.12.4.1  Assay design, sequencing library preparation, and PCR amplification 
Previously extracted cfDNA was quantified using the Universal SYBR Green 
Quantitative PCR protocol (Sigma-Aldrich), according to the manufacturer’s 
instructions. DNA sequencing libraries for germ line and tumour DNA, cfDNA from 
each patient, and cfDNA from negative control samples from healthy individuals (non-
pregnant females) were prepared by blunt end repair, ligation with standard 
sequencing adaptors, and library amplification using 50X Advantage® 2 Polymerase 
Mix (Clontech Laboratories, Inc.) in a volume of 40µl. Adaptor-ligated templates were 
purified using Agencourt AMPure SPRI beads (Beckman Coulter) eluted in 50µl 
volume. PCR primers were designed using the Primer3 software package (Untergasser 
et al. 2012). Interacting primers were estimated in silico and placed in separate 
amplification pools. Table 4 summarises the chosen variants and multiplex primer 
designs. Multiplex PCR-NGS was performed with 2 assay pools. PCR was performed 
using AmpliTaq Gold® (Life Technologies), 25nM of each primer, and 6µl purified 
library in a 20µl reaction volume. The multiplex PCR product was diluted 1:10 and 1µl 
of the diluted PCR product was used as a template for sample bar-coding (BC-PCR), 
using Q5® High-Fidelity 1X PCR master mix (New England BioLabs), up to 96 sample 
barcodes, and 1µM forward and reverse primers in a 10µl total volume. For each of the 
two primer pools, the BC-PCR products were pooled (8µl of each library product and 
2µl of each DNA product) and purified. The pool was quantified with Qubit® dsDNA HS 
assay kit (Life Technologies).   
 
2.12.4.2  Targeted sequencing using the HiSeq 2500 platform and statistical 
analysis 
Sequencing libraries were sequenced using a HiSeq 2500 (Illumina, San Diego, CA) 
with a paired end 50bp read length. For the cfDNA samples, sequencing resulted in a 
median depth of read of 62,399x per target and a median depth of read of 62,335x per 
call. Reads were aligned to the human genome (hg19) using BWA-mem v0.7.10 
aligner (Li & Durbin 2009). Bases observed across reads were piled and counted with 
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SAMtools mpileup (Li et al. 2009). Target assays with < 100 reads in the tumour or < 
10,000 reads in the plasma samples were tagged as failed assays and were not 
analysed further. A background error model was constructed using negative-control 
cfDNA samples from healthy individuals. These negative control samples were 
sequenced in the same sequencing run as positive test samples to account for run-
specific artefacts. Noisy positions with a normal median VAF > 0.5% were removed. 
Outlier samples were iteratively removed from the model to account for noise and 
contamination. For each base substitution at every genomic locus, the depth of read 
weighted mean and standard deviation of the error were calculated. In matched tumour 
and cfDNA, variant calls with at least 5 variant reads, a z-score of 10 and a confidence 
of 99.9% (using a Bayesian likelihood fit that involved parameter estimation from the 
control samples) against the background error model were called as a candidate 
mutation. 
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Pt Gene Type Genomic coordinates 
Primer sequences 
Forward Reverse 
L012 
BRIP1 SNV chr17:59924572 
ACACGACGCTCTTCCGATC
TAATTGTGTACTTCTGTTCC
AAAGC 
AGACGTGTGCTCTTCCGA
TCTCCTTAAACTTCATTTT
GGTTCTGTGT 
CARS SNV chr11:3062181 
ACACGACGCTCTTCCGATC
TGTTGGCCCACAGCAATAC
C 
AGACGTGTGCTCTTCCGA
TCTGTGTTCATACCTCAA
GATGGGAAAAA 
CDKN2A SNV chr9:21971177 ACACGACGCTCTTCCGATCTGGCAGCGCCCGAGTG 
AGACGTGTGCTCTTCCGA
TCTCGCCGTGGAGCAGC
A 
CIC SNV chr19:42797381 ACACGACGCTCTTCCGATCTCACGGCCCGGAGCAG 
AGACGTGTGCTCTTCCGA
TCTGCTCCTCAGCAGGT
GGG 
FAT1 SNV chr4:187519147 
ACACGACGCTCTTCCGATC
TACAACGGAGGCTTTGTTT
GC 
AGACGTGTGCTCTTCCGA
TCTAAATACACATACCTC
TGACCAGTATATAA 
KDM6A SNV chrX:44921898 
ACACGACGCTCTTCCGATC
TACTATATTCTCTTTTTGTTC
TTCTTCTAGCA 
AGACGTGTGCTCTTCCGA
TCTGGATTTAAATTATTTC
TATTTGCGCGGAG 
LEMD2 SNV chr6:33756755 ACACGACGCTCTTCCGATCTGCCTCCTCCCGCAGC 
AGACGTGTGCTCTTCCGA
TCTAAGCTGCGCCGCCT
G 
MLLT4 SNV chr6:168347475 ACACGACGCTCTTCCGATCTCCCAAGGCAGCTGAGGAC 
AGACGTGTGCTCTTCCGA
TCTATAATAATTCAACTCA
AAATGGGTCTCC 
NBEAL2 SNV chr3:47044229 ACACGACGCTCTTCCGATCTGGCAACGCAGCACTCCA 
AGACGTGTGCTCTTCCGA
TCTCGAGCTGGCGCCAC
AG 
NFE2L2 SNV chr2:178098801 
ACACGACGCTCTTCCGATC
TGGCTGGCTGAATTGGGAG
A 
AGACGTGTGCTCTTCCGA
TCTTTTCGCTCAGTTACA
ACTAGATGAA 
RASA1 SNV chr5:86642517 
ACACGACGCTCTTCCGATC
TAAGATGGTTCCATGGGAA
GATTTC 
AGACGTGTGCTCTTCCGA
TCTAGCAAGTAAATATGT
AAGTACCTGTCAT 
TLX1 SNV chr10:102891574 ACACGACGCTCTTCCGATCTAGGAGCCGGTCAGAGGA 
AGACGTGTGCTCTTCCGA
TCTGAGGTCCCGGCGGC
C 
TP53 SNV chr17:7578406 ACACGACGCTCTTCCGATCTAGCAGCGCTCATGGTGG 
AGACGTGTGCTCTTCCGA
TCTACATGACGGAGGTTG
TGAGG 
TP53 SNV chr17:7578190 
ACACGACGCTCTTCCGATC
TACATAGTGTGGTGGTGCC
C 
AGACGTGTGCTCTTCCGA
TCTGCAAACCAGACCTCA
GGCG 
CELSR3 SNV chr3:48698933 ACACGACGCTCTTCCGATCTCGGATAAGGCCGCTCTGC 
AGACGTGTGCTCTTCCGA
TCTCGCTGGAGCTGTTCA
GCAT 
L013 
EGFR SNV chr7:55241708 ACACGACGCTCTTCCGATCTTGCCGAACGCACCGG 
AGACGTGTGCTCTTCCGA
TCTGGAAACTGAATTCAA
AAAGATCAAAGTG 
EGFR SNV chr7:55242511 
ACACGACGCTCTTCCGATC
TCACAGCAAAGCAGAAACT
CACA 
AGACGTGTGCTCTTCCGA
TCTATCTCCGAAAGCCAA
CAAGGAA 
FBXO46 SNV chr19:46216357 ACACGACGCTCTTCCGATCTGGGTCAAGACAGCGCCTC 
AGACGTGTGCTCTTCCGA
TCTGCACTGGGGCAGCG
ATAG 
HERC4 SNV chr10:69793756 
ACACGACGCTCTTCCGATC
TCTATCTTTGGATGGGGAC
GCA 
AGACGTGTGCTCTTCCGA
TCTTTCATCATTAAGACC
TAGCTGACCAA 
JAK2 SNV chr9:5022084 
ACACGACGCTCTTCCGATC
TCACCTGAAGAACTGGATC
TATTTGC 
AGACGTGTGCTCTTCCGA
TCTTGGTGATATTTCTGG
AAATGCCA 
KMT2C SNV chr7:151947008 
ACACGACGCTCTTCCGATC
TAGTCCACACTGAAGAGCA
ACA 
AGACGTGTGCTCTTCCGA
TCTGTGTCAAGACTTTCT
GAGGGATGA 
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MSH2 SNV chr2:47693816 ACACGACGCTCTTCCGATCTGGCTTGGACCCTGGCAA 
AGACGTGTGCTCTTCCGA
TCTCCAAACTGTGCACTG
GAATCC 
MTOR SNV chr1:11292495 
ACACGACGCTCTTCCGATC
TGGATTCCTCTTTGTTGGCC
AAAA 
AGACGTGTGCTCTTCCGA
TCTGCTCAATCAGGAAGC
AGTAATACTC 
PLCG2 SNV chr16:81942036 
ACACGACGCTCTTCCGATC
TGGCCCAGGATATACCCCC
T 
AGACGTGTGCTCTTCCGA
TCTTGTGGAACCATTTCT
CCCCAA 
TP53 SNV chr17:7579509 
ACACGACGCTCTTCCGATC
TCTGGCATTCTGGGAGCTT
CA 
AGACGTGTGCTCTTCCGA
TCTATGGTTCACTGAAGA
CCCAGG 
AGAP2 SNV chr12:58131938 ACACGACGCTCTTCCGATCTGCTCGAGTCGGTGCCTC 
AGACGTGTGCTCTTCCGA
TCTCAGTCTCGGAGCCTC
TGG 
L015 
ALK SNV chr2:29940530 
ACACGACGCTCTTCCGATC
TTTCCATGTAAAATAATCAG
GAGAAGGA 
AGACGTGTGCTCTTCCGA
TCTAGGTCATAGCTCCTT
GGAATCAC 
ATHL1 SNV chr11:290854 ACACGACGCTCTTCCGATCTGCAGCTGCAGGGCCT 
AGACGTGTGCTCTTCCGA
TCTCCAGGCTGAGGCTC
AGG 
CD8B SNV chr2:87088972 ACACGACGCTCTTCCGATCTTGCGCGGCCAAGAGG 
AGACGTGTGCTCTTCCGA
TCTCGGGGCCAGGTGTC
C 
FOXK1 SNV chr7:4799190 ACACGACGCTCTTCCGATCTGGGGCTCCCATGATGCG 
AGACGTGTGCTCTTCCGA
TCTCCCAGGTCCAGCAC
GG 
GABRG1 SNV chr4:46060315 
ACACGACGCTCTTCCGATC
TGAAAGAACAACTGTCAGA
ATGCATG 
AGACGTGTGCTCTTCCGA
TCTGACCTGAGCAGAAG
AATGGGATAT 
KDM6A SNV chrX:44922755 ACACGACGCTCTTCCGATCTGCTGTGGCTGCTGGC 
AGACGTGTGCTCTTCCGA
TCTCTCATCACTGCCTAC
AAACTCAG 
MLL2 SNV chr12:49443815 ACACGACGCTCTTCCGATCTCCGGTGCACGTGGCT 
AGACGTGTGCTCTTCCGA
TCTCAGGGCTCACCATGT
GAAGAA 
RHOXF1 SNV chrX:119249598 ACACGACGCTCTTCCGATCTGCGGTGTGAACCACGAGA 
AGACGTGTGCTCTTCCGA
TCTGATCATGCCGCCATC
GC 
ROS1 SNV chr6:117687379 
ACACGACGCTCTTCCGATC
TGATCCAGAACAGCCGACC
A 
AGACGTGTGCTCTTCCGA
TCTATTTCCCAGAATGCA
CTGATGTAC 
SLC39A4 SNV chr8:145638322 ACACGACGCTCTTCCGATCTCAGCCCCGCGTGCAG 
AGACGTGTGCTCTTCCGA
TCTGTGGACTCGCCCGC
A 
TP53 SNV chr17:7578254 
ACACGACGCTCTTCCGATC
TCCTCAGCATCTTATCCGAG
TGG 
AGACGTGTGCTCTTCCGA
TCTCATCCAAATACTCCA
CACGCAAA 
ZFHX4 SNV chr8:77776735 
ACACGACGCTCTTCCGATC
TCCATCTAGGCCAGAAGCA
GG 
AGACGTGTGCTCTTCCGA
TCTGCTAGAAGACTTAGA
TAATTCTTTGGAAGT 
ZMYM4 SNV chr1:35827319 
ACACGACGCTCTTCCGATC
TTGGTGCCATTGCTTTGTCA
TAC 
AGACGTGTGCTCTTCCGA
TCTTCAAATATTAGAATTA
AAGAAGAACCTTTGGA 
BRCA2 SNV chr13:32914959 
ACACGACGCTCTTCCGATC
TACCAACTGTTGTTTGTCTT
GTTG 
AGACGTGTGCTCTTCCGA
TCTCAGAAAATAATCACT
CTATTAAAGTTTCTCCA 
L017 
EIF2AK1 SNV chr7:6098705 ACACGACGCTCTTCCGATCTGCCGGCGATGCAGGG 
AGACGTGTGCTCTTCCGA
TCTGCGCTTGCGGACCC
C 
KRAS SNV chr12:25398284 
ACACGACGCTCTTCCGATC
TGAATATAAACTTGTGGTAG
TTGGAGCT 
AGACGTGTGCTCTTCCGA
TCTGCTGTATCGTCAAGG
CACTCT 
NF1 SNV chr17:29653134 
ACACGACGCTCTTCCGATC
TGTGCTCAGCCAGTTTCCC
A 
AGACGTGTGCTCTTCCGA
TCTGCCTCAAAGGTAGCA
AAAGGC 
NF1 SNV chr17:29528088 
ACACGACGCTCTTCCGATC
TCCACATCTGCAGGCTGAC
T 
AGACGTGTGCTCTTCCGA
TCTCCTGCTTTTTAATCC
AAGTAAGCCA 
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PAX8 SNV chr2:113984793 ACACGACGCTCTTCCGATCTGCTGCCCGGATACCCAC 
AGACGTGTGCTCTTCCGA
TCTGCCCTGTCCGCTGG
TG 
TP53 SNV chr17:7577079 ACACGACGCTCTTCCGATCTACCGGCGCACAGAGGA 
AGACGTGTGCTCTTCCGA
TCTCTCCCCTTTCTTGCG
GAGAT 
TP53 SNV chr17:7577610 
ACACGACGCTCTTCCGATC
TTGGTGGTACAGTCAGAGC
CA 
AGACGTGTGCTCTTCCGA
TCTATCTTGGGCCTGTGT
TATCTCC 
TRIM67 SNV chr1:231299607 ACACGACGCTCTTCCGATCTGACTGGGGGCAGCACG 
AGACGTGTGCTCTTCCGA
TCTGGGACACGTGGGGA
ACTTG 
TRIP11 SNV chr14:92471631 
ACACGACGCTCTTCCGATC
TCCTTGATAGTGTTACTGAA
CTAGCATC 
AGACGTGTGCTCTTCCGA
TCTTGTTCCTTGATCGTG
TTCAGTTG 
Table 4 Primer designs (Natera)  
Genomic coordinates, forward and reverse primer sequences for each mutation. 
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2.13  Fluorescence in situ hybridisation 
2.13.1 Sample preparation and centromeric probe hybridisation 
The SPOT-Light® Tissue Pretreatment kit (Invitrogen) was used for enzyme and heat 
pretreatment of FFPE slides prior to hybridisation. Each TMA slide was placed in a dry 
oven at 55˚C for 1 hour, after which it was deparaffinised twice using fresh xylene in a 
coplin jar for 5 minutes each time. Each slide was then rehydrated twice in 100% 
ethanol for 3 minutes. 250µl of 100% ethanol was added to each slide under a 
22x50mm coverslip and placed on a heat block at 98˚C until the ethanol had 
evaporated. Each slide was then washed twice using distilled water in a coplin jar on a 
shaker for 3 minutes. 40ml of SPOT-Light Tissue Pretreatment solution (reagent 1) pre-
heated to 98-100˚C was added to each slide and kept at 98-100oC for 15 minutes in a 
water bath. The slides were then washed twice with distilled water in a coplin jar on a 
shaker for 3 minutes. 60µl of the digestion enzyme (reagent 2) was added to each slide 
at room temperature (RT), and a 22x50mm coverslip placed on top. This was 
incubated at RT for 5 minutes prior to washing twice with distilled water in a coplin jar 
for 3 minutes.  
 
In order to capture underlying numerical CIN, rather than structural CIN resulting from 
intra-chromosomal rearrangements, chromosomes 2 and 15 were chosen based on a 
previous discovery cohort in our laboratory (Roylance et al. 2011), whereby infrequent 
copy number alterations were seen for these chromosomes in a series of breast 
tumours analysed by 1 Mb array comparative genomic hybridisation (aCGH). Dual 
colour FISH was carried out using centromeric probes CEP2 (D2Z1, Abbott Molecular) 
and CEP15 (D15Z1, Abbott Molecular) labelled with spectrum red and green, 
respectively. A solution of 1.5µl for each centromeric probe was mixed and diluted to 
give a final volume of 10µl per slide and placed on wet ice. 10µl of this mixture was 
placed on a 22x22mm coverslip, the slides were placed on the coverslip such that the 
mixture covered the TMA directly, and then the coverslip was sealed to the slide with 
rubber solution. This was placed on a heat block at 80˚C for 10 minutes. The slides 
were then placed inside a wet chamber and incubated overnight at 37˚C. The following 
day they were removed from the incubator, the rubber seal broken and the coverslip 
taken off. Each slide was placed inside a coplin jar containing a solution of 0.5X saline-
sodium citrate (SCC) at 37˚C for 5 minutes, and then washed three times with 100ml of 
phosphate-buffered saline (PBSA) solution in a coplin jar on the shaker at RT. After 
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washing, 2-3 drops of ProLong® Gold antifade mounting media (Life technologies, 
1:10,000 dilution) was added to a 22x50mm coverslip, each slide was placed on top of 
this to cover the TMA, and then stored at 4˚C.   
 
2.13.2 Scoring of centromere signals 
Slides were scanned on the Applied Imaging Ariol System (Applied Imaging), and 
images were captured using a 40x objective with seven 0.5mm z-stacks. Depending on 
the TACT study site, each TMA slide contained between 100-200 tissue cores. Each 
core was magnified so that forty nuclei per core with clear and discrete hybridisation 
signals for both chromosomes were chosen and scored manually (Figure 14). The 
number of centromeres in each nucleus for each chromosome was counted and 
recorded on scoring sheets.  
 
Figure 14 TMA slide from the TACT cohort 
A single tumour core from a TACT TMA slide (A), and magnified nuclei from within a core with 
discrete CEP2 and CEP15 centromere signals (B).  
 
2.14  Defining the MCD group 
2.14.1 Calculating the CIN score 
Using previously established methods (Roylance et al. 2011), a CIN score was derived 
by counting the numbers of centromeres for chromosomes 2 and 15 in 40 nuclei per 
core. The mean (counts for chromosomes 2 and 15 combined) percentage of cells 
deviating from the modal centromere number was used to define 4 CIN score groups 
A B
CEP2
CEP15
DAPI
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(Modal Centromere Deviation groups 1 to 4: MCD1, 0%–15%; MCD2, 15%–30%; 
MCD3 30%–45%; and MCD4, >45%). The MCD4 cohort was classified as having an 
MCD score greater than 45%, in keeping with the definition for "unstable aneuploidy" 
previously used in an analysis of 20 breast tumours (Lingle et al. 2002). To avoid false 
classification of CIN due to sectioning artefacts, and to control for bimodality in diploid 
tumours, all centromere counts equal to 1 were removed in deriving the CIN score.  
2.15  Calculating the Shannon Diversity Index (SDI) 
To confirm the validity of the MCD score approach in identifying tumours with the most 
extreme CIN, the MCD score was compared with the Shannon Diversity Index (SDI) 
(Maley et al. 2006), a measure of clonal heterogeneity, where centromere counts equal 
to 1 were included. The SDI was estimated for chromosomes 2 and 15 using the 
following formula: 𝐻 =   − 𝑝!ln  (𝑝!)!  
where pi is the frequency of the centromere number i. 
2.16   CIN and clinical outcome statistical analysis 
Blinded outcome data were analysed at the Institute of Cancer Research Clinical Trials 
and Statistics Unit, which was responsible for the TACT trial management and data 
analysis. The primary clinical endpoint was invasive disease-free survival as previously 
reported (Ellis et al. 2009). Patients who were alive and disease-free at the last follow-
up were censored. Correlation between patient characteristics and biomarkers was 
examined using Spearman’s rank correlation coefficient. For survival-related endpoints, 
Kaplan-Meier product limit curves were plotted and prognostic and predictive effects 
examined by use of Cox proportional hazards regression models. Time-to-event 
analyses were stratified by the control regimen and included all patients with available 
biomarker data on an intention-to-treat basis. With 382 events a hazard ratio (HR) of 
1.4 would be detectable with approximately 85% power, and a two-sided 5% 
significance level would be achieved if patients were allocated into two approximately 
equal sized groups on the basis of biomarker values. A p-value of 0.05 was used to 
define statistical significance, but confidence intervals were also considered relevant. 
In order to define the relationship between MCD group and prognosis, the more 
sensitive method of calculating the value for p trend was used, which assesses 
whether a statistically significant tendency for trend in the HR exists as MCD group 
increases from 1 to 4 in a multivariate analysis (Peto et al. 1977). 
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3 Results 1: Intratumour heterogeneity in patients with 
NSCLC 
3.1 Introduction 
The NSCLC pilot (UCLHRTB 10/H1306/42) and TRACERx (13/LO/1546, 
NCT01888601) cohort consisted of patients with primary NSCLC eligible for curative 
surgical resection (stages IA to IIIA). Multiple tumour regions were collected from each 
primary tumour for whole-exome sequencing (WES) using DNA extracted from each 
tumour region. WES was also performed on whole blood for the germ line reference. 
Where possible, lymph node samples were also sequenced. All the variants identified 
by WES were manually reviewed, and subsequently validated in a subset of patients 
using Ion AmpliSeq sequencing at a mean sequencing depth of 1369x, and an overall 
validation rate of > 90% for SNVs and indels. In the NSCLC pilot cohort, variants 
identified in tumours were validated by Ion AmpliSeq sequencing, except for tumours 
L022 and L023. In the TRACERx cohort, tumours were not validated, but instead 
variants were filtered using thresholds derived from the NSCLC pilot cohort proven to 
confidently predict the presence or absence of a mutation in a given tumour region. As 
previously described (Section 2.5.2), variants that were filtered met the following 
criteria: 
 
• A variant allele frequency (VAF) ≥ 5% in at least one tumour region 
• A minimum variant count ≥ 5 reads in at least one tumour region 
• A germ line VAF < 0.01 
• Not detected in a pre-defined artefact blacklist region of the human genome 
 
A variant was considered to be present in a tumour region provided the VAF was ≥ 1%. 
In addition, variants were further filtered using a somatic p-value of ≤ 0.01, which was 
derived based on the variants that had been manually reviewed and validated using 
high-depth Ion AmpliSeq sequencing. Ubiquitous (truncal) variants were those present 
in all tumour regions, and heterogeneous (branch) mutations were those present in one 
or several, but not all, tumour regions.  
 
Work from our laboratory has previously shown extensive intratumour heterogeneity, in 
terms of mutations and copy number alterations, in a small cohort of 7 NSCLC patients 
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(de Bruin et al. 2014). Multi-region WES demonstrated branched tumour evolution with 
predicted drivers of disease occurring both early and late in tumour evolution. In this 
chapter, the genomic landscape of NSCLC is investigated in a larger cohort of 27 
patients, including adenocarcinoma and squamous cell carcinoma histological 
subtypes with greater power to infer subclonal mutational events. In each tumour, the 
spatial heterogeneity of mutations, mutational signatures, and somatic copy number 
aberrations are assessed. In addition, there are three cases in which paired primary 
and metastatic tumours, have been sequenced. The bioinformatics pipeline was 
developed by Gareth Wilson and Richard Mitter (The Francis Crick Institute).  
 
3.1.1 Baseline characteristics and histopathological variables 
Table 5 and Table 6 show the baseline characteristics of the patients in the NSCLC 
pilot and TRACERx cohort. All patients had either lung adenocarcinoma (LUAD) or 
squamous cell carcinoma (LUSC), and were eligible for curative surgical resection at 
diagnosis (stage IA-IIIA). The number of smoking pack-years was calculated by 
multiplying the number of cigarette packs smoked per day by the total number of years 
smoked. Median values are given since the clinical variables were not normally 
distributed. In the combined cohort of 27 patients, the median age was 67-years (range 
47-79 years), 13/27 (48%) were female, 14/28 (52%) were male, 12/27 (44%) had 
LUAD, 15/27 (58%) had LUSC, 14/27 (52%) were current smokers, 10/27 (37%) were 
ex-smokers, and 3/27 (11%) were never-smokers. A detailed smoking history was 
taken from each patient, with regards to the number of smoking pack-years, and how 
long before surgery they had stopped smoking in the case of ex-smokers. The 
distribution of tumour stage was 6/27 (22%) for stage IA, 5/27 (19%) for stage IIA, 4/27 
(15%) for stage IIIA, 9/27 (33%) for stage IB, and 3/27 (11%) for stage IIB. There was 
evidence of lymph node involvement in 5/27 (19%) of the patients, two of whom 
subsequently developed recurrent disease. The median tumour size was 30mm (range 
10-67mm). In the pilot NSCLC cohort, in addition to the primary tumours, metastatic 
tumours were sequenced in patients L011, L017 and L023. These cases are discussed 
separately in Sections 3.5.1, 3.5.2, and 3.5.3.  
 
3.1.2 Recurrence and clinical outcome  
Patients were followed-up after surgery for evidence of disease recurrence. Follow-up 
data were collected up to June 2015. Four out of twenty-seven patients (15%) 
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developed recurrent disease during the follow-up period. Four patients (15%) died 
during the follow-up period, three of whom died as a result of disease progression. 
Patient LTX030 was diagnosed with brain metastases 4 months after surgery. Given 
the short time to recurrence, it is likely that this patient had occult metastatic disease at 
diagnosis, which was not detected since imaging of the brain was not clinically 
indicated at the time. Table 7 and Table 8 show the clinical outcome data, in terms of 
recurrence and survival, for the NSCLC pilot and TRACERx cohort.  
 
Pt Age Gender 
Smoking 
status 
(pack-
years) 
Smoking 
stopped 
(years) 
Histo Stage 
Tumour 
location/
max 
diameter 
(mm) 
Lymph 
node 
involve-
ment 
L011 49 F Smoker (45)  LUAD IB LUL/55 No 
L012 69 F Smoker (40)  LUSC IB RLL/40 No 
L013 68 F Smoker (50)  LUSC IB RLLL/50 No 
L015 68 M Smoker (100)  LUSC IA LUL/30 No 
L016 65 M Smoker (40)  LUSC IIIA RLL/27 No 
L017 61 F Smoker (48)  LUAD IIB 
RUL/14 
and 
RUL/20 
No 
L019 47 M Never  LUAD IIIA LUL/25 Yes 
L022 54 M Smoker (35)  LUAD IIIA RUL/32 Yes 
L023 50 F Smoker (60)  LUAD IIIA 
RUL/10 
and 
RML/25 
No 
L029 66 F Ex-smoker (40) 2 LUAD IA LLL/15 No 
L030 79 F Ex-smoker (40) 10 LUAD IA LLL/24 No 
Table 5 Baseline characteristics of the NSCLC pilot cohort 
Baseline patient and tumour characteristics of the NSCLC pilot cohort. Abbreviations: Pt, 
patient; Histo, histology; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; 
RUL, right upper lobe; RLL, right lower lobe; LUL, left upper lobe; and LLL, left lower lobe. 
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Pt Age Gender 
Smoking 
status 
(pack-
years) 
Smoking 
stopped 
(years) 
Histo Stage 
Tumour 
location/
max 
diameter 
(mm) 
Lymph 
node 
involve
-ment 
LTX001 68 F 
Ex-
Smoker 
(35) 
20 LUAD IB RUL/26 No 
LTX012 65 M 
Ex-
Smoker 
(35) 
16 LUSC IIA RUL/35 Yes 
LTX015 64 M Smoker (51)  LUSC IB RLL/32 No 
LTX016 67 M 
Ex-
Smoker 
(20) 
15 LUSC IIB RLL/66 No 
LTX019 65 M Smoker (50)  LUSC IIA RML/50 Yes 
LTX022 72 M Smoker (50)  LUSC IIA LUL/30 No 
LTX028 66 M 
Ex-
Smoker 
(40) 
3 LUSC IIA RLL/55 No 
LTX029 78 F 
Ex-
smoker 
(40) 
28 LUAD IB RUL/22 No 
LTX030 76 M Smoker (50) 1 LUSC IIA RUL/45 Yes 
LTX031 50 F Smoker (30)  LUSC IA RUL/15 No 
LTX033 73 M 
Ex-
Smoker 
(50) 
10 LUSC IB RLL/35 No 
LTX034 73 F Never  LUAD IA RLL/30 No 
LTX036 68 M Smoker (30)  LUAD IB RUL/25 No 
LTX038 76 M 
Ex-
Smoker 
(30) 
26 LUSC IIB RUL/67 No 
LTX051 67 F Never  LUAD IA RUL/26 No 
LTX058 73 F 
Ex-
Smoker 
(45) 
13 LUSC IB RUL/44 No 
Table 6 Baseline characteristics of the TRACERx cohort 
Baseline patient and tumour characteristics of the TRACERx cohort. Abbreviations: Pt, patient, 
Histo, histology; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; RUL, right 
upper lobe; RLL, right lower lobe; LUL, left upper lobe; and LLL, left lower lobe. 
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Table 7 Clinical outcome in the NSCLC pilot cohort 
For each patient, if applicable, the site of recurrence and time to recurrence is shown. The 
current status and the overall survival from the date of surgery are shown. In patients who died, 
whether the cause of death was cancer-related is noted.  
 
 
Patient Recurrence (months) Current status Cancer-related death? 
Survival 
(months) 
LTX001 No Alive 
 
15 
LTX012 No Alive 
 
12 
LTX015 No Alive 
 
11 
LTX016 No Alive 
 
11 
LTX019 No Alive 
 
12 
LTX022 No Alive 
 
11 
LTX028 No Alive 
 
10 
LTX029 No Alive 
 
10 
LTX030 Yes - brain (4) Dead Yes 4 
LTX031 No Alive 
 
11 
LTX033 No Alive 
 
11 
LTX034 No Alive 
 
11 
LTX036 No Alive 
 
11 
LTX039 No Alive 
 
10 
LTX051 No Alive 
 
9 
LTX058 No Alive 
 
9 
Table 8 Clinical outcome in the TRACERx cohort 
For each patient, if applicable, the site of recurrence and time to recurrence is shown. The 
current status and the overall survival from the date of surgery are shown. In patients who died, 
whether the cause of death was cancer-related is noted.  
 
Patient    Recurrence (months)    Current status     Cancer-related death? 
Survival  
(months) 
L011 Yes - brain (14) Dead Yes 19 
L012 No Dead No 2 
L013 No Alive 
 
33 
L015 No Alive 
 
36 
L016 No Alive 
 
35 
L017 Yes - lung (4) Alive 
 
35 
L019 Yes - liver (8) Dead Yes 15 
L022 No Alive 
 
34 
L023 No Alive 
 
33 
L029 No Alive 
 
29 
L030 No Alive 
 
29 
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3.2 Regional distribution of mutations and phylogenetic trees 
Heat maps representing the regional distribution of non-silent SNVs and indels in 
tumours were created for the NSCLC pilot cohort as shown in Figure 16 and Figure 17, 
and for the TRACERx cohort as shown in Figure 18 and Figure 19. Where available, 
validated non-synonymous mutations were used to create the heat maps, and 
otherwise filtered non-synonymous mutations were used based on thresholds proven 
to confidently predict the presence or absence of a mutation, as previously described. 
In the NSCLC pilot cohort, phylogenetic trees were created using validated non-
synonymous SNV and indel mutations. In the TRACERx cohort, they were created 
using filtered non-synonymous and synonymous SNV and indel mutations. Consistent 
with previous findings from our laboratory (de Bruin et al. 2014), intratumour 
heterogeneity was evident in all tumours, regardless of smoking status, tumour stage 
or histological subtype. Certain mutations were present in all tumour regions (shared, 
truncal), certain mutations were present in some, but not all, tumour regions (shared, 
branch), and certain mutations were present in one tumour region only (private, 
branch). This degree of heterogeneity in the spatial distribution of mutations is shown 
in the heat map for each tumour (Figure 16 to Figure 19). Using this regional 
distribution, the temporal heterogeneity of each tumour was represented by 
phylogenetic trees demonstrating branched tumour evolution, with mutations present 
on the blue trunks of the trees occurring prior to tumour initiation or early in tumour 
evolution, and mutations present on the yellow and red branches of the trees occurring 
later in tumour evolution (Figure 16 to Figure 19). These heat maps and trees depict 
the extent of spatial and temporal heterogeneity in these tumours, and demonstrate the 
variation in heterogeneity from one tumour to another. Tumours from patients who had 
never smoked often had shorter trunks compared to tumours from patients who were 
either current or ex-smokers (p = 0.24, Figure 15A). This was most likely related to the 
high mutational burden associated with smoking-related NSCLC (Hammerman et al. 
2012; Govindan et al. 2012; Lawrence et al. 2013), supported by the fact that the 
proportion of C>A transversions (Pfeifer & Hainaut 2003), which have been shown to 
be associated with a history of smoking, was greater in the trunks of patients who were 
current smokers compared to patients who were either ex-smokers or had never 
smoked before (p = 0.064, Figure 15B).  
 
Robust and accurate measures of intratumour heterogeneity are yet to be determined, 
but one potential measure developed in our laboratory is the pairwise intratumor 
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heterogeneity index. This was calculated by determining the mean proportion of 
heterogeneous (branch) mutations relative to the total number of mutations for each 
possible pairwise comparison of all tumour regions. However, including ubiquitous 
(truncal) mutations can introduce a bias against tumours that arise in the context of 
smoking, since these tumours will generally have a greater number of somatic 
mutations associated with exposure to tobacco smoke (Pfeifer & Hainaut 2003), and 
therefore a greater number of truncal mutations. One alternative is to calculate the 
index in the absence of the truncal mutations, such that the relative lengths of the 
branches are determined indicating the degree of evolution that has taken place after 
clonal diversification (branching of the tree). This was calculated as the mean of the 
branch length for each pairing of tumour regions, divided by the sequencing depth after 
it had been adjusted for tumour purity. This measure was used to calculate an 
intratumour heterogeneity index for each tumour.  
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Figure 15 Phylogenetic tree trunk length and smoking status 
The trunk length of phylogenetic trees in the NSCLC pilot and TRACERx cohort (A), and the 
relative ratio of C>A transversions in the trunk compared to branch mutations, associated with 
tobacco smoke exposure (B). 
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Figure 16 Heat maps and phylogenetic trees in LUADs from the NSCLC pilot 
cohort 
Heat maps representing the regional distribution of mutations, where the presence of a mutation is 
indicated by blue and its absence by grey. Alongside each heat map is a vertical bar, where blue 
represents mutations that are present in all regions (truncal), yellow represents mutations that are present 
in some, but not all, regions (shared, branch), and red represents mutations that are present in one region 
only (private, branch). Underneath each heat map is the total number of non-synonymous mutations, the 
stage of the tumour, the intratumour heterogeneity index, the number of smoking pack-years, and how 
many years ago smoking was stopped (for ex-smokers). Phylogenetic trees annotated by genes 
representing predicted driver category 1 to 3 mutations, with arrows pointing towards the part of the tree 
on which they have been acquired. Ubiquitous mutations (present in all tumour regions) are shown on the 
blue trunks of trees, shared mutations (present in some, but not all, tumour regions) are shown on the 
yellow branches of trees, and private mutations (present in only one tumour region) are shown on the red 
branches of trees.  
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Figure 17 Heat maps and phylogenetic trees in LUSCs from the NSCLC pilot 
cohort 
Heat maps representing the regional distribution of mutations, where the presence of a mutation is 
indicated by blue and its absence by grey. Alongside each heat map is a vertical bar, where blue 
represents mutations that are present in all regions (truncal), yellow represents mutations that are present 
in some, but not all, regions (shared, branch), and red represents mutations that are present in one region 
only (private, branch). Underneath each heat map is the total number of non-synonymous mutations, the 
stage of the tumour, the intratumour heterogeneity index, the number of smoking pack-years, and how 
many years ago smoking was stopped (for ex-smokers). Phylogenetic trees annotated by genes 
representing predicted driver category 1 to 3 mutations, with arrows pointing towards the part of the tree 
on which they have been acquired. Ubiquitous mutations (present in all tumour regions) are shown on the 
blue trunks of trees, shared mutations (present in some, but not all, tumour regions) are shown on the 
yellow branches of trees, and private mutations (present in only one tumour region) are shown on the red 
branches of trees.  
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Figure 18 Heat maps and phylogenetic trees in LUADs from the TRACERx cohort 
Heat maps representing the regional distribution of mutations, where the presence of a mutation is 
indicated by blue and its absence by grey. Alongside each heat map is a vertical bar, where blue 
represents mutations that are present in all regions (truncal), yellow represents mutations that are present 
in some, but not all, regions (shared, branch), and red represents mutations that are present in one region 
only (private, branch). Underneath each heat map is the total number of non-synonymous mutations, the 
stage of the tumour, the intratumour heterogeneity index, the number of smoking pack-years, and how 
many years ago smoking was stopped (for ex-smokers). Phylogenetic trees annotated by genes 
representing predicted driver category 1 to 3 mutations, with arrows pointing towards the part of the tree 
on which they have been acquired. Ubiquitous mutations (present in all tumour regions) are shown on the 
blue trunks of trees, shared mutations (present in some, but not all, tumour regions) are shown on the 
yellow branches of trees, and private mutations (present in only one tumour region) are shown on the red 
branches of trees. Underneath each tree is the total number of filtered non-synonymous and synonymous 
mutations.  
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Figure 19 Heat maps and phylogenetic trees in LUSCs from the TRACERx cohort 
Heat maps representing the regional distribution of mutations, where the presence of a mutation is 
indicated by blue and its absence by grey, in ex-smokers (A) and current smokers (B). Alongside each 
heat map is a vertical bar, where blue represents mutations that are present in all regions (truncal), yellow 
represents mutations that are present in some, but not all, regions (shared, branch), and red represents 
mutations that are present in one region only (private, branch). Underneath each heat map is the total 
number of non-synonymous mutations, the stage of the tumour, the intratumour heterogeneity index, the 
number of smoking pack-years, and how many years ago smoking was stopped (for ex-smokers). 
Phylogenetic trees annotated by genes representing predicted driver category 1 to 3 mutations, with 
arrows pointing towards the part of the tree on which they have been acquired. Ubiquitous mutations 
(present in all tumour regions) are shown on the blue trunks of trees, shared mutations (present in some, 
but not all, tumour regions) are shown on the yellow branches of trees, and private mutations (present in 
only one tumour region) are shown on the red branches of trees. Underneath each tree is the total number 
of filtered non-synonymous and synonymous mutations. 
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3.3 Predicted driver mutations 
All identified non-silent mutations were compared against a list of 582 potential driver 
genes. The driver gene list consisted of all genes identified in the Catalogue of Somatic 
Mutations in Cancer (COSMIC) cancer gene census (downloaded June 2014) (Futreal 
et al. 2004), and those identified in a large scale pan-cancer analysis (using q < 0.05 
as a cut-off for statistical significance) (Lawrence et al. 2013), and previous NSCLC 
sequencing studies (Lawrence et al. 2014; Cancer Genome Atlas Research Network, 
2015). Any variants that were located within one of these genes underwent 
categorisation based on pre-set criteria, as previously described (Section 2.9). In 
summary, driver categories 1 to 3 were defined as:  
 
• Category 1 - high confidence driver mutations containing all inactivating 
mutations in tumour suppressor genes (TSGs) or activating mutations in 
oncogenes (OGs)  
• Category 2 - putative driver mutations containing all mutations in driver genes 
located up to 15bp away from other mutations present in COSMIC or mutations 
meeting category 1 criteria but not annotated as a TSG or OG 
• Category 3 - low confidence driver mutations containing all other non-silent 
mutations in genes that were present in the lists of cancer-related genes  
 
The phylogenetic trees in Figure 16 to Figure 19 are annotated with genes 
representing category 1 to 3 predicted driver mutations, demonstrating both spatial and 
temporal heterogeneity of driver mutations, with driver mutations occurring both early 
(present on the trunks of the trees) and late (present on the branches of the trees) in 
tumour evolution. Category 1 to 3 predicted driver mutations for each tumour are listed 
in Section 8.4. 
 
The exome capture panel used in TRACERx has been adapted to detect common 
translocation events as part of the bioinformatics pipeline, but when the NSCLC pilot 
tumours were sequenced, detection of such events relied on histopathological 
assessment alone. The EML4-ALK translocation, a known driver event in NSCLC, was 
identified in patient L019 from the NSCLC pilot cohort by the UCL Advanced 
Diagnostics department using a dual colour FISH assay with a fusion probe for 
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ALK/EML4 t(2;2); inv(2)  (KreatechTM FISH probe, Leica Biosystems) (Figure 21). In 
collaboration with Illumina, the EML4-ALK translocation was identified in the tumour 
region R1 and all lymph nodes (LN1-LN3) based on PCR (Figure 22) and subsequent 
MiSeq sequencing, which showed that the number of mutant reads for the 
translocation was significantly higher in the tumour and lymph node regions compared 
to the germ line and control DNA (see Section 5.3 and Table 21). These data indicated 
that the translocation was likely to be present in all regions, and was therefore 
considered to be an early truncal driver event. 
 
Across the cohort, there were 366 category 1 to 3 predicted driver mutations; 253/366 
(69%) of these were truncal, and 113/366 (31%) of these were branch mutations 
(Figure 20). Amongst the branch driver mutations, 24/27 (89%) patients had a 
category 1 to 3 mutation, and 15/27 (56%) patients had at least one category 1 
mutation. Overall, there were 93 category 1 driver mutations, which contained all 
inactivating mutations in TSGs or activating mutations in OGs, 69/93 (74%) of these 
were truncal (predicted to be clonal in origin) mutations, and 24/93 (26%) of these were 
branch (predicted to be subclonal in origin) mutations. Amongst all 
heterogeneous/branch category 1 to 3 driver mutations, at least 2 or more driver 
mutations occurred in the following recurrent genes: ARHGEF12 (rho guanine 
nucleotide exchange factor 12, shown to have oncogenic properties in haematological 
malignancies), ARID1A (AT rich interactive domain 1A, a known TSG), ATM (ATM 
serine/threonine kinase, a known TSG), BCLAF1 (BCL2-associated transcription factor 
1, activating mutations found in cancers, in particular melanoma), CIC (capicua 
transcriptional repressor, a known TSG), FANCA (Fanconi anemia, complementation 
group A, shown to have TSG properties in haematological malignancies), HIST1H3B 
(histone cluster 1, H3b, shown to have oncogenic properties in gliomas), JAK2 (janus 
kinase 2, shown to have OG properties in haematological malignancies), PIK3CA 
(activating mutations found in several cancers, including lung), and RB1 (a known 
TSG).  
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Figure 20 Truncal and branch predicted driver mutations 
The number of category 1 to 3 predicted driver mutations (A), and the number of category 1 
predicted driver mutations in the NSCLC pilot and TRACERx cohort (B).  
 
 
 
 
Figure 21 EML4-ALK FISH in L019 
Dual colour FISH assay with a fusion probe for ALK/EML4 t(2;2); inv(2)  (KreatechTM FISH 
probe, Leica Biosystems) using a representative tumour sample from L019. Cells containing two 
sets of overlapping green and red signals represent wild type cells (green arrow), and cells 
containing one overlapping green and red signal and one separated green and red signal 
represent cells harbouring the translocation (red arrow). Image produced by UCL Advanced 
Diagnostics.
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Figure 22 PCR amplification for EML4-ALK in L019 
PCR amplification of DNA extracted from tumour region R1 and lymph nodes LN1 to LN3 in 
patient L019 showing the presence of PCR products in tumour regions R1 and lymph node 
regions LN1-LN3, but not in the germ line (GL) or control DNA (NA12878). PCR performed by 
Clare fielding, Illumina.  
 
3.3.1 Category 1 and 2 driver mutations in genes relevant to NSCLC 
Category 1 and 2 mutations were predicted to be either high confidence or putative 
cancer driver mutations. Several of these driver mutations had either existing or 
potential value in guiding NSCLC patient management. Several truncal category 1 
mutations were seen in KRAS. In patient L023 there was a KRAS G12C mutation (42% 
frequency in KRAS-mutated NSCLC, (Forbes et al. 2011)), in patient L029 there was a 
KRAS G12A mutation (7% frequency in KRAS-mutated NSCLC, (Forbes et al. 2011)), 
in patients L017 and LTX001 there was a KRAS G12V mutation (20% frequency in 
KRAS-mutated NSCLC, (Forbes et al. 2011)), and in patient LTX058 there was a 
KRAS G12S mutation (5% frequency in KRAS-mutated NSCLC, (Forbes et al. 2011)). 
KRAS mutations occur in approximately 15-25% of LUAD tumours, and are uncommon 
in LUSC tumours (Brose et al. 2002; Riely et al. 2008). Over 90% of all KRAS 
mutations are associated with changes in the glycine residue coded by codon 12 of 
wild type KRAS. In NSCLC, G12C accounts for most of these mutations, followed by 
G12V and G12D (Forbes et al. 2011; Garassino et al. 2011). This is likely to be related 
to the association between NSCLC and tobacco smoke exposure, since G>C or G>T 
transversions of the guanine nucleotide residues located in the wild type KRAS codon 
12 are known to be associated with smoking (Ahrendt et al. 2001), and are uncommon 
in NSCLCs amongst non-smokers (Riely et al. 2008). Although the prognostic 
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significance of KRAS mutations in NSCLC is yet to be determined (Mascaux et al. 
2005; Schiller et al. 2001), they have been associated with decreased response to 
adjuvant chemotherapy in early-stage NSCLC (Tsao et al. 2007; Winton et al. 2005), 
and EGFR TKIs, such as erlotinib and gefitinib (Pao et al. 2005; Mitsudomi & Yatabe 
2007). KRAS-mutated NSCLCs may benefit from the MEK (mitogen-activated protein 
kinase kinase) inhibitors, such as selumetinib, in combination with chemotherapy 
(Jänne et al. 2013).  
 
Truncal category 1 driver mutations in EGFR were identified. In patient L013 there 
were two mutations identified in the kinase domain of EGFR. There was an exon 18 
G719A mutation (0.6% frequency, (Forbes et al. 2011)), which is known to confer 
increased sensitivity to EGFR TKIs (Han et al. 2005; Lynch et al. 2004; Rosell et al. 
2005; Taron et al. 2005). In addition to this, there was an exon 19 D761Y mutation, 
which was the first non-T790M secondary mutation identified to be associated with 
resistance to EGFR TKIs. This mutation was originally described in a patient with a 
known TKI sensitising EGFR mutation (L858R) with metastatic resistant disease (Balak 
et al. 2006). Although the frequency of non-T790M mutations in EGFR-mutated TKI-
resistant tumours is below 5% (Kosaka et al. 2006; Balak et al. 2006; Bean et al. 2008), 
detecting this mutation in patients may have clinical implications, for example such 
patients may be monitored closer for the development of resistant disease whilst on 
EGFR TKI therapy. Three regions were deep-sequenced in this tumour; the VAFs for 
the G719A mutation were 21%, 25% and 55%, and the VAFs for the D761Y mutation 
were 20%, 17% and 48% in the respective tumour regions. With similar VAFs for each 
mutation in each tumour region, it is likely that these mutations were present in all the 
tumour cells for each region. The fact that one mutation conferred sensitivity and 
another conferred resistance, suggested that this tumour would have had intrinsic 
resistance to EGFR TKI therapy and that such drug resistance may have manifested 
early during treatment. This example illustrates the likely clonal nature of intrinsic drug 
resistance mechanisms (Swanton et al. 2014), which has previously been shown in 
other tumours, such a melanoma (Turajlic et al. 2014). In patient L030 there was an 
exon 19 deletion (48% frequency in EGFR-mutated NSCLC, (Mitsudomi & Yatabe 
2010)), and in patient LTX051 there was an exon 21 L858R mutation (43% frequency, 
(Mitsudomi & Yatabe 2010)). Both of these mutations are known to confer increased 
sensitivity to EGFR TKIs. Truncal driver category 2 mutations in EGFR were also 
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identified in patients LTX051 (A86T), and LTX001 (G630E). These mutations were 
predicted to be putative driver mutations.  
 
EGFR mutations occur within exons 18-21, and are usually heterozygous, with 
evidence of amplification in the mutant allele (Soh et al. 2009). Approximately 90% of 
these mutations are exon 19 deletions or exon 21 L858R point mutations (Ladanyi & 
Pao 2008). EGFR mutations are mostly found in female never-smokers with LUAD 
histology (Lynch et al. 2004; Paez et al. 2004; Pao et al. 2004). All the above patients 
were female, patient L030 was an ex-smoker (40 pack-years, quit 10-years ago) with 
LUAD histology, patient L013 was a smoker (50 pack-years) with LUSC histology, and 
patient LTX051 was a never-smoker with LUAD histology.  
 
Several category 1 driver mutations were identified in the PIK3CA gene. The E545K 
mutation (26.7% frequency in PIK3CA-mutated NSCLC, (Forbes et al. 2011)) was 
found in patients LTX030 (truncal) and LTX038 (branch), and the PIK3CA E542K 
mutation (8.9% frequency in PIK3CA-mutated NSCLC, (Forbes et al. 2011)) was found 
in patients LTX019 (truncal) and LTX029 (branch). The E542K and E545 mutations 
occur within the highly conserved helical domain of the PIK3CA gene, and are 
frequently observed as PI3-kinase mutations (Kang et al. 2005). These mutations have 
been shown to increase the catalytic activity of PIK3CA proteins resulting in 
oncological transformation in in vitro studies (Kang et al. 2005). Patient LTX016 had a 
truncal PIK3CA V344G mutation, which has previously been described in glioblastoma 
multiforme tumours (Gallia et al. 2006). Truncal driver category 2 mutations in PIK3CA 
were also identified in patients L023 (A533V), LTX015 (C147R) and LTX028 (T727K). 
These mutations were predicted to be putative driver mutations.  
 
Somatic PIK3CA mutations have been found in 1-3% of all NSCLC patients (Samuels 
et al. 2004; Kawano et al. 2006), and are more common in the LUSC compared to 
LUAD histological subtype (Kawano et al. 2006). The clinical characteristics of patients 
with PIK3CA-mutated NSCLC tumours are yet to be determined. However, NSCLC cell 
lines with activating PIK3CA mutations have been shown to be sensitive to dual 
PIK3CA/mTOR inhibitors (Zou et al. 2009), and the introduction of an activating 
PIK3CA mutation in EGFR-mutant lung cancer cell lines is associated with EGFR TKI 
resistance (Engelman et al. 2006). In addition, PIK3CA mutations have been found in 
EGFR-mutant lung cancers with acquired resistance to EGFR TKI therapy (Sequist et 
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al. 2011). In a cohort study of 79 patients with LUSC, Paik and colleagues performed 
WES on paired primary and metastatic tumours and identified PIK3CA-mutant tumours 
as an aggressive disease subset associated with brain metastases and poor outcome 
(Paik et al. 2015).  
 
In patient LTX012 there was a truncal category 1 NRAS Q61K driver mutation (10-25% 
frequency, (Ohashi et al. 2013), (Forbes et al. 2011)). This mutation has been shown to 
drive aberrant pathway signalling, tumour cell survival, and tumour growth in 
melanoma in vivo studies (Li et al. 2012). Mutations in NRAS have been identified in 
approximately 1% of all NSCLCs (Brose et al. 2002; Ohashi et al. 2013), and are more 
commonly found in patients with LUADs and a history of smoking (Ohashi et al. 2013). 
In NRAS-mutant lung cancer cell lines, these mutations have been associated with 
sensitivity to MEK inhibitors, such as selumetinib and trametinib (Ohashi et al. 2013). 
Patient LTX012 had LUSC histology and was an ex-smoker.  
 
3.3.2 The significance of predicted driver mutations in branches 
Tumours with shared or private branch mutations in genes with diagnostic, therapeutic 
or prognostic relevance were identified using the TARGET (tumour alterations relevant 
for genomics-driven therapy) database 
(https://www.broadinstitute.org/cancer/cga/target, version 3, updated February 2015) 
as shown in Table 9. Many of these genes either predict sensitivity or resistance to a 
class of targeted drug therapies, and their detection at diagnosis, or at relapse, may 
have significant implications in terms of treatment stratification, and therefore patient 
outcome. Given that these subclonal mutations were heterogeneous as a result of 
branched tumour evolution, that is they were present in some parts of the tumour and 
not others, identification of these mutations in clinically relevant genes may have been 
restricted if only one tumour region had been sampled and sequenced. This is 
analogous to the potential sampling bias with a single biopsy, and further adds to the 
challenges posed by intratumour heterogeneity and the difficulties in adequately 
profiling a tumour with therapeutic intervention in mind. 
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Patient Gene Driver category Clinical relevance 
LTX015 ATM 1 Biallelic inactivation may predict sensitivity to 
PARP inhibitors 
LTX016 ATM 3  
LTX036 ATM 1  
LTX036 BCL2 3 Translocation is prognostic/diagnostic in 
some haematological cancers and activating 
alterations may be sensitive to BCL2 
inhibitors 
L016 BRCA1 1 Biallelic inactivation predicts sensitivity to 
PARP inhibitors 
LTX019 EGFR 3 Mutations may predict sensitivity to TKIs, and 
other mutations predict resistance to TKIs 
LTX019 FBXW7 1 Mutations may predict sensitivity to MTOR 
inhibitors, and resistance to anti-tubulin 
chemotherapy 
L023 GNAS 3 Mutations may be diagnostic of tumours 
arising in McCune-Albright syndrome, and 
may be targetable with JAK inhibitors 
L013 JAK2 3 Mutations may predict sensitivity to JAK2 
inhibitors 
LTX001 JAK2 3  
LTX058 JAK2 3  
LTX038 KDR 2 Activating mutations may predict sensitivity to 
specific KDR inhibitors 
L023 MAP2K1 3 Mutations may predict resistance to RAF and 
MEK inhibitors 
LTX016 MED12 3 May predict resistance to targeted therapies 
LTX038 MLH1 1 Prognostic/Diagnostic in colon cancer 
LTX015 MPL 3 Mutations may predict sensitivity to JAK2 
inhibitors 
L013 MSH2 1 Prognostic/Diagnostic in colon cancer 
L013 MTOR 2 Activating mutations may predict sensitivity to 
MTOR inhibitors, and secondary mutations 
may predict resistance to MTOR inhibitors 
LTX036 MYC 2 May be prognostic/diagnostic in some cancer 
types 
LTX019 NF1 1 Biallelic inactivation may predict sensitivity to 
PI3K pathway inhibitors (PI3K/AKT/MTOR).  
Biallelic inactivation may predict resistance to 
RAF and MEK inhibitors. 
LTX038 NOTCH1 2 Activating mutations may predict sensitivity to 
Notch inhibitors 
Chapter 3 Results 1 
 97 
LTX016 PIK3CA 3 Mutations may predict sensitivity to PI3K 
pathway inhibitors (PI3K/(AKT/PKB)/MTOR). 
Mutations may predict resistance to anti-RTK 
therapy, including cetuximab, anti-EGFR 
TKIs, and trastuzumab and lapatinib 
LTX029 PIK3CA 1  
LTX038 PIK3CA 1  
LTX015 RB1 2 May be prognostic or diagnostic in some 
tumour types.  Loss may predict resistance to 
CDK inhibitors 
LTX034 RB1 1  
L023 TET2 3 Prognostic in myelodysplastic syndrome 
LTX034 TP53 1 Biallelic inactivation or mutation may be 
prognostic in some tumour types.  May 
predict sensitivity to some cell cycle inhibitors 
and p53 specific gene therapies or 
immunotherapies. 
Table 9 Clinically relevant genes from the TARGET database in branches 
Genes with driver category 1 to 3 branch mutations in the NSCLC pilot and TRACERx cohort 
were screened against the TARGET database to identify clinically relevant genes. 
Abbreviations: PARP, poly ADP ribose polymerase; TKI, tyrosine kinase inhibitor; RTK, receptor 
tyrosine kinase; MEK, mitogen-activated protein kinase; JAK, jannus kinase; AKT/PKB, protein 
kinase-B; PI3K, phosphoinositide 3-kinase; and MTOR, mammalian target of rapamycin. 
 
3.4 Early versus late mutation signatures in the TRACERx cohort 
With greater sequencing depth and an adequate number of filtered non-synonymous 
and synonymous mutations, the mutational spectra and associated signature patterns 
for tobacco smoke exposure and APOBEC enrichment were explored in the TRACERx 
cohort only. A two-sided Fisher’s exact test was used to compare the relative 
frequency of each mutation type between early and late mutations. In the LUAD 
histological subtype, 2/5 of the tumours (LTX001 and LTX036) had a statistically 
significant shift in the spectra of the six different mutation types (C>A, C>G, C>T, T>A, 
T>C, T>G), when comparing early with late mutations (p <0.05, Figure 23A). In 3/5 of 
the tumours (LTX001, LTX034 and LTX036), there was a statistically significant 
difference in the proportion of C>A transversions in early compared with late mutations 
(p < 0.05). In tumours LTX001 and LTX036, there was a decrease in the proportion of 
C>A transversions in the late mutations, whereas in tumour LTX034 an increase was 
seen. However, patient LTX001 and LTX036 were ex- and current smokers, whereas 
patient LTX034 was a never-smoker in whom a smoking-associated mutation signature 
would not have been expected. There was no history of passive tobacco smoke or 
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other carcinogen exposure in this patient. There was a statistically significant increase 
in the proportion of C>T transitions and C>G transversions at TpC sites in late 
compared with early mutations, indicative of APOBEC cytidine deaminase activity 
(Roberts et al. 2013; Burns et al. 2013; Alexandrov, Nik-Zainal, Wedge, Aparicio, et al. 
2013; de Bruin et al. 2014) in tumours LTX001 (p < 0.01) and LTX036 (p < 0.01) 
(Figure 24).  
 
In the LUSC histological subtype, 7/11 of the tumours (LTX012, LTX015, LTX019, 
LTX028, LTX033, LTX038 and LTX058) had a statistically significant shift in the 
spectra of the six mutation types (C>A, C>G, C>T, T>A, T>C, T>G), when comparing 
early with late mutations (p < 0.05, Figure 23B). In 6/11 of the tumours (LTX012, 
LTX015, LTX019, LTX028, LTX038 and LTX058), all of which came from either ex- or 
current smokers, there was a statistically significant decrease in the proportion of C>A 
transversions in the late compared with early mutations (p < 0.05). There was a 
statistically significant increase in the APOBEC-associated mutation signature in 
tumours LTX019 (p < 0.001), LTX028 (p < 0.05), and LTX038 (p < 0.05) (Figure 25). 
The 95% confidence intervals for the APOBEC enrichment odds ratio was particularly 
wide in tumours LTX012 and LTX016 due to the small number of late mutations in 
LTX012, and the few mutations detected overall in LTX016.  
 
Overall, there was a statistically significant shift in the mutational spectra of the six 
different mutation types in 9/16 (56%) tumours, a decrease in the smoking-associated 
signature in the late mutations in 8/16 (50%) tumours, and an increase in the 
APOBEC-associated mutation signature in the late mutations in 5/16 (31%) tumours. 
Since C>A transversions are known to be associated with the mutagenic effects of 
tobacco smoke (Pfeifer & Hainaut 2003), a decrease in their proportion in the late 
mutations implies a decrease in the overall mutational burden attributable to smoking in 
late tumour evolution. This suggests that the mutagenic effects of tobacco smoke may 
play a more prominent role in the early tumourigenesis of some NSCLCs. This 
association was not seen in all the tumours from patients who were either current or 
ex-smokers. In the case of tumours from patients who were ex-smokers, the time since 
smoking cessation took place did not appear to influence the presence or absence of a 
smoking-associated signature. A significant increase in APOBEC enrichment in the late 
mutations suggests a potential role for APOBEC cytidine deaminase activity in the late 
tumourigenesis of some NSCLCs (de Bruin et al. 2014; McGranahan & Swanton 2015). 
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Determining the temporal significance of such signatures in tumours, allows one to 
interpret the relevance of specific mutational processes and pathways that may be 
involved in the initiation and progression of tumours. In addition, it may identify 
potential therapeutic strategies aimed at, for example, limiting genetic diversity.  
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Figure 23 Mutational spectra in the TRACERx cohort 
Proportion of early mutations (present on the trunk) and late mutations (present on the 
branches) accounted for by each of the six mutation types (C>A, C>G, C>T, T>A, T>C and 
T>G) in the LUADs (A) and LUSCs (B). Tumours for which there was a statistically significant 
difference between late compared with early mutations for signatures associated with smoking 
(decrease in C>A transversions in late mutations) and APOBEC deaminase activity (increase in 
C>T and C>G transversions at TpC sites in late mutations) are highlighted. In the case of ex-
smokers, the number of years since smoking cessation is shown in brackets. 
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Figure 24 APOBEC mutation enrichment in LUADs 
APOBEC mutation enrichment odds ratio for early (blue) versus late (red) mutations in LUADs. 
Statistically significant APOBEC enrichment in late compared with early mutations was seen in 
tumours LTX001 and LTX036 (p < 0.01). The 95% confidence intervals are indicated.  
 
 
 
Figure 25 APOBEC mutation enrichment in LUSCs 
APOBEC mutation enrichment odds ratio for early (blue) versus late (red) mutations in LUSCs. 
Note: there were too few mutations in LTX030 for an analysis of late events. Statistically 
significant APOBEC enrichment in late compared with early mutations was seen in tumours 
LTX019 (p < 0.001), LTX028 (p < 0.05) and LTX038 (p < 0.05). The 95% confidence intervals 
are indicated. 
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3.5 Patients with primary and metastatic tumours 
3.5.1 Patient L011 
Patient L011 was a 49-year-old female smoker (45 pack-years) diagnosed with LUAD 
who received adjuvant chemotherapy, but stopped treatment after one cycle due to 
renal toxicity. Fourteen-months after surgery, the patient presented with headaches 
and unsteadiness, and was diagnosed with a large occipital brain metastasis 
associated with increased intracranial pressure. The patient underwent a debulking 
craniotomy, whereby part of the brain metastasis was surgically resected. From this 
resection, four FFPE tumour blocks were collected, and DNA extracted from these 
spatially separated regions (M1 to M4) was used for WES. The patient died 5-months 
after surgery.  
 
The heat map and phylogenetic tree demonstrate that mutations common to all four 
metastatic tumour regions M1 to M4 were shared with only region R3 from the primary 
tumour, suggesting that the metastasis originated from this region of the tumour 
(Figure 26). Intratumour heterogeneity was evident in both the primary and metastatic 
tumours. The intratumour heterogeneity index for the primary tumour was 0.05. Figure 
26A shows a region in M1 outlined with a red box, which highlights a set of mutations 
in genes present on chromosomes 1 and 9. The copy number and mirrored B allele 
frequency (mBAF) profile for this region, relative to the other regions in the metastasis, 
suggest that there was a copy number neutral loss of heterozygosity event in 
chromosome 1 and chromosome 9. Figure 27 shows the copy number and mBAF for 
region M1 relative to region M3. The incorporation of copy number aberrations in the 
analysis of SNV and indel mutations in such cases can identify absent mutations driven 
by copy number loss, and lead to a more accurate interpretation of branch mutations, 
and therefore the intratumour heterogeneity index. A statistically significant shift was 
seen in the mutation spectra of the six mutation types (C>A, C>G, C>T, T>A, T>C, 
T>G), comparing the early with late mutations for tumour regions R3 and M1 to M4 
only (p < 0.001, Figure 26B).  A significant decrease in the smoking-associated 
signature (p<0.001), and an increase in APOBEC enrichment (odds ratio 2.27, range 
1.09 to 4.45, p = 0.019) was seen in the late compared with early mutations for tumour 
regions R3 and M1 to M4. Since tumour region R3 was associated with the brain 
metastasis, this suggests that APOBEC cytidine deaminase activity may have had a 
role to play in tumour progression, and therefore the metastatic process, perhaps by 
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initiating genetic diversity upon which selection could act. Although APOBEC 
enrichment was not seen in tumour regions R1 and R2, there were few late mutations 
in these regions, and therefore APOBEC enrichment cannot be confidently excluded 
(Figure 28).  
 
This patient had a truncal BRAF V600E mutation (55% frequency in BRAF-mutated 
NSCLC (Forbes et al. 2011)). BRAF mutations occur in approximately 1-4% of all 
NSCLCs (Brose et al. 2002; Cardarella et al. 2013). BRAF mutations in NSCLC cell 
lines have been associated with decreased sensitivity to EGFR TKIs (Gandhi et al. 
2009; Pratilas et al. 2008), and sensitivity to MEK inhibitors (Pratilas et al. 2008) and 
BRAF inhibitors (Sen et al. 2012). Increasing evidence also supports the role of BRAF 
inhibitors in patients with NSCLC, such as vemurafenib (Gautschi et al. 2012) and 
dabrafenib (Rudin et al. 2013). Temporal heterogeneity was seen in predicted driver 
mutations, in particular branch mutations were identified in BCLAF1 (category 2, 
regions R3 and M1 to M4), and in CACNA1D (calcium channel, voltage-dependent, L 
type, alpha 1D subunit) (category 3, regions M1 and M2). There were three 
independent truncal category 2 driver mutations in the tumour suppressor gene FAT1 
(FAT atypical cadherin 1) (L1107R, I1601M, and a frameshift variant), suggesting that 
these mutations may have had a role to play in the early development of the primary 
tumour. Inactivating mutations in FAT1 have been shown to be associated with 
aberrant Wnt (wingless-type MMTV integration site family) pathway signalling and 
tumourigenesis (L. G. T. Morris et al. 2013). Although these specific FAT1 mutations 
have not been described before, they are located within 15bp away from other 
mutations that are present in COSMIC and have been identified in other cancers.  
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Figure 26 Heat map, phylogenetic tree and mutational spectra for L011 
Heat map representing the regional distribution of mutations in the primary (R1-R3) and brain 
metastatic tumours (M1-M4) (A), and phylogenetic tree annotated with genes in which driver 
mutations have been predicted and trunk/branch-specific mutational spectra (B). The red box in 
region M1 represents a potential copy number neutral loss of heterozygosity event.  
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Figure 27 Copy number and mBAF profile for L011 tumour region M1 and M3 
Chromosomal segments with copy number profile above and mirrored b allele frequency 
(mBAF) profile below for regions M1 (A) and M3 (B). Relative to region M3, the red box 
indicates increased mBAF for chromosome 1 in both the short p arm and long q arm, and the 
blue box indicates increased mBAF for chromosome 9 in the long q arm. The copy number 
does not change at these points, suggesting a copy number neutral loss of heterozygosity.  
A
B
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Figure 28 APOBEC enrichment in L011 
APOBEC enrichment odds ratio for early (blue) and late (red) mutations in L011.  
 
3.5.2 Patient L017 
Patient L017 was a 61-year-old female smoker (48 pack-years) diagnosed with LUAD 
who initially presented with two tumours in the right upper lobe (RUL). The patient 
underwent surgical resection of both tumours and completed four cycles of adjuvant 
chemotherapy. Regions R1 and R2 were collected from the first tumour, and region R3 
was collected from the second tumour. Four-months after surgery, the patient was 
diagnosed with disease recurrence in a single lymph node and was treated with radical 
radiotherapy to the mediastinum. Nineteen-months after surgery, the patient was 
diagnosed with disease recurrence in a peripheral lesion in the right lower lobe (RLL), 
treated again with surgical resection. From this resection, one region (M1) was 
collected, and DNA was extracted from fresh frozen tissue for WES. This patient was 
alive at the time of her last follow-up assessment (35-months after surgery) with no 
evidence of further disease recurrence.  
 
Despite a distance of only 8mm between the two tumours, the heat map and 
phylogenetic tree supported the diagnosis of two separate synchronous primary 
tumours in this patient (Figure 29). Only tumour regions R1 and R2, collected from one 
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tumour, had mutations in common. Tumour region R3, which was collected from the 
second tumour, had only private mutations. Region M1 from the metastatic tumour had 
mutations in common with R3 only, suggesting that the metastasis originated from R3. 
Intratumour heterogeneity was evident in the primary tumour from which R1 and R2 
were collected, with an intratumour heterogeneity index of 0.15 for the primary tumour, 
which consisted of regions R1 and R2 (Figure 29A). A statistically significant shift was 
seen in the spectra of the six mutation types (C>A, C>G, C>T, T>A, T>C, T>G), 
comparing the early with late mutations for both tumour regions R1 and R2 (p < 0.01), 
and R3 and M1 (p < 0.01) (Figure 29B). A significant decrease in the smoking-
associated signature was seen in the late compared with early mutations in tumour 
regions R1 and R2 (P < 0.001) and R3 and M1 (p < 0.001), suggesting a role for 
tobacco smoke in early tumourigenesis. APOBEC enrichment in the late compared 
with early mutations was seen in tumour regions R1 and R2 (odds ratio 3.15, range 
1.96 to 4.96, p < 0.001), but not in regions R3 and M1 (Figure 30).  
 
Temporal heterogeneity in the predicted driver mutations was seen, in particular 
branch mutations in the tumour suppressor gene BCOR (BCL6 corepressor) (category 
1, region R1), and the oncogenes TPR (translocated promoter region, nuclear basket 
protein) (category 3, R1), TRIP11 (thyroid hormone receptor interactor 11) (category 3, 
R1), PAX8 (paired box 8) (category 3, R1), HIST1H3B (histone cluster 1, H3b) 
(category 3, R2), HOXD13 (homeobox D13 ) (category 3, M1) and RANBP17 (RAN 
binding protein 17) (category 3, M1). Relevant to NSCLC, a category 1 truncal KRAS 
G12V mutation (20% frequency in KRAS-mutated NSCLC, (Forbes et al. 2011)), 
known to confer decreased sensitivity to EGFR TKIs (Pao et al. 2005; Mitsudomi & 
Yatabe 2007), was also detected in this tumour. Interestingly, despite the existence of 
two separate lesions, there were four independent driver category 1 mutations in the 
tumour suppressor gene ATRX (α-thalassaemia/mental retardation syndrome X-
linked); two on each tumour trunk (T1621A and S25X for R1/R2 and R2164S and 
D2144Y for R3/M1). Inactivating mutations in the ATRX gene are known to be 
associated with increased activity of the alternative lengthening of telomeres (ALT) 
pathway (Lovejoy et al. 2012; Heaphy et al. 2011; Bower et al. 2012; Schwartzentruber 
et al. 2012). Such increased activity can enable cancer cells to escape replicative 
senescence or apoptosis, promoting tumour cell proliferation (Bryan et al. 1997). In 
addition, there were two independent driver category 1 mutations in the TP53 gene; 
one on each tumour trunk (E155X for R1/R2 and an exon 4 splice site mutation for 
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R3/M1). This suggests that the patient’s germ line may have predisposed the patient to 
such mutations, and therefore have selected for the ATRX gene, or its combination 
with the TP53 gene, as drivers of disease and tumour growth. Furthermore, the 
selection of such driver events may have also been influenced by the patient’s 
microenvironment. 
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Figure 29 Heat map, phylogenetic tree and mutational spectra for L017 
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Figure 29 Heat map, phylogenetic tree and mutational spectra for L017 
Heat map representing the regional distribution of mutations in the primary (R1-R3) and 
metastatic tumours (M1) (A), and phylogenetic tree annotated with annotated with genes in 
which driver mutations have been predicted and trunk/branch-specific mutational spectra (B). 
Both tumour trunks have independent category 1 driver mutations in ATRX and TP53.  
 
 
 
Figure 30 APOBEC enrichment in L017 
APOBEC enrichment odds ratio for early (blue) and late (red) mutations in L017. Statistically 
significant APOBEC enrichment in late compared with early mutations was seen in tumour 
regions R1 and R2 (p < 0.001).  
 
3.5.3 Patient L023 
Patient L023 was a 50-year-old female smoker (60 pack-years) diagnosed with LUAD 
who initially presented with two separate tumours; one in the RUL and one in the right 
middle lobe (RML), from which tumour regions R2 and R1 were collected, respectively. 
The patient was alive at the time of her last follow-up with no evidence of further 
disease recurrence. 
 
The heat map and phylogenetic tree identified common mutations between the two 
tumours, as well as mutations private to each region, suggesting that one tumour in 
one lobe had metastasised to the other in another lobe (Figure 31). A statistically 
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T>C, T>G), comparing the early mutations with late mutations (p < 0.001) (Figure 31B). 
There was no significant difference in smoking-associated signature or APOBEC 
enrichment signatures in the late compared with early mutations (Figure 32). Temporal 
heterogeneity in predicted driver mutations was seen; in particular branch mutations in 
the tumour suppressor genes FANCA (category 1, region R1) and CASP8 (caspase 8, 
apoptosis-related cysteine peptidase) (category 1, R2) were identified. Private driver 
category 3 mutations were seen in R1 in the following genes: GMPS (guanine 
monphosphate synthase), TET2 (tet methylcytosine dioxygenase 2), PIM1 (pim-1 
proto-oncogene, serine/threonine kinase), ARID1A and HNRNPA2B1 (heterogeneous 
nuclear ribonucleoprotein A2/B1), and in R2 in the following genes: GNAS (GNAS 
complex locus), CCNB1IP1 (cyclin B1 interacting protein 1, E3 ubiquitin protein ligase), 
MAP2K1 (mitogen-activated protein kinase kinase 1), and SETBP1 (SET binding 
protein 1). Relevant to NSCLC, a truncal KRAS G12C mutation (42% frequency in 
KRAS-mutated NSCLC, (Forbes et al. 2011)), known to confer decreased sensitivity to 
EGFR TKIs (Pao et al. 2005; Mitsudomi & Yatabe 2007), was identified. 
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Figure 31 Heat map, phylogenetic tree and mutational spectra for L023 
Heat map representing the regional distribution of mutations in the two primary tumours (R1 and 
R2) (A), and phylogenetic tree annotated with genes in which driver mutations have been 
predicted and trunk/branch-specific mutational spectra (B). 
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Figure 32 APOBEC enrichment in L023 
APOBEC enrichment odds ratio for early (blue) and late (red) mutations in L023. 
 
3.6 Intratumour heterogeneity in copy number aberrations 
With higher tumour purity and greater sequencing depth, copy number aberrations 
were explored in the TRACERx cohort only. Using TCGA LUAD and LUSC data, 
recurrent chromosomal segment gains and/or amplifications and losses were identified 
as described in Section 2.11. These were used to identify potential driver copy number 
aberrations in the TRACERx cohort. Figure 33 and Figure 34 demonstrate the 
regional distribution of potential driver copy number amplifications and/or gains in 
patients with LUAD and LUSC histological subtypes, respectively. Predicted driver 
genes within each chromosomal segment were identified and used to annotate each 
heat map. Intratumour spatial heterogeneity in copy number gains and/or amplifications 
was seen in all patients, except in patients LTX012 and LTX051 where only ubiquitous 
amplifications were seen. A gain and/or amplification of the chromosomal segment 
(chr7p11.2) containing the EGFR gene was identified as a ubiquitous event in all 
patients with LUAD (Figure 33). This was also identified as a heterogeneous event in a 
subset of patients with LUSC (LTX015, LTX019, LTX038 and LTX058). In addition to a 
gain and/or amplification, a mutation in the EGFR gene (category 1 to 3) was also 
identified in some of these patients; patient LTX001 with LUAD had a category 2 
truncal EGFR G630E mutation, and patient LTX051 with LUAD had a category 1 
truncal EGFR exon 21 L858R mutation. There were no EGFR mutations found 
amongst the patients with LUSC. In a cohort study of lung adenocarcinoma by Li and 
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colleagues, EGFR amplifications were found to often accompany EGFR mutations, 
whereby EGFR amplifications were seen in 15/29 (52%) EGFR-mutant tumours, but in 
only 5/31 (6%) non-mutant tumours (Li et al. 2008).  
 
Figure 35 and Figure 36 demonstrate the regional distribution of potential driver copy 
number losses in patients with LUAD and LUSC histological subtypes, respectively. 
Intratumour spatial heterogeneity was also seen in copy number losses in both LUAD 
and LUSC histological subtypes. Chromosomal segments containing known tumour 
suppressor genes, such as FAT1, CDKN2A (cyclin-dependent kinase inhibitor 2A), 
PTEN, and RB1 were found to be ubiquitously aberrant in some patients, and 
heterogeneously aberrant in others. For example, the chromosomal segment 
containing FAT1 was ubiquitously lost in patients LTX015, LTX022, LTX028, LTX029, 
LTX033, and LTX036, and heterogeneously lost in patients LTX016, LTX019, and 
LTX038. The existence of heterogeneous gains and/or amplifications and losses 
across the cohort suggests branched tumour evolution of copy number aberrations, 
with ubiquitous and heterogeneous aberrations potentially involved in early and late 
tumourigenesis, retrospectively.  
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Figure 33 Copy number gains and amplifications in LUADs 
Heat map representing the regional distribution of potential driver copy number gains and/or 
amplifications in the TRACERx LUAD cohort, based on recurrently amplified chromosomal 
segments identified in TCGA LUAD data. For each tumour region amplifications and gains were 
determined relative to the mean ploidy. Each cytoband range defines a chromosomal segment, 
and each segment is annotated by predicted driver genes contained within the segment.  
 
ch
r1
 q
21
.3
ch
r3
 q
26
.2
 − 
q2
6.
31
ch
r5
 p
15
.3
3
ch
r6
 p
21
.1
ch
r7
 p
11
.2
ch
r8
 p
11
.2
1
ch
r1
1 
q1
3.
3
ch
r1
2 
p1
2.
1
ch
r1
4 
q1
3.
3
SETDB1
MLLT11
ARNT
MECOM
EIF5A2
PRKCI
CCND3
TFEB EGFR KAT6A CCND1 KRAS
Copy number aberration Gain Ampliﬁcation No change
Cytobands
LTX051 R2
LTX051 R1
LTX036 R6
LTX036 R4
LTX036 R3
LTX029 R2
LTX029 R1
LTX001 R3
LTX001 R2
LTX001 R1
LTX034 R2
LTX034 R1
Predicted 
driver 
genes
Chapter 3 Results 1 
 116 
 
Figure 34 Copy number gains and amplifications in LUSCs 
Heat map representing the regional distribution of potential driver copy number gains and/or 
amplifications in the TRACERx LUSC cohort, based on recurrently amplified chromosomal 
segments identified in TCGA LUSC data. For each tumour region amplifications and gains was 
determined relative to the mean ploidy. Each cytoband range defines a chromosomal segment, 
and each segment is annotated by predicted driver genes contained within the segment. 
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Figure 35 Copy number losses in LUADs 
Heat map representing the regional distribution of potential driver copy number losses in the 
TRACERx LUAD cohort, based on recurrently deleted chromosomal segments identified in 
TCGA LUAD data. For each tumour region losses were determined relative to the mean ploidy. 
Each cytoband range defines a chromosomal segment, and each segment is annotated by 
predicted driver genes contained within the segment. 
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Figure 36 Copy number losses in LUSCs 
Heat map representing the regional distribution of potential driver copy number losses in the 
TRACERx LUSC cohort, based on recurrently deleted chromosomal segments identified in 
TCGA LUSC data. For each tumour region losses and deletions were determined relative to the 
mean ploidy. Each cytoband range defines a chromosomal segment, and each segment is 
annotated by predicted driver genes contained within the segment. 
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3.7 Correlation between the intratumour heterogeneity index 
and clinical variables 
The intratumour heterogeneity index was calculated for the primary tumours in the 
combined NSCLC pilot and TRACERx cohort (Table 10), with a median index of 0.22 
(range 0.01 to 0.64). Using a two-sided Wilcoxon rank-sum test or a Spearman’s rank 
correlation coefficient (Rs), the correlation between the index and the smoking status, 
histological subtype, tumour stage, tumour size (maximum diameter), lymph node 
involvement, and disease recurrence was assessed, as shown in Figure 37 A-G. 
Patient L023 from the NSLCC pilot cohort, who had two tumours, was excluded since 
only one region had been sequenced from each tumour. Statistically significant 
correlations were not identified in this cohort, potentially due to the small number of 
patients. Such correlations are likely to be identified in larger patient cohorts, such as 
TRACERx, in which different measures of heterogeneity can be assessed with 
sufficient power for detection, in order to define an index that is truly representative of 
the underlying intratumour heterogeneity, with potential predictive and prognostic value.  
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Figure 37 Intratumour heterogeneity index and clinical correlates 
Intratumour heterogeneity (ITH) index and correlation with smoking status (A), tumour stage (B), 
tumour size (C), lymph node involvement (D), histological subtype (E), disease recurrence (F), 
and age (G). Thick red lines represent median values, and thin red lines represent the 
interquartile range. Abbreviations: Rs, Spearman’s rank correlation coefficient; LUAD, lung 
adenocarcinoma; LUSC, lung squamous cell carcinoma. Abbreviations: Rs; Spearman’s rank 
correlation coefficient.  
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Patient Age 
Smoking 
status 
(pack-
years) 
Histo Stage 
Max 
diameter 
tumour 
size 
Lymph 
node 
involvement 
Recurrence 
(mths) 
PW 
ITH 
L011 49 Smoker LUAD IB 55 No Yes 0.05 
L012 69 Smoker LUSC IB 40 No No 0.35 
L013 68 Smoker LUSC IB 50 No No 0.26 
L015 68 Smoker LUSC IA 30 No No 0.15 
L016 65 Smoker LUSC IIIA 27 No No 0.04 
L017 61 Smoker LUAD IIB 14 No Yes 0.15 
L019 47 
Never-
smoker 
LUAD IIIA 25 Yes Yes 0.41 
L022 54 Smoker LUAD IIIA 32 Yes No 0.28 
L029 66 Ex-smoker LUAD IA 15 No No 0.07 
L030 79 Ex-smoker LUAD IA 24 No No 0.14 
LTX001 68 Ex-smoker LUAD IB 26 No No 0.21 
LTX012 65 Ex-smoker LUSC IIA 35 Yes No 0.01 
LTX015 64 Smoker LUSC IB 32 No No 0.18 
LTX016 67 Ex-smoker LUSC IIB 66 No No 0.64 
LTX019 65 Smoker LUSC IIA 50 Yes No 0.46 
LTX022 72 Smoker LUSC IIA 30 No No 0.13 
LTX028 66 Ex-smoker LUSC IIA 55 No No 0.22 
LTX029 78 Ex-smoker LUAD IB 22 No No 0.27 
LTX030 76 Smoker LUSC IIA 45 Yes Yes 0.03 
LTX031 50 Smoker LUSC IA 15 No No 0.04 
LTX033 73 Ex-smoker LUSC IB 35 No No 0.11 
LTX034 73 Never LUAD IA 30 No No 0.32 
LTX036 68 Smoker LUAD IB 25 No No 0.23 
LTX038 76 Ex-smoker LUSC IIB 67 No No 0.45 
LTX051 67 Never LUAD IA 26 No No 0.27 
LTX058 73 Ex-smoker LUSC IB 44 No No 0.26 
Table 10 Intratumour heterogeneity index and clinical variables 
Intratumour heterogeneity index in the combined NSCLC pilot and TRACERx cohort. 
Abbreviations: Histo, histology; PW ITH, pairwise intratumour heterogeneity index.  
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3.8 Conclusions and discussion  
Although work within our laboratory has previously demonstrated intratumour 
heterogeneity in NSCLC (de Bruin et al. 2014), the data presented here are based on a 
larger cohort of tumours, in particular squamous cell carcinoma tumours, which have 
been sequenced to a greater depth. In the combined NSCLC pilot and TRACERx 
cohort, 93 spatially distinct tumour regions from 27 patients were subjected to WES. 
These data demonstrated intratumour heterogeneity in SNV, indel and copy number 
aberrations. Furthermore, heterogeneity was seen in predicted driver mutations, and 
copy number aberrations involving predicted driver genes, with some aberrations 
occurring early (truncal) and some occurring late (branch) in tumour evolution.  
 
Truncal, that is clonal in origin, mutations are those that are present in all of the cancer 
cells within a tumour. A mutation that is present in a small population of cancer cells, 
and therefore subclonal in origin, may be present in all tumour regions, but would not 
be truly truncal. One limitation of the data presented here is that a truncal mutation has 
been defined as a mutation that is present in every tumour region, suggesting that the 
degree of intratumour heterogeneity may have been underestimated in some of the 
NSCLC tumours. Furthermore, subclonal mutations, present in only a subset of cancer 
cells, are not necessarily later events, but may instead represent copy number driven 
intratumour heterogeneity. Thus, a mutation may have occurred prior to the emergence 
of the most recent common ancestor and yet still be heterogeneous within a tumour. 
As such, from a clinical perspective, it may be more meaningful to consider whether a 
mutation is clonal or subclonal given that this provides information on the number of 
cells harbouring a genetic aberration of interest at a given point in time, rather than in 
the past. In the TRACERx study, the definition of truncal and branch mutations will take 
into account the cancer cell fraction associated with each mutation, and with the 
incorporation of copy number data and deeper sequencing, a more accurate 
interpretation of the clonal architecture, as well as the true extent of intratumour 
heterogeneity in NSCLC, can be made. 
 
Intratumour heterogeneity potentially poses significant challenges in the management 
of NSCLC patients with regards to the identification of predictive and prognostic 
biomarkers based on a single diagnostic biopsy. The significance of branch aberrations, 
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in terms of therapeutic response and clinical outcome, is yet to be determined in 
longitudinal genomic studies, such as TRACERx. However, with increasing evidence 
for intratumour heterogeneity in NSCLC, the current methods of tumour profiling based 
on single diagnostic, often historical, biopsies are unlikely to represent the true tumour 
genomic landscape of tumours. This in turn can lead to inadequately informed clinical 
decision-making, potentially compromising patient care. The insight into NSCLC 
evolution, and its complex genomic landscape, has led to the development and 
justification of the TRACERx study, which aims to take forward and further develop the 
analyses presented here, with the added benefit of using copy number data to 
confidently identify the clonality of detected mutations. In particular, TRACERx will 
explore the following: 
 
• The prevalence of predicted driver mutations and copy number aberrations in 
multiple compared with single regions 
• The prevalence of therapeutically targetable subclonal mutations  
• The identification of new potential subclonal drivers of NSCLC  
• The identification of significant correlations between indices of intratumour 
heterogeneity and clinical variables and outcome  
• The identification of mutational signatures, and their evolution from diagnosis to 
relapse. 
 
Chapter 4 Results 2 
 126 
4 Results 2: Intratumour heterogeneity in lung 
adenocarcinoma in situ lesions 
4.1 Introduction 
Patients recruited into the TRACERx study either had a confirmed histological 
diagnosis of NSCLC based on a pre-surgical diagnostic biopsy, or were highly 
suspected to have such a diagnosis based on their clinical presentation and pre-
operative imaging. Five patients recruited into the study were subsequently found to 
have a histological diagnosis of adenocarcinoma in situ. These patients were 
withdrawn from the study, but still underwent surgical resection of their presumed 
primary NSCLC tumours, which were subjected to multi-region WES using the same 
TRACERx bioinformatics pipeline. These cases were analysed as a separate substudy, 
and are discussed in this chapter.  
 
Adenocarcinoma in situ (AIS) is recognised as a non-invasive form of glandular 
hyperplasia, with the potential to undergo malignant transformation to invasive 
adenocarcinoma. Little is known about the genetic aberrations and biological pathways 
involved in the early development of lung adenocarcinomas. In a cohort study by 
Izumchenko and colleagues (Izumchenko et al. 2014) targeted sequencing of cancer-
related genes performed on AIS samples, identified mutations in the genes KIT, KRAS, 
HRAS (Harvey Rat Sarcoma Viral Oncogene Homolog), IGF1R (Insulin-Like Growth 
Factor 1 Receptor), FGFR3 (Fibroblast Growth Factor Receptor 3), MET and TSC2 
(Tuberous Sclerosis 2) in four out of five patients. Unsurprisingly, most of the lesions 
harboured mutations in genes associated with DNA repair and chromatin remodelling, 
suggesting that abnormalities in the DNA repair machinery may be associated with the 
early development and tumourigenesis of lung adenocarcinoma as a result of 
increased genomic instability. The study of pre-invasive lung lesions, such as AIS 
lesions, may give some insight into the mutational pathways involved in initiating and 
driving the progression of pre-invasive lesions to invasive tumours.  
 
4.2 Baseline characteristics and histopathological variables 
Table 11 shows the baseline characteristics of the patients from whom AIS lesions 
were collected and sequenced. All five patients were ex-smokers, the median age was 
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74-years (range 71-86 years), three were male and two were female. The median 
lesion size was 40mm (range 20-53 mm).  
 
Patient Age Gender Smoking status (pack-years) Histology 
Size on 
path 
(mm) 
LTX013 86 M Ex-Smoker (13) Adenocarcinoma in situ 53 
LTX021 74 F Ex-Smoker (56) Adenocarcinoma in situ 40 
LTX041 76 M Ex-Smoker (74) Adenocarcinoma in situ 43 
LTX049 68 F Ex-Smoker (53) Adenocarcinoma in situ 20 
LTX055 71 M Ex-Smoker (52) Adenocarcinoma in situ 40 
Table 11 Baseline characteristics of the AIS cohort 
Baseline patient and lesion characteristics of the AIS cohort. 
 
 
4.3 Regional distribution of mutations and phylogenetic trees   
Filtered non-synonymous mutations were used to create heat maps representing the 
regional distribution of non-silent SNVs and indels, and phylogenetic trees were 
created using filtered non-synonymous and synonymous SNV and indel mutations 
(Figure 38). Both spatial and temporal heterogeneity was evident in the AIS lesions, 
with evidence for branched evolution. This suggested that similar to what was seen in 
the evolution of the NSCLC tumous, different populations of cells harbouring specific 
mutations existed in the pre-invasive lesions, and that they had undergone a degree of 
clonal evolution up until the point of surgical resection. Having previously shown that 
NSCLC tumours from patients who had never smoked often had shorter trunks 
compared to tumours from patients who were either current or ex-smokers, patient 
LTX013 had the shortest trunk, most likely related to his reduced exposure to tobacco 
smoke (13 pack-year history) compared with the other patients.   
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Figure 38 Heat maps and phylogenetic trees in AIS lesions 
Heat maps representing the regional distribution of mutations, where the presence of a mutation 
is indicated by blue and its absence by grey. Alongside each heat map is a vertical bar, where 
blue represents mutations that are present in all regions (truncal), yellow represents mutations 
that are present in some, but not all, regions (shared, branch), and red represents mutations 
that are present in one region only (private, branch). Underneath each heat map is the total 
number of non-synonymous mutations. Phylogenetic trees annotated by genes representing 
predicted driver category 1 to 3 mutations, with arrows pointing towards the part of the tree on 
which they have been acquired. Ubiquitous mutations (present in all regions) are shown on the 
blue trunks of trees, shared mutations (present in some, but not all, regions) are shown on the 
yellow branches of trees, and private mutations (present in only one region) are shown on the 
red branches of trees. Underneath each tree is the total number of filtered non-synonymous and 
synonymous mutations.  
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4.4 Predicted driver mutations 
As previously described, category 1 to 3 predicted driver mutations were identified in 
each lesion and used to annotate the phylogenetic trees shown in Figure 38. Both 
spatial and temporal heterogeneity of driver mutations was evident, with certain driver 
mutations occurring early (present on the trunks of the trees), and certain driver 
mutations occurring late (present on the branches of the trees) during the evolution of 
the pre-invasive lesions. Overall, there were 59 category 1 to 3 driver mutations, 17/59 
(29%) were category 1, 19/59 (32%) were category 2, and 23/59 (39%) were category 
3 predicted driver mutations. Amongst the category 1 high confidence driver mutations, 
14/17 (82%) of them were truncal (predicted to be clonal in origin), and 3/17 (17%) of 
them were branch mutations (predicted to be subclonal in origin). Category 1 to 3 
predicted driver mutations for each AIS lesion are listed in Table 12. 
 
Patient Gene Mutation type Driver category Truncal/Branch 
LTX013 
ABL1 SNV 2 Truncal 
WHSC1L1 SNV 3 Truncal 
SEPT6 SNV 3 Branch 
LTX021 
BRAF SNV 1 Truncal 
ATRX SNV 1 Truncal 
NRAS SNV 1 Branch 
PDGFRB SNV 2 Truncal 
EBF1 SNV 2 Truncal 
OMD SNV 2 Truncal 
CCND2 SNV 2 Branch 
ERBB3 SNV 2 Branch 
MBD1 SNV 2 Branch 
PALB2 SNV 3 Truncal 
MED12 SNV 3 Truncal 
ETV6 SNV 3 Branch 
SETBP1 SNV 3 Branch 
SETBP1 SNV 3 Branch 
CBLC SNV 3 Branch 
SRGAP3 SNV 3 Branch 
FGFR2 SNV 3 Branch 
LTX041 
KRAS SNV 1 Truncal 
TP53 SNV 1 Truncal 
PBRM1 Indel 1 Truncal 
FBXW7 SNV 1 Truncal 
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NT5C2 SNV 2 Truncal 
PICALM SNV 2 Truncal 
MYH11 SNV 2 Truncal 
ATP2B3 SNV 2 Truncal 
POU2AF1 SNV 3 Truncal 
TRIP11 SNV 3 Truncal 
BCL11B SNV 3 Truncal 
LTX049 
KRAS SNV 1 Truncal 
TSC2 SNV 1 Truncal 
DNM2 SNV 1 Truncal 
SMARCA4 SNV 1 Truncal 
ATRX SNV 1 Truncal 
ARID2 SNV 2 Truncal 
PRDM16 SNV 2 Truncal 
NTRK3 SNV 2 Truncal 
GATA2 SNV 2 Truncal 
DNAH12 SNV 2 Truncal 
WAS SNV 2 Truncal 
ATM SNV 3 Truncal 
GPHN SNV 3 Truncal 
FUBP1 SNV 3 Truncal 
FGFR1 SNV 3 Truncal 
LTX055 
FUBP1 SNV 1 Branch 
KRAS SNV 1 Branch 
KRAS SNV 1 Truncal 
NF1 SNV 1 Truncal 
PHOX2B SNV 1 Truncal 
NOTCH2 SNV 2 Truncal 
KLK2 SNV 2 Truncal 
TAL1 SNV 3 Branch 
TCF7L2 SNV 3 Truncal 
CCDC6 SNV 3 Truncal 
FUBP1 SNV 3 Truncal 
ROS1 SNV 3 Truncal 
AKAP9 SNV 3 Truncal 
 
Table 12 Category 1 to 3 predicted driver mutations in the AIS cohort 
Predicted category 1 to 3 driver mutations identified in each AIS lesion. The gene name, type of 
variant (SNV or indel), and whether the mutation is truncal or branch is shown.  
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Category 1 driver mutations in the KRAS gene were identified in 3/5 patients. In patient 
LTX041 there was a truncal G12C mutation, in patient LTX049 there was a truncal 
G12V mutation, and in patient LTX055 there was both a truncal G12C and a branch 
G12V mutation. In 2/5 patients there was a category 1 truncal driver mutation in the 
ATRX gene (E851X in LTX021 and R445N in LTX049). The presence of these 
activating mutations in the KRAS oncogene, mostly as truncal events, suggests that 
RAS-dependent signalling may play a significant role in the early development of AIS 
lesions. In the case of patient LTX055, the presence of both truncal and branch driver 
mutations in the KRAS gene, suggests that such signalling may be involved in both 
early and late evolution of AIS lesions. Since G>C or G>T transversions of the guanine 
nucleotide residues located in the wild type KRAS codon 12 are known to be 
associated with smoking (Ahrendt et al. 2001), and are uncommon in NSCLC amongst 
non-smokers (Riely et al. 2008), it is not surprising that these mutations existed in 
these ex-smoker patients with significant numbers of smoking pack-years (Table 11).  
 
Interestingly, in patient LTX021 there was a category 1 truncal driver mutation in BRAF 
(G466E, exon 11 kinase domain), as well as a category 1 branch driver mutation in 
NRAS (Q61K). This suggests that the BRAF mutation occurred early, and that the 
NRAS mutation occurred late, in the development of the AIS lesion. Both BRAF and 
NRAS are components of the MAPK/ERK pathway, which controls various cellular 
processes, including cellular proliferation, growth, migration and apoptosis (Dhillon et al. 
2007). Although distinct mutations in the BRAF and NRAS genes have occurred in 
different regions of the lesion, they converge on the same signalling pathway, 
representing a case of convergent evolution. If this in situ lesion were to progress 
further and transform into an invasive tumour, a single diagnostic biopsy would most 
likely only identify the truncal BRAF mutation as a driver of disease. Applying a 
selection pressure, such as treatment with a BRAF inhibitor, could allow the subclone 
harbouring the NRAS mutation to dominate the tumour mass and continue to drive 
disease through MAPK/ERK pathway activation, potentially leading to drug resistance 
and disease progression. Inhibiting the MAPK/ERK pathway downstream of its BRAF 
and NRAS components, for example with MEK or ERK inhibition, could potentially 
result in better disease control. In melanoma cell lines harbouring a BRAF V600E and 
NRAS Q61K mutation, resistance to the BRAF inhibitor vemurafenib, but sensitivity to 
the MEK inhibitor selumetinib, has been previously shown (Atefi et al. 2011). Inhibition 
with the ERK1/2 inhibitor PLX7904 has also been shown to inhibit tumour growth in 
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melanoma cell lines harbouring both the BRAF V600E and NRAS Q61K mutations (D. 
B. Johnson et al. 2014; Le et al. 2013). Similarly in a BRAF-, KRAS- and NRAS-mutant 
xenograft models of melanoma, sensitivity and tumour response to the ERK1/2 
inhibitor SCH772984 has also been shown (E. J. Morris et al. 2013). One potential 
treatment option in the context of both mutations and advanced invasive 
adenocarcinoma might be combination therapy with a BRAF and MEK inhibitor in 
melanoma, such as dabrafenib and trametinib, which has been shown to significantly 
improve PFS and OS (Long et al. 2015).  
 
4.5 Intratumour heterogeneity in copy number aberrations 
Copy number aberrations have been previously demonstrated in pre-invasive lung 
cancer lesions (Massion et al. 2009). Recurrent chromosomal segment gains and/or 
amplifications, and losses and/or deletions were identified in the AIS lesions as 
described in Section 2.11, and were used to identify potential driver copy number 
aberrations (Figure 39 and Figure 40). Predicted driver genes within each 
chromosomal segment were identified and used to annotate each heat map. 
Intratumour spatial heterogeneity in copy number gains and/or amplifications was seen 
in all of the AIS lesions, apart from in patients LTX049, in whom only two regions had 
been sequenced (Figure 39). Similarly, intratumour spatial heterogeneity in copy 
number losses and/or deletions was seen in all of the AIS lesions (Figure 40). Overall, 
the existence of heterogeneous copy number aberrations in pre-invasive lung lesions 
suggests that branched evolution of copy number events can occur in the early stages 
of cancer development prior to the development of invasive disease.  
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Figure 39 Copy number gains and/or amplifications in AIS lesions 
Heat map representing the regional distribution of potential driver copy number gains and/or 
amplifications in the AIS lesiosn, based on recurrently amplified chromosomal segments 
identified in TCGA data. For each tumour region amplifications and gains were determined 
relative to the mean ploidy. Each cytoband range defines a chromosomal segment, and each 
segment is annotated by predicted driver genes contained within the segment. 
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Figure 40 Copy number losses and/or deletions in AIS lesions 
Heat map representing the regional distribution of potential driver copy number losses in the 
AIS lesions, based on recurrently deleted chromosomal segments identified in TCGA data. For 
each tumour region losses were determined relative to the mean ploidy. Each cytoband range 
defines a chromosomal segment, and each segment is annotated by predicted driver genes 
contained within the segment.  
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4.6 Conclusions and discussion  
Whilst sequencing studies have given us some insight into the heterogeneous genomic 
landscape of tumours, and the genetic aberrations involved in tumourigenesis, our 
understanding of the early stages of cancer development remains limited. The somatic 
mutational burden, the dynamics of potentially competing populations of cells, and the 
effect of driver mutations, in pre-invasive solid tumour disease is yet to be determined. 
Since the development of cancer, and the evolution of tumours, is thought to rely on 
the accumulation of driver mutations in cancer-related genes (Vogelstein et al. 2013), 
the existence of acquired somatic mutations, including those in known driver genes, in 
pre-invasive lesions is not surprising. Furthermore, recent evidence has shown the 
existence of significant mutational burden, and high frequency of oncogenic driver 
mutations subject to positive clonal selection in physiologically normal skin cells 
(Martincorena et al. 2015).  
 
The spatial and temporal heterogeneity of mutations and copy number aberrations 
seen in these AIS lesions suggests that prior to the potential development of invasive 
disease, these pre-invasive lesions have already undergone a degree of clonal 
evolution, such that they are composed of different populations of cells harbouring 
specific driver mutations. Although the identified drivers in these lesions may have not 
led to the development of invasive disease at the time of surgical resection, it is 
conceivable that under certain microenvironmental selection pressures, such as 
hypoxia or altered vasculature, these drivers may have the opportunity to play a role in 
driving clonal expansion, and therefore invasive transformation. Further investigation of 
pre-invasive lung lesions may reveal essential components of the pathways involved in 
the early stages of cancer development, and the combination of driver mutations 
necessary to aid the pre-invasive to invasive transition.  
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5 Results 3: Detection of genetic aberrations in cfDNA 
from patients with NSCLC 
5.1 Introduction 
Several studies have demonstrated the use of cfDNA in tracking tumour evolution and 
mutational burden in patients with cancer over time (Murtaza et al. 2014; Diehl et al. 
2008; Diehl et al. 2005; Dawson et al. 2013; Diaz et al. 2012; Carreira et al. 2014; 
Siravegna et al. 2015). Circulating biomarkers have the potential to aid early detection 
and guide treatment initiation and stratification. Given the sampling bias associated 
with single tumour biopsies, and the difficulties in repeated tumour sampling, the use of 
cfDNA to identify therapeutically targetable mutations and the emergence of 
therapeutic resistance mechanisms, may have significant implications for the 
management of patients with cancer. The accurate identification of, and the distinction 
between, clonal and subclonal mutations in cfDNA can give some insight into the 
heterogeneous genomic landscape of tumours. Furthermore, the use of such 
circulating biomarkers to monitor tumour clonal dynamics has the potential to enable 
real-time monitoring of tumour evolution at clinically relevant stages of disease, such 
as disease progression and the development of resistance to therapy (Jamal-Hanjani, 
Quezada, et al. 2015). Further evidence supporting the use of circulating biomarkers to 
detect early stage cancers may inform cancer screening strategies, and the detection 
of tumors at earlier time points in their evolution. Such strategies could potentially aid 
early therapeutic intervention prior to the onset of intratumour heterogeneity.  
 
The concordance between mutations detected in tumours and cfDNA in early stage 
disease remains unclear. Furthermore, exactly how representative cfDNA is of the 
underlying genomic landscape of tumours, and whether subclonal, as well as clonal, 
mutations can be successfully detected is yet to be determined. In this chapter, three 
different approaches were used to detect aberrations in cfDNA extracted from patients 
with early stage NSCLC in order to define an optimal approach to address these 
questions. Mutations were chosen based on multi-region WES and Ion AmpliSeq deep-
sequencing validation data from a selection of patients in the NSCLC pilot cohort from 
whom plasma was collected prior to surgical resection of their primary tumours. Both 
ubiquitous truncal mutations, predicted to be clonal in origin, and heterogeneous 
branch mutations, predicted to be subclonal in origin, were chosen to represent the 
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heterogeneous landscape of each tumour, and to determine the sensitivity of the 
different approaches in detecting mutations with low variant allele frequencies (VAFs). 
Having previously defined reliable VAF thresholds to determine the presence or 
absence of a mutation in each tumour region (Section 2.5.1), a VAF threshold of 1% for 
SNVs and 2% for indels was used. Where Ion AmpliSeq data was not available, WES 
data was used. Germ line DNA was extracted from whole blood using the QIAamp 
DNA Blood Mini Kit (Qiagen). Plasma was extracted from approximately 10ml whole 
blood samples collected from patients prior to surgical resection of their primary 
NSCLC tumours (Section 2.3). The plasma extraction protocol was established in 
collaboration with Professor Jacqueline Shaw (University of Leicester), and is the 
recommended protocol by the ECMC and NCRI Biomarker and Imaging Clinical 
Studies Group (cfDNA consensus meeting, 2014). cfDNA was extracted from 
approximately 2ml plasma samples using the QIAamp Circulating Nucleic Acid kit 
(Qiagen).  
 
In collaboration with Agena Bioscience (Michael Mosko and Anders Nygren, San Diego, 
CA, USA), the presence of mutations in cfDNA was analysed using multiplex PCR and 
Matrix Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) mass 
spectrometry, in collaboration with Illumina (Claire Fielding and Mark Ross, Cambridge, 
UK), multiplex PCR and targeted MiSeq sequencing was used, and in collaboration 
with Natera (Robert Pelham, San Carlos, CA, USA), multiplex PCR and targeted HiSeq 
sequencing was used.  
 
5.2 Multiplex PCR and MALDI-TOF mass spectrometry 
In collaboration with Agena Bioscience (Michael Mosko and Anders Nygren, San Diego, 
CA, USA), this approach involved determining the presence of mutations in cfDNA 
using a novel minor variant detection technique called UltraSEEK, which involves 
multiplex PCR followed by a mutation specific single base extension reaction and 
characterisation using MALDI-TOF mass spectrometry. Six patients (L003, L008, L011, 
L013, L017 and L019) from the NSCLC pilot cohort were analysed using this approach 
(Table 13). Patients L003 and L008 were from a previously published NSCLC pilot 
cohort (de Bruin et al. 2014), which has also been set-up prior to the TRACERx study. 
The UltraSEEK technique was used on the germ line DNA, DNA from each tumour 
region, and cfDNA. Mutations were detected using a median absolute deviation (MAD)-
Chapter 5 Results 3 
 140 
based z-score, which was calculated for each assay using the median and the MAD 
values previously established with cfDNA samples from normal healthy volunteers 
(Section 2.12.2.6). This data served as the baseline for the mutation detection and was 
used for each data analysis. Samples that exceeded the user-defined assay z-score 
cut-off (default of 10) and met the peak quality criteria (adjustable minimum peak 
intensity and the call probability of 0.8 or better) were labelled as containing the 
mutation by the analysis software (Typer Software, Agena Bioscience). 
 
Patient ID Age Gender Histology Stage Vascular invasion 
Pleural 
invasion 
Smoking 
status (pack 
years) 
L003 84 F LUAD IIIB N N Never-Smoker 
L008 75 M LUAD IIIA Y Y Ex-Smoker (25) 
L013 68 F LUSC IB Y Y Smoker (50) 
L017 61 F LUAD IIB Y N Smoker (48) 
L019 47 M LUAD IIIA N Y Never-smoker 
L011 49 F LUAD IB N N Smoker (45) 
Table 13 Clinical characteristic of the patient cohort.  
Abbreviations: LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. 
 
In patient L003, all selected mutations were identified in the tumour and lymph node 
DNA, with a regional distribution concordant with the sequencing data (Table 14). 
However, none of these mutations were identified in the cfDNA. Figure 41 shows the 
average adjusted normalised intensity for each mutation in the germ line, tumour DNA 
and cfDNA compared to the wild type control DNA.  
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Table 14 Summary of UltraSEEK results for L003 
The VAF for each selected mutation from the Ion AmpliSeq or WES data, and whether the 
mutation was detected in the tumour DNA and cfDNA is shown here. Genes highlighted in red 
represent category 1 to 3 predicted driver mutations. Abbreviations: nd, not detected.  
 
 
 
Figure 41 Distribution of detected mutations in L003 
The average adjusted normalised intensity for each mutation (gene name on the x-axis) in the 
germ line, tumour, and wild type control DNA, and cfDNA. 
 
In patient L008, all the selected mutations were identified in the tumour DNA, with a 
regional distribution concordant with the sequencing data (Table 15). Four truncal 
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 LN R2 R4 LN R2 R4 cfDNA 
EGFR (L858R) Truncal 20.8 6.1 68.8 ✓ ✓ ✓ nd 
MUC1 (H116D) Branch 6.3 0 15.8 ✓  ✓ nd 
BRAF (G30D) Branch 19.0 0 0 ✓   nd 
MLL (S2834L) Branch 0 0 9.5   ✓ nd 
JAK1 (E613K) Branch 0 6.4 0  
✓ 
 nd 
CTNNB1 (S37F) Branch 0 7.1 0  
✓ 
 nd 
FOXP1 (Y25X) Branch 0 16.3 0  
✓ 
 nd 
IL7R (P132S) Branch 0 17.7 0  
✓ 
 nd 
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mutations were identified in the cfDNA; BRAF (G469A), MLL2 (A5010T), RB1 (5829X) 
and TP53 (H193Y) (Figure 42A). cfDNA detection of these mutations was confirmed 
for BRAF, RB1 and TP53 in two replicate assays, and for MLL2 in one replicate assay 
(Figure 42B). 
 
Gene (amino acid 
change) 
Truncal/Branch Ion AmpliSeq/WES VAF 
(%) UltraSEEK detection 
 
 R1 R3 R5 R1 R3 R5 cfDNA 
BRAF (G469A) Truncal 28.3 10.5 2.9 ✓ ✓ ✓ ✓ 
MLL2 (A5010T) Truncal 41 10.5 6.5 ✓ ✓ ✓ ✓ 
RB1 (S829X) Truncal 44.4 12.6 5.6 ✓ ✓ ✓ ✓ 
TP53 (H193Y) Truncal 43 9.8 8.1 ✓ ✓ ✓ ✓ 
PIK3CA (E542K) Branch 0 6.7 0  
✓ 
 nd 
MAGI2 (D575N) Branch 0 4.4 0  
✓ 
 nd 
TNK2 (G6S) Branch 6.6 0 0 ✓   nd 
Table 15 Summary of UltraSEEK results for L008 
The VAF for each selected mutation from the Ion AmpliSeq or WES data, and whether the 
mutation was detected in the tumour DNA and cfDNA is shown here. Genes highlighted in red 
represent category 1 to 3 predicted driver mutations. Abbreviations: nd, not detected.  
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Figure 42 Distribution of mutations in L008 
The average adjusted normalised intensity for each mutation (gene name on the x-axis) in the 
germ line, tumour, and wild type control DNA, and cfDNA (A), magnified portion of the y-axis 
with lower intensities showing the separation between wild type control and replicate cfDNA 
assays (B).  
 
In patient L011, all the selected mutations were identified in the tumour DNA, with a 
regional distribution concordant with the sequencing data (Table 16). None of the 
selected mutations was identified in the cfDNA (Figure 43).  
 
Gene (amino acid 
change) 
Truncal/Branch Ion AmpliSeq/WES VAF 
(%) UltraSEEK detection 
  R1 R2 R3 R1 R2 R3 cfDNA 
BRAF (V600E) Truncal 19.3 31.2 15.8 ✓ ✓ ✓ nd 
TP53 (E166X) Truncal 22.6 32 19.5 ✓ ✓ ✓ nd 
OR10Z1 (R270S) Branch 6.8 0 0 ✓   nd 
LGALSL (D75Y) Branch 9.2 0 0 ✓   nd 
CSMD3 (G2956R) Branch 0 10.7 0  
✓ 
 
nd 
CHD2 (K1022M) Branch 0.1 8.5 0  
✓ 
 
nd 
GPX6 (K106fs) Branch 0.7 1 7.8 nd nd ✓ nd 
HSP90AA1 Branch 0 0 9.4   
✓ nd 
Table 16 Summary of UltraSEEK results for L011 
The VAF for each selected mutation from the Ion AmpliSeq or WES data, and whether the 
mutation was detected in the tumour DNA and cfDNA is shown here. Genes highlighted in red 
represent category 1 to 3 predicted driver mutations. Abbreviations: fs, frameshift mutation; nd, 
not detected.   
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Figure 43 Distribution of mutations in L011 
The average adjusted normalised intensity for each mutation (gene name on the x-axis) in the 
germ line DNA, tumour DNA from each respective region, wild type control DNA, and cfDNA. 
 
In patient L013, all the selected mutations were identified in the tumour DNA, with a 
regional distribution concordant with the sequencing data. In addition, UltraSEEK 
detected the mutation in JAK2 in tumour region R1, which was below the sequencing 
reliable detection threshold (VAF of 0.2%) (Table 17). One truncal mutation, EGFR 
(D761Y), was identified in the cfDNA (Figure 44). 
 
Gene (amino acid 
change) 
Truncal/Branch Ion AmpliSeq/WES VAF 
(%) UltraSEEK detection 
 
 R1 R2 R3 R1 R2 R3 cfDNA 
EGFR (G719A) Truncal 21.4 24.8 55.2 ✓ ✓ ✓ nd 
EGFR (D761Y) Truncal 20.1 17.3 48 ✓ ✓ ✓ ✓ 
TP53 (P21S) Truncal 7 4.3 15.6 ✓ ✓ ✓ nd 
MSH2 (Q510H) Truncal 5 4 11 ✓ ✓ ✓ nd 
JAK2 (K33X) Branch (0.2) 11 7 ✓ ✓ ✓ nd 
MLL3 (K589R) Branch 0 0 4.1   
✓ nd 
FBXO46 (R133W) Branch 0 0 9.5   
✓ nd 
Table 17 Summary of UltraSEEK results for L013 
The VAF for each selected mutation from the Ion AmpliSeq or WES data, and whether the 
mutation was detected in the tumour DNA and cfDNA is shown here. Genes highlighted in red 
represent category 1 to 3 predicted driver mutations. Abbreviations: nd, not detected.   
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Figure 44 Distribution of mutations in L013 
The average adjusted normalised intensity for each mutation (gene name on the x-axis) in the 
germ line, tumour, and wild type control DNA, and cfDNA (A), magnified portion of the y-axis 
with lower intensities showing the separation between wild type control and cfDNA assays (B).  
 
In patient L017, all the selected mutations were identified in the tumour DNA, with a 
regional distribution concordant with the sequencing data. In addition, UltraSEEK 
detected the mutation in TRIM67 in tumour region R1, which was below the reliable 
sequencing detection threshold (VAF of 0.21%) (Table 18). The mutation in EIF2AKI 
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was not assessed due to assay failure, and none of the selected mutations were 
identified in the cfDNA (Figure 45).  
 
Gene (amino acid 
change) Truncal/Branch 
Ion AmpliSeq/WES VAF 
(%) UltraSEEK detection 
  R1 R2 R3 R1 R2 R3 cfDNA 
KRAS (G12V) Truncal 20 22 0 ✓ ✓  nd 
BRCA2 (S2156F) Truncal 16 28 0 ✓ ✓  nd 
TP53 (E155X) Truncal 19.5 34.9 0 ✓ ✓  nd 
NF1 (C1690Y) Truncal 20 25 0 ✓ ✓  nd 
PAX8 (P273L) Branch 9 0 0 ✓   nd 
TRIP11 (E897Q) Branch 6.6 0 0 ✓   nd 
TRIM67 (R298C) Branch (0.21) 66 0 ✓ ✓  nd 
TP53 (splice variant) NA 0 0 16   
✓ nd 
NF1 (R366X) NA 0 0 20   
✓ nd 
Table 18 Summary of UltraSEEK results for L017 
The VAF for each selected mutation from the Ion AmpliSeq or WES data, and whether the 
mutation was detected in the tumour DNA and cfDNA is shown here. Genes highlighted in red 
represent category 1 to 3 predicted driver mutations. Abbreviations: nd, not detected; NA, not 
applicable.  
 
 
Figure 45 Distribution of mutations in L017 
The average adjusted normalised intensity for each mutation (gene name on the x-axis) in the 
germ line, tumour, and wild type control DNA, and cfDNA. 
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In patient L019, the UltraSEEK approach identified all the selected mutations in the 
tumour DNA, with a regional distribution concordant with the sequencing data. The 
UltraSEEK approach was able to detect the mutation in KNTC1 in R1, which was 
unexpected since this mutation was found to be absent in this region based on the 
WES data with 0/467 mutant reads (VAF = 0%). Table 19 summarises the results for 
patient L019. The mutations in ARID5A and MYCN, and the EML4-ALK translocation 
were not assessed due to assay failure (Figure 46A). In addition, the mutation in 
LEPRE1 was identified in R1 and LN3, despite a VAF of 0.8% and 0.1%, respectively 
(Figure 46B).  
 
Gene 
(amino 
acid 
change) 
Truncal/Branch Ion AmpliSeq/WES VAF (%) UltraSEEK detection 
 
 R1 LN1 LN2 LN3 R1 LN1 LN2 LN3 cfDNA 
AKAP9 
(T1741A) 
Truncal 11 13 13 3 ✓ ✓ ✓ ✓ nd 
XRRA1 
(R100S) 
Branch 0 10.3 19.2 3.3  
✓ ✓ ✓ nd 
KNTC1 
(Q173R) 
Branch 0 18 19 4 ✓ ✓ ✓ ✓ nd 
LEPRE1 
(D36Y) 
Branch (0.8) 1.7 1.4 (0.1) ✓ ✓ ✓ ✓ nd 
POU2AF1 
(S89F) 
Branch 4 0 0 0 ✓    
nd 
Table 19 Summary of UltraSEEK results for L019  
The VAF for each selected mutation from the Ion AmpliSeq or WES data, and whether the 
mutation was detected in the tumour DNA and cfDNA is shown here. Genes highlighted in red 
represent category 1 to 3 predicted driver mutations. Abbreviations: nd, not detected.  
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Figure 46 Distribution of mutations in L019 
The average adjusted normalised intensity for each mutation (gene name on the x-axis) in the 
germ line, tumour, and wild type control DNA, and cfDNA (A), magnified portion of the y-axis 
with lower intensities showing the separation between wild type control and cfDNA assays (B).  
 
5.2.1 Summary of the UltraSEEK technique 
The UltraSEEK technique was successful in detecting 44/48 (92%) of the selected 
mutations in tumour DNA, providing validation for a targeted approach in tumour DNA. 
In general, the pattern of detection in the tumour DNA was in keeping with the regional 
distribution for each mutation based on the sequencing data using a VAF threshold for 
detection of 1%. There were 4 failed assays in which the predicted aberration was not 
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identified in tumour DNA using the UltraSEEK technique. Three of these were 
mutations that had failed Ion AmpliSeq amplification (EIF2AK1, ARID5A and MYCN), in 
which case the WES data was used instead to predict the presence or absence of the 
mutation in each tumour region. The mutations in EIF2AK1 and ARID5A were both 
C>A mutations that were subsequently identified as sequencing artefacts associated 
with the Nextera library reparation kit (Illumina). A failure in primer design was thought 
to be the reason why the mutation in MYCN was not detected. Finally, a failure to 
detect the EML4-ALK translocation was also thought to be due to a failure in primer 
design. Therefore, this technique was able to detect 44/46 of the chosen variants in 
tumour and lymph node DNA. Although the UltraSEEK technique was able to detect 
mutations in tumour DNA with VAFs as low as 0.2% (JAK2 in L013 and TRIM67 in 
L017) and 0.1% (LEPRE1 in L019), this was not consistently seen across all tumours, 
since several other mutations with similar or even higher VAFs were not detected. Only 
5/44 (11%) of the identified mutations were detected in cfDNA. Four of these mutations 
(BRAF G469A, MLL2 A5010T, RB1 5829X, and TP53 H193Y) were detected in patient 
L008, who was a 75-year-old male with stage IIIA lung adenocarcinoma (LUAD) and 
evidence for both vascular and pleural invasion (Table 13). He was an ex-smoker with 
a 25 pack-year history, having stopped smoking 10-years ago. The remaining mutation 
(EGFR D761Y) was detected in patient L013, who was a 68-year-old female with stage 
IB lung squamous cell carcinoma (LUSC) and evidence for both vascular and pleural 
invasion. She was a current smoker with a 50 pack-year history. All five mutations were 
predicted to be truncal events based on the sequencing data, and were either category 
1 or 2 predicted driver mutations. These mutations were amongst those with higher 
tumour VAFs compared to others (48% for EGFR in L013, 28.3% for BRAF in L008, 
41% for MLL2 in L008, 44.4% for RB1 in L008, and 43% for TP53 in L008). There was 
a statistically significant difference in the median tumour VAF between the mutations 
that were detected in cfDNA (20.3%, range 13.9 to 28.5%), and those that were not 
detected (9.3%, range 1.3 to 33.8%) (Mann-Whitney test, p = 0.01207), suggesting that 
mutations with higher tumour VAFs are more likely to be detected in cfDNA using this 
approach.  
 
5.3 Multiplex PCR and targeted MiSeq sequencing 
In collaboration with Illumina (Claire Fielding and Mark Ross, Cambridge, UK), this 
approach involved determining the presence of mutations in cfDNA using multiplex 
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PCR and targeted MiSeq sequencing in one patient (L019) from the NSCLC pilot 
cohort (Table 20).  
 
Patient ID Age Gender Histology Stage Vascular invasion 
Pleural 
invasion 
Smoking 
status (pack 
years) 
L019 47 M LUAD IIIA N Y Never-smoker 
Table 20 Clinical characteristics of Patient L019 
Abbreviations: LUAD, lung adenocarcinoma.  
 
Targeted MiSeq sequencing was performed using germ line, tumour DNA and cfDNA. 
Five SNVs, 2 indels, and one EML4-ALK translocation were analysed in the cfDNA, 
with a mean sequencing coverage of 309,065x (range 9,495x - 701,653x) (Table 21). 
The number of mutant reads and VAFs for each variant are shown in Figure 47 and 
Figure 48. The SNV mutation in ARID5A had low mutant reads and VAFs across all 
samples. This mutation was subsequently found to be a sequencing artefact 
associated with the Nextera XT library preparation kit (Illumina), and was therefore not 
taken forward. Variant mutant reads were detected in the germ line and control DNA 
samples, which was not unexpected at this level of ultra-deep sequencing. 
Furthermore, since germ line DNA was extracted from whole blood, mutant reads 
present in the germ line DNA may have been associated with contamination from 
circulating tumour DNA. As expected, the number of mutant reads (range 5 to 203) and 
the VAFs (range 0.015 to 0.094%) identified for each variant in the control DNA were 
significantly lower compared with the tumour and lymph node samples.  
 
In order to determine whether variants were detected in the cfDNA, the number of 
mutant reads and the VAFs for each variant were compared with their corresponding 
control DNA results. In all variants, apart from the mutation in ZNF175 and XRRA1, the 
number of mutant reads detected in the cfDNA was higher compared to the control 
DNA. This was most evident in the DIS3L2 (truncal indel), LEPRE1 (branch SNV), and 
the EML4-ALK translocation variants (Figure 47). Only the variants in DIS3L3 and 
LEPRE1 had VAFs that were higher in the cfDNA compared with the control DNA 
(Figure 48). These data suggest that the variants in DIS3L3, LEPRE1, and EML4-ALK 
may have been successfully detected in the cfDNA. However, with too few data points 
it is not possible to assign any statistical significance to this, and therefore the data is 
only suggestive. Patient L019 was also investigated using the UltraSEEK technique, 
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with three overlapping mutations between the two approaches (XRRA1, POU2AF1 and 
LEPRE1). None of these mutations were detected in cfDNA using the UltraSEEK 
technique. 
 
5.3.1 Summary 
In summary, this approach detected mutations in the tumour DNA from patient L019, 
with a regional distribution in keeping with the sequencing data. Of the eight variants 
that were tested in cfDNA, one of the mutations (ARID5A) was disregarded since it was 
a sequencing artefact, and although the data suggest that the variants in DIS3L3, 
LEPRE1, and EML4-ALK may have been successfully detected in the cfDNA, this 
cannot be interpreted with any statistical confidence. 
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Table 21 Summary results for L019 
Results of targeted MiSeq sequencing (performed by Illumina) of 8 variants in L019. Mutant and  
wild type reads for each variant are shown, with corresponding VAFs. Genes highlighted in red 
represent category 1 to 3 predicted driver events.  
 
 
 
 
Gene ZNF175 DIS3L2 XRRA1 LEPRE1 POU2AF1 MYCN EML4-ALK 
 
Germ 
line 
WT 
reads 351983 334273 623397 274003 265457 1211   
Mutant 
reads 55 65 251 208 54 1 18 
VAF 
(%) 0.016 0.019 0.040 0.076 0.020 0.083   
R1 
WT 
reads 331354 249215 556200 244527 253986 3945   
Mutant 
reads 36280 24827 260 29106 11650 3 7003 
VAF 
(%) 9.9 9.1 0.047 10.6 4.4 0.076   
LN1 
WT 
reads 291810 249820 475613 266533 243945 2500   
Mutant 
reads 43077 28155 48933 36819 220 1 8541 
VAF 
(%) 12.9 10.1 9.3 12.1 0.090 0.040   
LN2 
WT 
reads 267553 228526 428459 301177 223676 4037   
Mutant 
reads 45946 39748 74027 55837 49 613 8215 
VAF 
(%) 14.7 14.8 14.7 15.6 0.022 13.2   
LN3 
WT 
reads 268721 264745 454662 358989 222236 4731   
Mutant 
reads 12524 11038 12335 16924 44 21 1749 
VAF 
(%) 4.5 4.0 2.6 4.5 0.020 0.442   
Control 
WT 
reads 246309 204118 603413 151341 205466 9969   
Mutant 
reads 36 38 203 142 50 5 37 
VAF 
(%) 0.015 0.019 0.034 0.094 0.024 0.050   
cfDNA 
WT 
reads 637046 585543 1769824 1319598 468821 40073   
Mutant 
reads 3 190 156 806 68 25 277 
VAF 
(%) 0.001 0.033 0.010 0.198 0.019 0.035   
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Figure 47 Number of mutant reads comparison between tumour, control, and 
cfDNA 
The number of mutant reads for each mutation/translocation in germ line, control, tumour region 
R1, lymph node regions LN1 to LN3 DNA, and cfDNA in patient L019 (A), magnified y-axis 
scale demonstrating the detected variants with low number of mutant reads (B). 
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Figure 48 VAF comparison between tumour, control, and cfDNA 
The variant allele frequency (VAF) for each mutation in germ line, control, tumour region R1, 
lymph node regions LN1 to LN3 DNA, and cfDNA (A), magnified y-axis scale demonstrating the 
detected variants with low number of mutant VAFs (B). 
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5.4 Multiplex PCR and targeted HiSeq sequencing 
In collaboration with Natera (Robert Pelham, San Carlos, CA, USA), this approach 
involved determining the presence of mutations in cfDNA using multiplex PCR and 
targeted HiSeq sequencing. Four patients (L012, L013, L015 and L017) from the 
NSCLC pilot cohort were analysed using this approach (Table 22). Fifty SNV mutations 
were selected for analysis, including both ubiquitous truncal and heterogeneous branch 
mutations. This approach was used on the germ line DNA, DNA from each tumour 
region, and cfDNA for each patient, as well as cfDNA obtained from presumed-normal 
healthy volunteers representing negative controls for each mutation (n=48). Primers 
designed for each mutation were combined in a multiplex PCR approach, followed by 
targeted sequencing on the HiSeq 2500 system (Illumina). The median coverage per 
mutation target in cfDNA was 62,399x. One mutation (CYFIP1 in patient L012) was 
disregarded, since it was subsequently found to be a sequencing artefact associated 
with the Nextera XT library preparation kit (Illumina). Of the remaining 49 SNV 
mutations, 12 assays failed to detect a mutation in the tumour DNA or cfDNA due to 
low coverage. A total of 37 mutations were taken forward. 
 
Patient ID Age Gender Histology Stage 
Vascular 
invasion 
Pleural 
invasion 
Smoking 
status (pack 
years) 
L012 69 F LUSC IB Y Y Smoker (40) 
L013 68 F LUSC IB Y Y Smoker (50) 
L015 68 M LUSC IA N N Smoker (100) 
L017 61 F LUAD IIB Y N Smoker (48) 
Table 22 Clinical characteristics of the patient cohort 
Abbreviations: LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. 
 
In the germ line and tumour DNA there was good concordance between the VAFs 
identified by prior sequencing (WES and IonAmpliSeq), and those identified by the 
Natera approach, with a significant linear correlation between the two (coefficient of 
determination, R2 = 0.9144, p < 0.0001) (Figure 49). The VAFs ranged from 0.1 to 
65.7% with prior sequencing, and 0.15 to 60.8% with the Natera approach (Table 23).  
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Figure 49 Concordance between VAFs  
Concordance between individual mutation variant allele frequencies (VAFs) and mean VAF 
(vertical line) identified by prior sequencing (WES and Ion AmpliSeq) and the Natera approach 
by direct comparison (A), and by linear regression modeling (B).  
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Patient 
Gene 
(amino 
acid 
change) 
WES/Ion AmpliSeq 
(VAF %) Natera (VAF %) cfDNA 
(VAF %) 
Truncal/ 
Branch R1 R2 R3 R1 R2 R3 
L012 
LUSC 
Stage IB 
Smoker 
(40) 
BRIP1 
(R173C) 14.0 6.0 8.0 22.6 7.7 10.1 3.71 Truncal 
CARS 
(T51A) 22.0 11.0 16.0 22.4 10.5 18.2 5.02 Truncal 
CIC (E61X) 0.1 nd 7.0 nd nd 8.2 1.71 Branch 
FAT1 
(D924Y) 8.0 4.0 1.2 9.8 4.3 0.8 0.57 Branch 
KDM6A 
(R4079K) 10 5.0 0.8 6.3 3.5 nd 0.28 Branch 
MLLT4 
(E478Q) 9.0 3.0 0.3 9.0 4.3 0.7 0.95 Branch 
NFE2L2 
(E1142D) 69.0 31.0 50 73.1 39.9 53.9 23.25 Truncal 
RASA1 
(E183X) 6.5 nd 0.7 7.4 nd 0.4 nd Branch 
TP53 
(R136H) 23.0 9.0 17.0 22.9 9.2 17.0 4.89 Truncal 
TP53 
(Y181C) 22.0 8.0 16.0 21.5 8.7 22.1 5.77 Truncal 
L013 
LUSC 
Stage IB 
Smoker 
(50) 
EGFR 
(G719A) 21.4 24.8 55.2 27.1 23.1 60.8 1.16 Truncal 
EGFR 
(D761Y) 20.1 17.3 48.0 23.9 18.0 56.3 1.09 Truncal 
HERC4 
(N217K) 0.1 3.0 6.0 0.2 1.9 5.7 nd Branch 
JAK2 
(K33X) 0.2 11.1 6.8 0.3 2.8 6.1 nd Branch 
MLL3 
(K589R) 0.2 0.2 4.1 nd nd 6.7 nd Branch 
MSH2 
(Q444H) 4.8 4.2 11.0 5.0 3.3 12.7 nd Truncal 
MTOR 
(Q838E) 2.0 0.6 3.0 2.4 1.4 6.0 nd Truncal 
PLCG2 
(E525X) 5.1 1.7 10.5 2.8 1.7 6.9 nd Truncal 
TP53  
(P60S) 7.0 4.3 15.6 6.1 3.8 15.4 0.4 Truncal 
L015 
LUSC 
Stage IA 
Smoker 
(100) 
ALK 
(P234R) 6.0 2.0 NS 7.2 1.4 NS nd Truncal 
GABRG1 
(I279F) 13.0 0.8 NS 11.8 2.0 NS nd Truncal 
KDM6A 
(S539C) 18.0 6.0 NS 6.5 0.9 NS 0.17 Truncal 
MLL2 
(E1186X) 5.0 0.3 NS 12.4 nd NS nd Branch 
ROS1 
(Y891C) 10.0 3.0 NS 10.8 2.9 NS 0.15 Truncal 
SLC39A4 
(A546T) 14.0 nd NS 18.6 nd NS nd Branch 
TP53 
(G199X) 19.0 3.0 NS 12.6 2.5 NS nd Truncal 
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ZFHX4 
(K3595N) 13.0 5.0 NS 10.3 2.3 NS nd Truncal 
ZMYM4 
(E257K) 14.0 2.0 NS 12.8 3.5 NS nd Truncal 
L017 
LUAD 
Stage IIB 
Smoker 
(48) 
BRCA2 
(S2156F) 16.0 28.0 nd 15.0 27.0 nd nd Truncal 
KRAS 
(G12V) 13.0 21.6 nd 14.2 23.8 nd nd Truncal 
NF1 
(C1711Y) 19.7 24.9 nd 18.6 23.1 nd nd Truncal 
NF1 
(R366X) nd nd 20.0 nd nd 17.8 0.37 NA 
PAX8 
(P350L) 9.3 nd nd 6.6 nd nd nd Branch 
TP53 
(E155X) nd nd 16.4 nd nd 19.0 nd NA 
TP53 
(Splice 
variant) 
19.5 34.9 nd 15.4 33.7 nd nd Truncal 
TRIM67 
(R298C) 21.0 65.7 nd 18.4 31.0 nd 0.57 Truncal 
TRIP11 
(E897Q) 6.6 nd nd 6.4 nd nd nd Branch 
Table 23 List of selected mutations for the Natera approach 
List of mutations and variant allele frequencies (VAFs) identified using WES/AmpliSeq 
sequencing and the Natera approach. VAFs are shown for each tumor region. Genes 
highlighted in red represent category 1 to 3 predicted driver mutations. Abbreviations: NA, not 
applicable; nd, not detected; NS, no sample; LUSC, lung squamous cell carcinoma; LUAD, lung 
adenocarcinoma. 
 
 
In patient L012, from the 10 selected mutations, 10/10 were identified in the tumour 
DNA, and 9/10 were identified in the cfDNA. Four of the mutations detected in the 
cfDNA were branch mutations (CIC, FAT1, KDM6A, and MLLT4). In patient L013, from 
the 9 selected mutations, 9/9 were identified in the tumour DNA, and 3/9 were 
identified in the cfDNA. The mutations identified in the cfDNA were all truncal mutations 
(EGFR G719A, EGFR D761Y, and TP53 P60S). This patient was also investigated 
using the UltraSEEK technique, and of the 6 overlapping selected mutations, 3 were 
detected in cfDNA using the Natera approach compared with only 1 (EGFR D761Y) 
using the UltraSEEK technique. In patient L015, from the 9 selected mutations, 9/9 
were identified in the tumour DNA, and 2/9 were identified in the cfDNA. The mutations 
identified in the cfDNA were truncal mutations (KDM6A and ROS1). In patient L017, 
from the 9 selected mutations, 9/9 were identified in the tumour DNA, and 2/9 were 
identified in the cfDNA (NF1 and TRIM67). This patient presented with two tumours at 
diagnosis; regions R1 and R2 came from one tumour, and region R3 came from 
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another tumour. The two mutations detected in the cfDNA were from separate tumours. 
The mutation in TRIM67 was truncal, and the status of the other mutation (NF1) could 
not be determined since it was identified in the second tumour from which only one 
region (R3) had been collected. This patient was also investigated using the UltraSEEK 
technique, and of the 9 overlapping selected mutations, 2 were detected in cfDNA 
using the Natera approach compared with none using the UltraSEEK technique. The 
median cfDNA VAF for truncal mutations was 1.16% (range 0.15 to 23.25%), and for 
branch mutations it was 0.76% (range, 0.28 to 1.71%) (Table 23). The number of 
branch mutations was too small for a statistical comparison between the two groups. 
Although the median tumour VAF for mutations that were detected in cfDNA was 
higher compared to those that were not detected (14.92%, range 3.27 to 55.63 vs. 
6.9%, range 2.6 to 24.55%), this was not statistically significant (Mann-Whitney test, p 
= 0.1584). To confidently call the mutations detected in cfDNA, and to estimate the 
background noise for each assay, the selected 37 mutations were also analysed in 
cfDNA from 48 presumed-normal healthy volunteers (Figure 50). The mean cfDNA 
VAF for the 37 mutations in the healthy volunteer cohort ranged from 0.001 to 0.343% 
(standard deviation range 0.001 to 0.036%). These samples represented normal 
baseline controls with background VAFs for comparison with mutation VAFs detected 
in cfDNA from patients. Since there was a normal distribution for VAF in the healthy 
volunteer cohort, for each mutation, a z-score was calculated using the mean VAF and 
standard deviation in this cohort of samples (negative controls), and the corresponding 
VAF in the patient samples. If the z-score was > 10, the mutation was considered to be 
present. None of the 16 mutations detected in cfDNA from the patient cohort were 
detected in cfDNA from the healthy volunteer cohort (p < 0.00001 for each mutation).  
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Figure 50 Detection of the mutations in cfDNA 
Detection of truncal and branch mutations in cfDNA from presumed-normal healthy volunteers 
(n=48) and patients L012, L013, L015 and L017. The mean VAF ± 3 standard deviations (SD) 
for the negative control cfDNA samples is shown in black, and the VAF for the 16 mutations 
detected in the patient cfDNA samples is shown in blue for the truncal mutations, and in red for 
the branch mutations (p<0.00001 for all 16 mutations).  
 
5.4.1 Summary 
In summary, this approach was able to detect all 37 selected mutations in tumour DNA, 
providing validation for the use of this technique in tumour profiling. However, less than 
half (16/37, 43%) of these mutations were detected in cfDNA. Four out of 16 (25%) of 
these were branch mutations, and 15/16 (94%) of these were predicted to be clinically 
relevant driver mutations. Overall, the 37 mutations consisted of 23 truncal mutations, 
11/23 (48%) of which were detected in cfDNA, and 12 branch mutations, 4/12 (33%) of 
which were detected in cfDNA. Two out of the 37 mutations were from tumour region 
R3 in patient L017, for which truncal or branch status could not be determined.  
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5.5 Conclusions and discussion 
The main aim of the work presented here was to determine how representative cfDNA 
was of the mutational burden in early stage primary NSCLC. In particular, the aim was 
to determine whether both truncal and branch mutations could be detected, such that 
the heterogeneous genomic landscape of tumours, and therefore a measure of 
intratumour heterogeneity, could be interpreted using cfDNA. In this chapter, three 
different approaches were used to detect a selection of mutations in cfDNA from a 
cohort of early stage NSCLC patients. All three approaches involved using mutation 
panels customised for each patient’s tumour based on prior deep sequencing. A 
multiplex PCR (mPCR) approach was combined with either mass spectrometry or next-
generation sequencing (MiSeq or HiSeq). The UltraSEEK technique (mPCR/mass 
spectrometry) detected 5/44 (11.4%) SNVs (all truncal) in cfDNA, and the Natera 
approach (mPCR/HiSeq) detected 16/37 (43.2%) SNVs in cfDNA (4 branch and 2 
truncal). The Natera approach detected the greatest proportion of selected mutations in 
cfDNA. In patients L013 and L017, both the UltraSEEK and Natera approaches were 
used, with the Natera approach detecting a greater number of mutations in comparison 
for both tumour DNA and cfDNA. Although it appeared that the Illumina approach 
(mPCR/MiSeq) was able to detect an SNV, an indel, and a translocation variant in 
cfDNA, this was based on single assays and overall there were very few selected 
mutations for testing, such that a measure of statistical significance could not be 
assigned. Table 24 summarises the results for all three approaches.  
 
A correlation between tumour burden or stage and the ability to detect genetic 
aberrations in circulating biomarkers, has been shown in several tumour types, 
including colorectal (Diehl et al. 2008), breast (Board et al. 2010; Dawson et al. 2013), 
ovarian (Forshew et al. 2012; Kuhlmann et al. 2012), hepatocellular (Chan et al. 2013), 
pancreatic (Yamada et al. 1998), and NSCLC (Nygaard et al. 2013). In the overall 
cohort of eight patients analysed here, there was no significant correlation identified 
between cfDNA mutation detection and stage (p = 1), lymph node involvement (p = 1), 
vascular invasion (p = 0.4286), pleural invasion (0.4286), or smoking status (0.4643). 
This is likely to have been due to the small sample size. 
 
The data presented here are not without limitations. The use of a relatively small 
amount (approximately 1ml) of plasma available for analysis may have influenced the 
ability to detect mutations in cfDNA. Increased plasma volume and further assay 
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optimisation, could considerably improve the analytical sensitivity of these approaches, 
and potentially allow the detection of mutations at lower VAFs, such as heterogeneous 
branch mutations. The incomplete concordance between mutations detected in tumour 
DNA and cfDNA may also have been a reflection of biological factors that can influence 
the release of tumour DNA into circulation, such as the extent of tumour vascularisation, 
rate of tumour growth and cellular apoptosis (Diaz & Bardelli 2014). In some cases, 
branch mutations that were predicted to be absent from some tumour regions based on 
prior Ion AmpliSeq and/or WES, were identified in these regions using the cfDNA 
approaches discussed here. Although the use of different sequencing platforms and 
greater sequencing coverage with the Illumina and Natera approaches may have 
increased the ability of these techniques to identify variants with low VAFs, any 
discrepancies between these approaches and prior sequencing was mostly due to the 
fact that with prior sequencing VAF thresholds were used to predict the presence or 
absence of a mutation in each tumour region. These thresholds were derived based on 
the multi-region WES and Ion AmpliSeq validation sequencing performed in the 
NSCLC pilot cohort, but if these thresholds were not used the concordance between 
prior sequencing and the MiSeq/HiSeq cfDNA approached would be 100%. In addition, 
the tumours presented here did not have copy number data, making it difficult to 
confidently rely on the VAFs obtained from variant calling alone, and therefore 
potentially affecting the comparison between VAFs obtained in cfDNA from NSCLC 
patients and from normal healthy volunteers in the Natera approache. There was one 
mutation in KNTC1 in tumour region R1 for patient L019, that was predicted to be 
absent with prior WES based on 0/467 mutant reads (VAF 0%) in this region, but was 
identified using the UltraSEEK technique. This approach involved the use of mass 
spectrometry, with little difference between the average adjusted normalised intensities 
for the mutation in region R1 and the wild type control, making it difficult to confidently 
interpret this result.  
 
Current assessments of treatment response and disease progression rely on clinical 
examination and the presence of measurable disease on radiological imaging. The 
detection of existing or new drivers of disease in plasma may precede such 
assessments, and therefore aid the early detection of disease recurrence and 
emerging drug resistance. This may in turn guide early therapeutic intervention, or the 
modification of ongoing treatment strategies. In addition, determining the clonality of 
these driver mutations may help identify the overriding drivers of disease at any given 
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time point during the disease course. Formal validation is required in clinical studies, 
such as TRACERx, where the use of circulating biomarkers is tested as part of the 
study endpoints to truly assess its utility in clinical practice and predicting survival 
outcome (Crowley et al. 2013). As a result of the sequencing artefacts and failed 
assays discussed here that were found to be associated with the Nextera XT library 
preparation kit (Illumina), this kit was not taken forward for use in the sequencing of 
tumours from the TRACERx lung study. 
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Pt Age G 
Smoking 
status 
(pack-
years) 
Histo Stage 
Tumour 
size (max 
diameter, 
mm) 
Lymph 
node 
involve
-ment 
Mutation 
detected 
in cfDNA 
T/B Detected by 
L008 75 M 
Ex-
smoker 
(25) 
LUAD IIIA 15 and 24 Yes BRAF (G469A) T UltraSEEK
 
        
MLL2 
(A5010T) 
T UltraSEEK 
        
RB1 
(S829X) 
T UltraSEEK 
        
TP53 
(H193Y) 
T UltraSEEK 
L012 69 F Smoker (40) LUSC IB 40 No 
BRIP1 
(R173C) 
T Natera 
        
CARS 
(T51A) 
T Natera 
        
CIC 
(E61X) 
B 
 
Natera 
        
FAT1 
(D924Y) 
B Natera 
        
KDM6A 
(R4079K) 
B Natera 
        
MLLT4 
(E478Q) 
B Natera 
        
NFE2L2 
(E1142D) 
T Natera 
        
TP53 
(R136H) 
T Natera 
        
TP53 
(Y181C) 
T Natera 
L013 68 F Smoker (50) LUSC IB 50 No 
EGFR 
(D761Y) 
T UltraSEEK
/Natera 
        
EGFR 
(G719A) 
T Natera 
 
       
TP53 
(P21S) 
T Natera 
L015 68 F Smoker (100) LUSC IA 30 No 
KDM6A 
(S539C) 
T Natera 
 
       
ROS1 
(Y891C) 
T Natera 
L017 61 F Smoker (48) LUAD IIB 14 and 20 No 
NF1 
(R366X) 
T Natera 
 
       
TRIM67 
(R298C) 
T Natera 
Table 24 Summary results for the mutations detected in cfDNA 
Clinical variables for patients in which cfDNA mutations were detected using the UltraSEEK, 
Illumina, and Natera approaches. Genes highlighted in red represent category 1 to 3 predicted 
driver mutations. Abbreviations: Pt, patient; G, gender; M, male; F, female; Histo, histology; 
LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; T, truncal; B, branch. 
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6 Results 4: CIN in the TransTACT cohort 
6.1 Introduction  
Work from our laboratory has previously demonstrated a complex relationship between 
CIN and clinical outcome in ER-negative breast cancer (Roylance et al. 2011; Birkbak 
et al. 2011). In a discovery cohort of 246 patients with primary breast cancer, ER-
negative breast cancers were found to have increased CIN and clonal heterogeneity 
relative to ER-positive breast cancers. Whilst there was a linear relationship between 
increasing CIN and worsening prognosis in ER-positive tumours, in ER-negative 
tumours extreme CIN was paradoxically associated with improved prognosis (Roylance 
et al. 2011; Birkbak et al. 2011). In this chapter the results of the largest validation 
cohort study are presented assessing the relationship between CIN and outcome, 
using the same established dual centromeric FISH assay with pre-defined CIN 
thresholds as the discovery cohort study (Jamal-Hanjani, A'Hern, et al. 2015). This 
cohort of patients was chosen from the TACT trial (Ellis et al. 2009), where detailed 
clinical and follow-up data were available for each patient. The CIN status of each 
tumour was assessed in relation to clinical and histopathological variables, treatment 
response and clinical outcome. As previously discussed (Section 2.13.2) TMA slides 
containing tumour cores for each patient were used to identify discrete hybridisation 
signals for chromosomes 2 and 15. Using previously established methods (Roylance et 
al. 2011), a CIN score was derived by counting the numbers of centromeres for 
chromosomes 2 and 15 in 40 nuclei per core. The mean (centromere counts for 
chromosomes 2 and 15 combined) percentage of cells deviating from the modal 
centromere number was used to define 4 CIN score groups (Modal Centromere 
Deviation groups 1 to 4: MCD1, 0%–15%; MCD2, 15%–30%; MCD3 30%–45%; and 
MCD4, >45%). Roger A’hern at the Institute of Cancer Research Clinical Trials and 
Statistics Unit performed the statistical analyses presented here. 
 
6.2 The TransTACT TMA cohort  
Thirty TMAs were assessed, with each TMA containing an average of 100 tumour 
cores. All TMA slides were hybridised using centromeric probes for chromosome 2 
(CEP2) and 15 (CEP15). For some TMA slides hybridisation was not successful, and in 
some cases tumour cores had fallen off the slides. Hybridisation was successful in 
1994 cores for CEP2, and in 1721 cores for CEP15. 1374 cores with successful 
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hybridisation for both CEP2 and CEP15 were selected, and those cores with full clinical 
and histopathological annotation and centrally assigned ER-receptor status were 
further selected to form the study population of 1173 patients (Figure 51A). The 
distribution of the percentage of nuclei deviating from the modal centromere count, and 
the thresholds used in the allocation of MCD groups is shown in Figure 51B. 
Representative images of nuclei from tumour cores allocated to different MCD groups 
are shown in Figure 52. No statistically significant differences were observed between 
the clinical and pathological characteristics of patients in the overall TACT trial 
compared with the TransTACT study population analysed here (Table 25). 
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Figure 51 TransTACT study population and allocation of MCD groups 
CONSORT diagram outlining the selected study population from the TACT study (A), and 
histogram distribution of the percentage of nuclei deviating from the modal centromere signals 
and allocation of MCD1 to MCD4 groups (B) (Jamal-Hanjani, A'Hern, et al. 2015). 
 
 
 
 
Figure 52 Dual centromeric FISH 
Representative FISH images of MCD1 to MCD4 tumours with centromeric probes for 
chromosomes 2 and 15 labelled in red and green respectively, and DNA stained with DAPI, 
40,6-diamidino-2-phenylindole (Jamal-Hanjani, A'Hern, et al. 2015). 
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  Study cohort (n=1173) 
Whole cohort 
(n=4162) 
  n (%) n (%) 
Median age in years (range) 48 (25-88) 49 (24-88) 
Positive lymph nodes     
0 242 (20.6) 835 (20.1) 
1-3 524 (44.7) 1839 (44.2) 
4+ 407 (34.7) 1488 (35.8) 
Tumour size (cm)     
0-2 771 (65.7) 2657 (63.9) 
2-5 311 (26.5) 1108 (26.6) 
>5 91 (7.8) 392 (9.4) 
Grade     
I 53 (4.5) 229 (5.5) 
II 378 (32.2) 1536 (36.9) 
III 742 (63.3) 2382 (57.2) 
ER status     
Negative 429 (40.4) 1041 (36) 
Positive 744 (59.6) 1851 (64) 
PR status     
Negative 579 (49.4) 1582 (50.2) 
Positive 594 (50.6) 1572 (49.8) 
HER2 status     
Negative 886 (75.5) 2724 (76.4) 
Positive 287 (24.5) 841 (23.6) 
Age ≥ 40     
<40 216 (18.4) 718 (17.3) 
≥40 957 (81.6) 3444 (82.8) 
Treatment     
Control 588 (50.1) 2089 (50.2) 
FEC-T 585 (49.9) 2073 (49.8) 
Table 25 The TACT trial and TransTACT cohorts 
Patient and tumour characteristics in the TACT trial and TransTACT patient cohorts (Jamal-
Hanjani, A'Hern, et al. 2015). 
 
 
6.3 Patient cohort characteristics and histopathological variables 
The distribution of histological grade, tumour size, lymph node involvement and ER- 
and HER2-receptor status in the study population across MCD groups is shown in 
Table 26. ER and PR-positive status was negatively correlated with increasing CIN 
(Table 26; Spearman’s rank correlation coefficient (Rs) = -0.09, p = 0.003 and -0.16, p 
< 0.001. HER2-positive status and increasing histological grade was positively 
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correlated with increasing CIN (Table 26; Rs = 0.16, p < 0.01 and 0.15, p < 0.01, 
respectively). In ER-positive tumours alone, there was a weak but significant positive 
correlation between increasing CIN and histologic grade (Rs = 0.14, p < 0.001, n 
(number of patients) = 744), which was not seen in ER-negative tumours (Rs = 0.06, p 
= 0.22, n = 429). Work from our laboratory has previously shown that CIN is associated 
with a younger age at diagnosis in ER-negative breast cancer (Endesfelder et al. 2011), 
however this was not demonstrated in the study population (Table 26). Figure 53A 
shows the relationship between histopathological parameters ER and HER2 status with 
MCD group, and Figure 53B shows the relationship between tumour size, lymph node 
status, and grade with MCD group.  
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  Study cohort MCD1 MCD2 MCD3 MCD4 Rs p 
  n n (%) n (%) n (%) n (%)    
   354 (30.2) 
447 
(38.1) 
283 
(24.1) 89 (7.7)    
Median age in 
yrs (range) 
49 (24-
88) 48 (25-88) 
49 (28-
67) 
49 (25-
70) 
49 (27-
75) 0.03 0.34 
<40 216 66 (30.6) 77 (35.7) 58 (26.9) 15 (6.9)    
≥ 40 957 288 (30.1) 370 (38.7) 
225 
(23.5) 74 (7.7)  0  0.80 
Positive 
lymph nodes               
0 242 61 (25.2) 105 (43.4) 59 (24.4) 17 (7)    
1-3 524 181 (34.5) 191 (36.5) 
114 
(21.8) 38 (7.3)    
4+ 407 112 (27.5) 151 (37.1) 110 (27) 34 (8.4) 0.03 0.38 
Tumour size 
(cm)               
0-2 311 103 (33.1) 124 (39.9) 63 (20.3) 21 (6.8)    
2-5 771 224 (29.1) 294 (38.1) 
195 
(25.3) 58 (7.5)    
>5 91 27 (29.7) 29 (31.9) 25 (27.5) 10 (11) 0.05 0.07 
Grade               
I 53 28 (52.8) 16 (30.2) 4 (7.6) 5 (9.4)    
II 378 137 (36.2) 144 (38.1) 76 (20.1) 21 (5.6)    
III 742 189 (25.5) 287 (38.7) 
203 
(27.4) 63 (8.5) 0.15*
 <0.001 
ER status               
Negative 429 93 (21.7) 179 (41.7) 
121 
(28.2) 36 (8.4)    
Positive 744 261 (35.1) 268 (36) 162 (21.8) 53 (7.1) -0.09*
 0.003 
PR status               
Negative 579 134 (23.1) 232 (40.1) 
160 
(27.6) 53 (9.2)    
Positive 594 220 (37) 215 (36.2) 
123 
(20.7) 36 (6.1) -0.16*
 <0.001 
HER2 status               
Negative 886 305 (34.4) 326 (36.8) 
193 
(21.8) 62 (7)    
Positive 287 49 (17.1) 121 (42.2) 90 (31.4) 27 (9.4) 0.16*
 <0.001 
Treatment                
Control 588 169 (28.7) 241 (41) 136 (23.1) 42 (7.1)    
FEC-T 585 185 (31.6) 206 (35.2) 
147 
(25.1) 47 (8) N/A   
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Table 26 Clinical and histopathological variables according to MCD group 
Distribution of clinical and histopathological variables according to MCD group. Percentages 
represent the proportion of patients in each variable category. Abbreviations: ER, oestrogen 
receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; Rs, 
Spearman’s rank correlation coefficient; and n, number of patients. * Statistically significant 
association between a variable and increasing MCD group (Jamal-Hanjani, A'Hern, et al. 2015).  
 
 
 
 
 
Figure 53 Histopathological parameters and MCD group 
Distribution of ER and HER status across MCD groups (A), and relationship between tumour 
size, number of lymph nodes involved, and tumour grade across MCD groups (Jamal-Hanjani, 
A'Hern, et al. 2015).  
 
6.4 Relationship between clonal heterogeneity and MCD group 
The Shannon Diversity Index (SDI) integrates both the number and abundance of 
clones within a tumour, and is therefore a measure of clonal heterogeneity (Maley et al. 
2006). Consistent with previous findings (Roylance et al. 2011), there was a highly 
significant correlation between MCD group and SDI for both chromosomes 2 and 15 
(Figure 54, Rs = 0.95 and 0.87, respectively). Tumours in the MCD4 group had the 
highest SDI, and therefore the greatest degree of clonal heterogeneity, which is 
keeping with CIN as a driver of heterogeneity (Figure 55). In a univariate analysis 
there was no statistically significant association found between SDI and DFS with 
either chromosome 2 (Rs = 0.76, 0.38-1.51; p = 0.43) or chromosome 15 (Rs = 0.71, 
0.38-1.31; p = 0.27) in ER-negative cancers. This was also the case in ER-positive 
cancers. Overall, there was a trend in ER-negative cancers toward improved outcome 
with increasing SDI, but this was not statistically significant on univariate analysis. A 
similar association or trend was not found in ER-positive cancers. 
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Figure 54 SDI and MCD group 
Correlation between the Shannon Diversity Index (SDI) and MCD group for chromosome 2 (A) 
and chromosome 15 (B). 
 
 
 
 
Figure 55 Median SDI and MCD group 
Correlation between the median SDI for both chromosome 2 and 15 and MCD group, with the 
MCD4 group having the greatest median SDI, and therefore a greater degree of clonal 
heterogeneity (Jamal-Hanjani, A'Hern, et al. 2015). 
 
 
6.5 Extreme CIN and clinical outcome in ER-negative breast cancers 
In our previous discovery cohort, extreme CIN was associated with an improved 
prognosis in patients with ER-negative breast cancer (Roylance et al. 2011). In the 
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TransTACT cohort with a median follow-up of 91 months, a univariate analysis of DFS 
showed that patients with ER-negative breast cancer in the MCD4 group with extreme 
CIN also had an improved outcome compared with the other MCD groups, but this was 
not statistically significant (hazard ratio, HR = 0.61, 95% CI 0.29-1.26; p = 0.18)  
(Figure 56A). In contrast, patients with ER-positive cancer in the MCD4 group had 
worse outcome, although this was again not statistically significant (HR = 1.28, 95% CI 
0.74-2.21; p = 0.38). Improved outcome in the MCD4 group was also seen in ER-
negative/HER2-negative cancers (0.41, 0.14-1.17; p = 0.1) (Figure 56B). Using breast 
cancer-specific death as a measure of outcome, a similar pattern was seen in ER-
negative cancers (0.67, 0.29-1.54, p = 0.35) (Figure 56C). A multivariate analysis of 
DFS according to ER status showed that in ER-positive cancers, positive nodal status 
(p < 0.001), tumour size 2-5cm (p = 0.002), and age range 40-49 years (p < 0.001) 
were significant determinants of DFS. In ER-negative cancers, positive nodal status (p 
< 0.001), tumour size > 5cm (p = 0.001), and extreme CIN (p trend = 0.03) were 
significant determinants of DFS. In ER-negative/HER2-negative cancers, positive nodal 
status (p < 0.001), being in the MCD3 group (p = 0.039), and extreme CIN (p trend = 
0.007) were significant determinants of DFS (Table 28). Overall, improved outcome 
was seen with increasing CIN in ER-negative (p trend = 0.03) and ER-negative/HER2-
negative cancers (p trend = 0.007). This further substantiates the previously 
demonstrated paradoxical relationship between extreme CIN and improved outcome in 
ER-negative cancers (Roylance et al. 2011), and the potential value in using tumour 
CIN status as a prognostic biomarker.  
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Figure 56 Clinical outcome and MCD group 
Kaplan-Meier survival curves for clinical outcome in ER-negative and ER-negative/HER2-
negatve breast cancers measured by DFS (A-B), and breast cancer-specific death in ER-
negative cancers (C) (Jamal-Hanjani, A'Hern, et al. 2015). § Multivariate analysis p values 
(Jamal-Hanjani, A'Hern, et al. 2015). 
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  ER-positive (n=744) ER-negative (n=429) 
  HR (95%CI)    p HR (95%CI)    p 
Nodal Status Pos. vs Neg. 1.71 (1.45-2.01) <0.001* 1.85 (1.58-2.16) <0.001* 
Tumour Size 0-2cm 1   1   
  2-5cm 0.56 (0.39-0.8) 0.002* 0.68 (0.45-1.02) 0.07 
  >5cm 1.13 (0.73-1.76) 0.58 2.2 (1.37-3.52) 0.001* 
Age Up to 39 1   1   
  40-49 0.41 (0.28-0.61) <0.001* 0.95 (0.62-1.46) 0.83 
  50-59 0.56 (0.39-0.81) 0.002* 0.96 (0.63-1.47) 0.85 
  >60 0.7 (0.42-1.16) 0.17 0.64 (0.32-1.29) 0.21 
Grade I 1   -   
  II 0.67 (0.38-1.17) 0.16 1   
  III 1.16 (0.67-2.02) 0.59 1.28 (0.83-1.96) 0.27 
Treated with 
taxane    1.08 (0.83-1.41) 0.57 0.93 (0.68-1.28) 0.66 
HER2 status Pos. vs Neg. 0.76 (0.54-1.08) 0.13 1.23 (0.89-1.7) 0.21 
PR status Pos. vs Neg. 0.77 (0.57-1.05) 0.1 0.62 (0.34-1.13) 0.12 
MCD group 1 1   1   
  2 1.19 (0.86-1.64) 0.3 0.98 (0.65-1.48) 0.94 
  3 1.06 (0.73-1.55) 0.75 0.67 (0.42-1.08) 0.1 
  4 1.06 (0.61-1.84) 0.85 0.59 (0.28-1.24) 0.17 
      0.80(p 
trend)   
0.03(p 
trend)* 
Table 27 Multivariate analysis of DFS according to ER status 
Multivariate analysis of DFS in ER-negative and ER-positive breast cancers to determine 
significant determinants of outcome (Jamal-Hanjani, A'Hern, et al. 2015). * Statistically 
significant associations.  
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    ER-positive/ HER2-negative (n=596) 
ER-negative/ 
HER2-negative (n=429) 
   HR (95%CI)      p HR (95%CI)    p 
Nodal Status Pos. vs Neg. 1.82 (1.52-2.19) <0.001* 1.87 (1.5-2.33) <0.001* 
Tumour Size 0-2cm 1   1   
  2-5cm 0.48 (0.32-0.72) <0.001* 0.76 (0.45-1.26) 0.28 
  >5cm 0.92 (0.55-1.57) 0.77 1.84 (0.93-3.64) 0.08 
Age Up to 39 1   1   
  40-49 0.34 (0.22-0.52) <0.001* 1.46 (0.8-2.64) 0.22 
  50-59 0.47 (0.31-0.7) <0.001* 1.43 (0.79-2.59) 0.24 
  >60 0.6 (0.35-1.03) 0.07 1.06 (0.44-2.55) 0.9 
Grade I 1   -   
  II 0.7 (0.39-1.26) 0.23 1   
  III 1.15 (0.65-2.05) 0.63 1.32 (0.75-2.33) 0.34 
Treated with 
taxane    1.09 (0.81-1.48) 0.56 0.97 (0.64-1.47) 0.89 
PR status Pos. vs Neg. 0.68 (0.48-0.96) 0.031* 0.56 (0.24-1.31) 0.18 
MCD group 1 1   1   
  2 1.17 (0.82-1.68) 0.39 0.99 (0.6-1.65) 0.98 
  3 0.94 (0.62-1.45) 0.79 0.51 (0.27-0.97) 0.039* 
  4 1.17 (0.63-2.16) 0.61 0.37 (0.13-1.06) 0.06 
      0.91(p 
trend)   
0.007(p 
trend)* 
Table 28 Multivariate analysis of DFS according to ER and HER2 status  
Multivariate analysis of DFS in ER-positive/HER2-negative and ER-negative/HER2 negative 
breast cancers to determine significant determinants of outcome (Jamal-Hanjani, A'Hern, et al. 
2015). * Statistically significant associations.  
 
6.6 Taxane response and MCD group 
Work from our laboratory has previously demonstrated an association between CIN 
and taxane resistance (Swanton et al. 2007; Swanton et al. 2009; Lee et al. 2011). In 
order to determine whether MCD group had any influence on response to taxane 
therapy in the TransTACT cohort, MCD1/MCD2 and MCD3/MCD4 groups were 
combined (due to small patient numbers), and the DFS in patients in the 
anthracycline/taxane-based treatment arm were compared to the DFS in patients in the 
anthracycline-based only treatment arm. In ER-negative cancers, the HR was 1.05 
(95% CI 0.72-1.53; p = 0.80) in the MCD1/MCD2 groups vs. 0.89 (95% CI 0.51-1.53; p 
= 0.66) in the MCD3/MCD4 groups, demonstrating no difference in DFS between the 
two treatment groups (Figure 57A). Similarly, there was no significant correlation found 
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in the ER-negative/HER2-negative cancers (Figure 57B). Overall there was no 
evidence that DFS in the anthracycline/taxane treated group was dependent on MCD 
group, but it is important to note that with such small patient numbers this analysis was 
insufficiently powered to detect an interaction, and therefore a difference in outcome 
between the two treatment arms. 
 
 
Figure 57 Taxane response and MCD group 
Forest plots for DFS in patients in the anthracycline/taxane-based treatment arm compared to 
those in the anthracycline-based only treatment arm according to MCD group, and ER (A) and 
HER2 (B) status.  n = number of patients in each respective MCD group (Jamal-Hanjani, 
A'Hern, et al. 2015). 
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6.7 Conclusions and discussion 
In the initial discovery cohort study of 246 patients, extreme CIN was associated with 
improved long-term survival in ER-negative cancers (HR = 0.0827, 95% CI 0.0097 - 
0.7066, p = 0.0228) (Roylance et al. 2011). This trend has been further validated in the 
TransTACT cohort, representing 1173 patients, using the same techniques and 
thresholds for analyses to demonstrate a statistically significant trend in improved 
prognosis with increasing CIN, as measured by MCD group (Jamal-Hanjani, A'Hern, et 
al. 2015). In order to optimise breast cancer treatment and management there is a 
need to identify and develop improved methods to predict prognosis, treatment benefit 
and risk of early relapse. The development of gene expression-based signatures has 
aided the assessment of outcome in certain breast cancer subtypes, in particular ER-
positive tumours (Kim & Paik 2010; Pusztai 2009). However, there remains a need to 
supplement existing, and identify new, prognostic signatures in ER-negative breast 
tumours. In view of the potential prognostic value of tumour CIN status, the 
development of reproducible and efficient techniques to assess CIN status in tumour 
samples may be of significant benefit. Using defined thresholds for CIN, such as MCD 
group, may help distinguish between good and bad prognostic groups, supporting both 
treatment and risk stratification in breast cancer patients. In addition, stratification of 
ER-negative breast cancer patients by MCD group may help identify a cohort of 
patients with improved outcome, which may be important to take into account when 
assessing therapeutic response and clinical outcome, especially in the context of 
clinical trials. Overall, the data presented here, from a large validation cohort study of 
patients with breast cancer, has further substantiated the paradoxical relationship 
previously demonstrated between extreme CIN and outcome in ER-negative breast 
cancers (Roylance et al. 2011), and the potential role for tumour CIN status as a 
prognostic biomarker. 
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7 Discussion 
7.1 Intratumour heterogeneity in NSCLC 
In this thesis, the spatial and temporal heterogeneity of NSCLC were explored in a 
cohort of 27 patients using multi-region WES of fresh frozen tissue collected from 
surgically resected primary NSCLC tumours. In keeping with previously published data 
from our laboratory (de Bruin et al. 2014), both spatial and temporal heterogeneity was 
seen in both LUAD and LUSC histological subtypes of NSCLC. This heterogeneity was 
seen for SNV and indel mutations, copy number aberrations, and potential mutational 
signatures, such as those associated with tobacco smoke exposure and APOBEC 
cytidine deaminase activity. These data support the premise of branched tumour 
evolution in NSCLC, with some aberrations present in all regions of a tumour (likely to 
be clonal in origin), occurring early in tumour evolution, and some aberrations being 
present in some, but not all, regions of a tumour (likely to be subclonal in origin), 
occurring late in tumour evolution.  
 
The importance of intratumour heterogeneity is increasingly recognised as a driver of 
tumour progression, drug resistance and treatment failure in solid tumours (Shah et al. 
2012; Campbell et al. 2010; Lee et al. 2011; Navin et al. 2011; Wu et al. 2012; Szerlip 
et al. 2012; Yap et al. 2012). The presence of subclonal driver mutations may prove to 
present a significant challenge, in terms of biomarker development and drug target 
discovery efforts, and contribute to drug resistance and poor survival outcome 
(Anderson et al. 2011; Navin et al. 2011; Navin et al. 2010). Despite the impressive 
developments of international large-scale sequencing consortia, the spatial separation 
of tumour subclones, the changing nature of tumour clonal architecture over time, and 
the impact of such diversity upon clinical outcome are yet to be determined 
systematically and longitudinally. The lung TRACERx study aims to integrate genomic 
data with detailed clinical annotation and outcome, in order to decipher the 
heterogeneity of the cancer genome and mutational pathways involved in NSCLC 
pathogenesis. It aims to develop clinically meaningful measures of intratumour 
heterogeneity to guide patient management and treatment stratification (Merlo et al. 
2010), and to prospectively define thresholds of tumour heterogeneity for clinical risk 
stratification. With increasing awareness for the need to obtain tissue and genetically 
profile cancers in order to stratify treatment, the concept of longitudinal tissue collection 
and analysis has become more acceptable in oncological practice. In following cancers 
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from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to 
therapeutic interventions, and determining the impact of clonal heterogeneity on clinical 
outcomes, TRACERx may also serve as a model applicable to other cancer types.  
 
7.2 Heterogeneity in lung adenocarcinoma in situ lesions 
Patients recruited into the TRACERx study either had a confirmed histological 
diagnosis of NSCLC, or were highly suspected to have such a diagnosis. Five patients 
recruited into the study were subsequently withdrawn after being diagnosed with 
adenocarcinoma in situ (AIS). These pre-invasive lesions were still subjected to multi-
region WES, using the same TRACERx bioinformatics pipeline, and were analysed 
separately. Whilst it is known that pre-invasive lung lesions can harbour some somatic 
mutations (Izumchenko et al. 2014) and copy number aberrations (Massion et al. 2009), 
whether clonal diversity and clonal evolution are prominent features of such lesions is 
yet to be determined. Similar to the NSCLC tumours described in this thesis, both 
temporal and spatial heterogeneity of mutations and copy number aberrations was 
evident in the AIS lesions analysed. Certain driver mutations appeared to be involved 
in early, and some appeared to be involved in late, clonal evolution of these lesions. In 
particular, there was an interesting case of convergent evolution where in one lesion 
there was a truncal mutation in the BRAF gene as well as a branch mutation in the 
NRAS gene, suggesting involvement of the MAPK/ERK signalling pathway throughout 
clonal evolution of the lesion up until the point of surgical resection. These data would 
support the hypothesis that prior to the development of invasive lung adenocarcinoma, 
pre-invasive lung lesions possess a heterogeneous clonal landscape, in which certain 
somatic mutations can give rise to a clonal selective advantage. Further insight into the 
clonal dynamics and evolution of these pre-invasive lesions may help improve our 
understanding of the earliest stages of lung cancer development, and the biological 
processes involved in the transition from pre-invasive to invasive disease.  
 
7.3 Metastatic disease and defining the origins of the lethal 
subclone(s) 
Clonal diversity between primary and metastatic tumours in the same patient has been 
demonstrated in different tumour types, including lung (Paik et al. 2015), breast (Shah 
et al. 2009), pancreatic (Campbell et al. 2010; Yachida et al. 2010), colorectal (Kogita 
et al. 2015; Tan et al. 2015), gastric (Nadauld et al. 2014), prostate (Haffner et al. 
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2013; Hong et al. 2015; Gundem et al. 2015) and medulloblastoma (Wu et al. 2012) 
tumours. The dynamics and patterns of clonal composition can indicate the tumour 
evolutionary paths that underlie tumour progression, including potential mechanisms 
involved in therapeutic resistance. Using WGS and WES, Juric and colleagues 
sequenced the primary and metastatic tumours in a breast cancer patient with a known 
activating PIK3CA mutation who had developed drug resistance whilst on treatment 
with a PIK3CA inhibitor (Juric et al. 2015). All the metastatic tumours were found to 
have a common copy number loss of PTEN, and those metastatic tumours that were 
identified as drug resistant based on imaging, were found to have acquired additional 
genetic aberrations in PTEN resulting in the loss of its expression, including SNVs, 
indels and copy number aberrations. This demonstrated parallel evolution in separate 
metastatic tumours with different aberrations in PTEN leading to a convergent 
phenotype resistant to PIK3CA inhibition.  
 
In order to investigate the evolving constellation of genetic aberrations involved in the 
metastatic process, and the patterns of intratumour heterogeneity that can vary 
between primary and metastatic tumours, there is a need for longitudinal tissue 
collection from multiple sites of disease from living patients. In general, this relies on 
tissue that is surplus to diagnostic and clinical requirements. There are several 
challenges in obtaining tissue from patients with advanced cancer including the 
increased biopsy risk associated with multiple site sampling, the technical difficulty in 
accessing sites of metastatic disease and the inevitable time, travel and costs incurred 
by patients who are often unwell with a poor performance status. Most patients with 
widely disseminated disease do not undergo tumour resection, and therefore the ability 
to perform multi-region sequencing of surgically resected tumours is limited. Obtaining 
a limited number of core biopsies at different disease time points is a possibility in this 
group of patients, but may not be representative of the entire tumour.  
 
In this thesis, the primary and metastatic NSCLC tumours of two patients who 
subsequently presented with disease recurrence were subjected to multi-region WES 
and analysed. In both cases, a region within the primary tumour from which the 
metastasis had originated was identified, and both spatial and temporal intratumour 
heterogeneity was evident in the primary and metastatic tumours. Patient L011 had a 
truncal BRAF V600E mutation, suggesting that this driver mutation was an early event 
in the evolution of her disease and that treatment with a BRAF or MEK inhibitor may 
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have been associated with an effective tumour response. Prior knowledge of the 
genomic profile of her primary tumour may have pre-empted early therapeutic 
intervention with such targeted drugs at the point of metastatic disease. Patient L017 
had a truncal KRAS G12V mutation, suggesting that treatment in the future with an 
EGFR TKI may have resulted in decreased tumour response. These examples 
demonstrate how early genomic profiling of tumours has the potential to guide 
therapeutic intervention and to inform tumour response.  Furthermore, the analysis of 
the clonal composition of paired primary-metastases tumours also has the potential to 
give some insight into the metastatic process and the origin of the lethal subclone(s). 
The general lack of paired primary and metastatic tumour samples in patients has 
meant that cancer research has been restricted to either established tumour cell lines 
or archival material (Rubin et al. 2000) limiting the systematic study of the metastatic 
process (Embuscado et al. 2005). Access to post-mortem tissue allows multi-region 
sampling within larger tumours, as well as sampling of all sites of metastatic disease, in 
order to define the relationship between metastatic tumours and the primary tumour.  
 
7.3.1 The PEACE study 
There are few studies in which post-mortem tissue sampling is performed immediately 
after death, including studies in breast cancer (Juric et al. 2015), prostate cancer 
(Rubin et al. 2000; Liu et al. 2009), pancreatic cancer (Embuscado et al. 2005), uveal 
melanoma (Borthwick et al. 2011), and idiopathic pulmonary fibrosis (Lindell et al. 
2006). None of these studies have explored the clonal composition of tumours, and in 
particular, the genetic aberrations and biological pathways involved in the metastatic 
process. The PEACE (Posthumous tissuE donAtion in CancEr, 13/LO/0972, UKCRN 
ID 18422) study has been set-up to address this, and to support cancer research 
projects that would benefit from access to tumour tissue. The PEACE study is a multi-
centre prospective observational study intended to facilitate tissue donation, in 
metastatic cancer, from multiple tumour sites in the post-mortem setting. This study 
also involves the collection of blood samples for germ line DNA, cfDNA and CTCs. The 
PEACE study will take advantage of the fresh tumour tissue sampling and processing 
protocols, and bioinformatics pipelines designed to accurately assess the mutational 
and copy number profiles of tumours, already developed and optimised within our 
laboratory.  
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The PEACE study aims to track the clonal evolution of primary to metastatic tumours, 
and to therefore establish a model for tumour progression and the metastatic process. 
By mapping the evolution of tumours from the primary to different metastatic sites, the 
study aims to reveal the lethal subclone(s) harbouring candidate driver mutations 
resulting in disease progression, therapeutic resistance, and subsequent overwhelming 
disease burden, which may have led to eventual death.  
 
The analysis of cfDNA and CTCs in the metastatic setting will also be used to 
determine the extent to which such circulating biomarkers can represent the underlying 
genomic landscape of primary (if still in situ) and metastatic tumours. The study allows 
for access to archival tissue samples in cases where the primary tumour in no longer in 
situ. Patients who develop metastatic NSCLC in the lung TRACERx study will be 
approached to enter the PEACE study. This would truly represent longitudinal tissue 
and blood sampling from diagnosis to relapse to death, allowing the assessment of 
tumour evolution and tumour biology throughout the disease course. Patients for the 
PEACE study will be selected using the following eligibility criteria: 
 
Inclusion criteria: 
• Age 18 years or older 
• Confirmed diagnosis of a solid malignancy with metastatic disease  
• Oral and written informed consent from patient to enter the study and to 
undergo post-mortem tissue sampling 
Exclusion criteria: 
• Medical or psychiatric condition that would preclude informed consent 
• History of high-risk infections (e.g. HIV-positive, hepatitis C, tuberculosis and 
Creutzfeldt-Jacob disease). 
 
I wrote and developed the protocol for this study under the guidance of my supervisor 
during the production of this thesis, with the input of clinicians, pathologists, palliative 
care teams, medical lawyers, ethicists, patient advocate groups, and hospital mortuary 
staff. This study is currently open to recruitment in University College London Hospital, 
The Royal Marsden Hospital, Guy’s and St Thomas’ Hospital, and the Royal Leicester 
Infirmary Hospital. This study is currently being set-up across the lung TRACERx study 
sites, as well as other national sites with the intention of recruiting patients with 
metastatic disease of different solid tumour types.  
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7.4 Implications of intratumour heterogeneity for precision 
medicine 
Given the evidence for spatial intratumour heterogeneity, using a single diagnostic 
tumour biopsy, representing a snap shot of a tumour in time, may limit the ability to 
identify and qualify effective biomarkers for clinical use (Jamal-Hanjani, Quezada, et al. 
2015). Although taking multiple tumour biopsies to determine the true clonal 
composition of tumours is not a simple or practical solution in daily clinical practice, it is 
an effective approach in order to better understand tumour evolution during the disease 
course in the context of clinical studies. Longitudinal studies, such as TRACERx, 
involving the analysis of both tissue and liquid biopsies may help develop predictive 
tools or cancer evolutionary ‘rule books’ allowing us to predict likely beneficial 
therapeutic interventions, mechanisms of drug resistance, and eventual disease 
progression based on the wealth of data and experience gained from tracking the 
clonal evolution of tumours at different disease time points (Turajlic et al. 2015). Such 
studies may also allow the characterisation of patients who respond to specific 
therapeutic interventions exceptionally or poorly, which may be of benefit in drawing 
parallels with other patients with similar genetic or phenotypic patterns of disease.  
 
Therapeutic studies aimed at delivering precision medicine may have a greater 
likelihood of determining the true impact of intratumour heterogeneity on clinical 
outcome if potential biomarkers of disease are identified and validated in the context of 
tumour spatial heterogeneity. Furthermore, drug combination designs may need to 
consider the impact of different potential drivers of disease during tumour evolution, 
and the existence of subclonal drivers of disease at any given time point, on drug 
efficacy and resistance (Zhao et al. 2014). The relevance of driver clonality and 
treatment response is yet to be determined in prospective clinical studies. Therapeutic 
targeting of actionable aberrations in dominant compared to minor subclones may not 
lead to the same therapeutic outcome. Therapeutic studies such as the DARWIN 
(Deciphering Anti-tumour Response With INtratumour Heterogeneity, ClinicalTrials.gov 
number NCT02183883) clinical trials programme, may help determine how driver 
clonally can influence therapeutic response (Jamal-Hanjani et al. 2014; Hiley et al. 
2014).  
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Precision medicine has the potential to improve clinical outcome and to reduce drug-
associated toxicity, but it is not without its challenges and significant cost implications. 
These include access to sequencing equipment, the development of clinical trials 
employing adequate tumour profiling to identify actionable aberrations, the validation of 
predictive and prognostic biomarkers, and the availability of targeted drugs (Jamal-
Hanjani, Quezada, et al. 2015). Infrastructure supporting adequate computing 
resources and approved sequencing technologies is necessary to help clinical practice 
move toward the implementation of genomics and detailed molecular characterisation 
of a patient’s tumour in order to enable tailored therapies and attempt to improve 
patient outcome. Furthermore, clinicians will need to adapt to the challenges in 
analysing the wealth of data that genomics studies can create, and to gain experience 
in the communication of increased risk or false-positive and false-negative results (May 
et al. 2014). The ultimate aim of such studies should be to develop economically 
feasible predictive and prognostic biomarkers to aid clinical decision-making and 
improve risk stratification. This way the medical and scientific community can work 
towards significant, as opposed to marginal, improvements in outcome (Fojo et al. 
2014).  
 
7.5 Representation of the tumour landscape in cfDNA 
Given the increasing evidence for intratumour heterogeneity, sampling tumour tissue at 
a single time point to identify predictive and prognostic biomarkers has significant 
limitations, in terms of sampling bias of spatially heterogeneous tumours, and the lack 
of information regarding temporal heterogeneity. Circulating biomarkers may be an 
effective non-invasive alternative to longitudinal tissue sampling, and have the potential 
to track the genomic landscape of tumours, and help monitor tumour burden, minimal 
residual disease, and detect the emergence of drug resistance (Diaz & Bardelli 2014; 
Bidard et al. 2013). In addition, further evidence supporting the use of circulating 
biomarkers in early stage disease may also inform cancer screening strategies, and 
could potentially aid early therapeutic intervention. Furthermore, with the ability to 
detect copy number aberrations in circulating biomarkers, regions of chromosomal 
instability could be assessed to determine the relevance of CIN as a predictive and/or 
prognostic biomarker (Schütz et al. 2015). 
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The analysis of cfDNA in cancer patients may further complement tumour sequencing 
data, and potentially identify additional genetic aberrations that have not been detected 
by primary or metastatic tumour sequencing depending on sequencing depth. In order 
for this to be true, robust and sensitive enough techniques need to be employed for the 
detection of both clonal and subclonal genetic aberrations. In this thesis, three 
approaches were used to identify genetic aberrations in cfDNA from patients with 
NSCLC prior to surgical resection of their primary tumours. Tumour-specific SNV and 
indel mutations, as well as a single translocation, were chosen based on WES and Ion 
AmpliSeq sequencing data. The main aim was to determine how representative cfDNA 
was of the mutational burden in early stage primary NSCLC, and in particular, to 
determine whether both truncal and branch mutations could be detected, such that the 
heterogeneous genomic landscape of tumours, and therefore a measure of intratumour 
heterogeneity, could be interpreted using cfDNA. The approaches involved combining 
multiplex PCR with mass spectrometry (in collaboration with Agena Bioscience, the 
UltraSEEK technique), MiSeq sequencing (in collaboration with Illumina), or HiSeq 
sequencing (in collaboration with Natera). The UltraSEEK technique was able to detect 
5/44 (11.4%) SNVs (all truncal) in cfDNA, and the Natera approach was able to detect 
16/37 (43.2%) SNVs in cfDNA (4 branch and 2 truncal). The Illumina approach 
appeared to detect an SNV, an indel, and a translocation variant in cfDNA, but this was 
based on single assays and very few selected mutations overall, such that a measure 
of statistical significance could not be assigned. The Natera approach detected the 
greatest proportion of selected mutations, and provides some early evidence for the 
detection of branch mutations in cfDNA. Increased plasma volume and further assay 
optimisation, could considerably improve the analytical sensitivity of these approaches, 
and potentially allow the detection of mutations at lower variant allele frequencies 
(VAFs), which is often the case with branch mutations. A cfDNA substudy has been 
set-up within TRACERx in collaboration with Natera, involving the longitudinal sampling 
of 100 patients from diagnosis to relapse in order to further explore the utility of cfDNA 
in tracking tumour evolution using customised SNV and CNV panels based on the 
sequencing data, as well as lung cancer specific SNV and CNV panels. 
 
Whilst cfDNA may have great potential, there are still obstacles to overcome before its 
use can be implemented in standard clinical practice. Standardisation of the methods 
and techniques employed is required, including the collection of blood samples, the 
methods used to extract plasma and subsequently cfDNA from whole blood, the 
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quantification of cfDNA, and the techniques used to identify and quantify tumour-
associated genetic aberrations. As previously discussed, several NGS techniques exist 
to detect genetic aberrations in cfDNA. The cost and logistics of developing these 
techniques for use in the clinic is not insignificant. Furthermore, the wealth of 
sequencing data that can be produced from such sequencing strategies will require 
substantial bioinformatic and computing resource infrastructure for data analysis and 
interpretation (Crowley et al. 2013). In addition, since cfDNA may represent cancer 
genomes derived from multiple metastatic sites within the body, the interpretation of 
data may be confounded by intratumour heterogeneity (Pantel et al. 2013). The 
method by which genetic aberrations are selected is also an important consideration. 
Customised panels specific to each patient’s tumour rely on screening of tumour 
biopsies so that the existing mutational profile is known on a patient-by-patient basis, 
take longer to design, and involve greater costs. Alternatively, generic cancer panels 
that are able to detect hundreds of somatic mutations, known to be commonly mutated 
in cancer, can be more cost-effective and would require less optimisation. The choice 
between the two approaches will depend on the question that is being asked. For 
example, if the intention is to track the clonal evolution of tumours and to monitor the 
rise and fall in the frequency of both known and rare drivers of disease, a customised 
approach would be appropriate, and if the intention is to identify a therapeutically 
targetable genetic aberration, a generic screening panel would be appropriate.  
 
Which technique is the most optimal in the field of circulating biomarkers, exactly how 
representative circulating biomarkers are of the underlying tumour landscape, and how 
sensitive they are in identifying clonal and subclonal alterations, is yet to be determined 
(Diaz & Bardelli 2014). Ultimately, formal validation in clinical studies, such as 
TRACERx, where the use of circulating biomarkers is tested as part of a study 
endpoint, is necessary to assess the use of such biomarkers in clinical practice 
(Crowley et al. 2013). Both the lung and breast TRACERx studies involve serial 
sampling of circulating biomarkers so that their assessment can be correlated with 
clinically relevant time points, such as disease progression and the development of 
drug resistance, as well as clinical and radiological examinations. 
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7.6 CIN as a prognostic biomarker in ER-negative breast 
cancer 
Increased CIN has been shown to be associated with poor prognosis in several tumour 
types (Carter et al. 2006; Walther et al. 2008; Habermann et al. 2009; Kronenwett et al. 
2006; Bakhoum et al. 2011; Sheffer et al. 2009; M'kacher et al. 2010), suggesting that 
greater genomic instability may promote cancer cell growth and therefore tumour 
progression. However, both aneuploidy and CIN have also been shown to be 
disadvantageous for cancer cell survival and fitness (Ganem et al. 2009; Sotillo et al. 
2010; Pavelka et al. 2010; Kops et al. 2004; Schmidt et al. 2005; Janssen et al. 2009), 
such that extreme levels of genomic instability are associated with improved clinical 
outcome (Birkbak et al. 2011; Roylance et al. 2011; Baumbusch et al. 2013). In this 
thesis, data from a large validation cohort of 1173 patients are presented supporting 
the previously shown significant association between CIN and improved outcome in 
ER-negative breast cancers. Both aneuploidy and CIN are features of malignant 
tumours, which may represent potential targetable phenotypes for cancer treatment 
(Roschke et al. 2003; Roschke et al. 2005; Roschke & Kirsch 2005). Given the clinical 
relevance of CIN in cancer, as a potential prognostic biomarker and therapeutic target, 
the identification of tumour CIN status may have significant exploitable benefits. 
Understanding the mechanisms contributing to numerical and structural CIN, and 
developing improved techniques to identify tumour CIN status, may help guide 
therapeutic intervention, and therefore improve outcome in cancer, in particular, 
patients with ER-negative breast cancers.  
 
7.6.1 The breast TRACERx study 
Intratumour heterogeneity is not simply manifested at the somatic mutational level, but 
also at the chromosomal level, in the form of structural and numerical chromosomal 
instability. Intratumour heterogeneity of copy number aberrations has been described 
in several studies, in which some copy number gains or losses can be clonal, occurring 
early in tumour evolution, and some can be subclonal, occurring late in tumour 
evolution (Szerlip et al. 2012; Snuderl et al. 2011; Sottoriva et al. 2013; Campbell et al. 
2010; Yachida et al. 2010; Nik-Zainal et al. 2012; Gerlinger et al. 2014; Shah et al. 
2012). Whilst these studies may shed some light on tumour heterogeneity in terms of 
numerical CIN status of a tumour, our understanding of both spatial and temporal 
heterogeneity in CIN is limited. The breast TRACERx study is a prospective 
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observational clinical study, which aims to address this, using different techniques for 
measuring CIN, including direct centroemric FISH and DNA ploidy analyses, on multi-
region samples within the same tumour. Patients with breast cancer suitable for 
neadjuvant or primary chemotherapy followed by surgery, in the case of resected 
primary tumours, will be eligible for the study, which aims to recruit 546 patients with a 
total 10-year follow-up period. The study involves the collection of multi-region tumour 
tissue at diagnosis, during neoadjuvant or primary chemotherapy, at surgery, and at 
relapse. Longitudinal blood sampling, similar to the TRACERx lung study, for cfDNA 
will also be analysed during follow-up. The study aims to define the impact of 
intratumour heterogeneity on the response to treatment (by assessing the pathological 
complete response (pCR) rate), and on clinical outcome in terms of DFS and OS. 
Similar to the lung study, it aims to also understand the molecular drivers of tumour 
progression and drug resistance. The sequential analysis of tumour through the 
disease course will determine whether exposure to anthracycline- and taxane-
containing regimens, as well as trastuzumab in HER2-positive patients, can select for 
intratumour heterogeneity. Patients will be selected using the following eligibility 
criteria: 
 
Inclusion criteria: 
• Written Informed consent 
• Patients ≥ 18-years of age, with histological confirmation of invasive breast 
cancer with known receptor status suitable for neoadjuvant or primary 
chemotherapy  
• Histological subtypes to include: with either TNBC (HER2-negative/ER-
negative/PR-negative), HER2-positive (ER-positive or ER-negative), or ER-
positive (HER2-negative) breast cancer  
• Neoadjuvant therapy, surgery, and any subsequent adjuvant therapy and follow-
up to be in accordance with NICE and local guidelines 
• Stage T2-4 tumours (including inflammatory cancers), with any nodal status, can 
be included 
• Multifocal cancer (as long as it is of the same subtype as the index cancer) can 
be included 
 
Exclusion criteria: 
• Confirmed metastatic disease at initial presentation 
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• Any other current malignancy, or malignancy diagnosed or relapsed within the 
last 5-years (other than non-melanomatous skin cancer and in situ cervical 
cancer) 
• Any concomitant medical or psychiatric problems which in the opinion of the 
investigator would prevent completion of treatment or follow-up 
• Lack of adequate tissue 
 
The objectives of the study are outlined below: 
 
Primary objectives: 
• To determine the relationship between intratumour heterogeneity and the pCR 
rate achieved  
• To determine the relationship between intratumour heterogeneity and clinical 
outcome, in terms of DFS and OS 
• To determine the relationship between intratumour heterogeneity and the 
different histological subtypes of breast cancer 
 
Secondary objectives: 
• To identify potential drivers of genomic instability, metastatic progression and 
drug resistance 
• To improve our understanding of the different breast cancer molecular subtypes 
and the extent of intratumour heterogeneity 
• To validate key driver mutations to help guide stratification of breast cancer 
treatment and clinical study inclusion 
• To establish whether cfDNA analysis can predict early relapse and track tumour 
clonal evolution through the disease course 
 
By tracking the somatic mutational heterogeneity, and chromosomal structural and 
numerical instability, in breast cancer disease using established methods (Jamal-
Hanjani et al. 2014; Roylance et al. 2011), this study aims to determine the clinical 
relevance of intratumour heterogeneity, in term of somatic mutations, copy number 
aberrations, and CIN, in breast cancer pathogenesis, recurrence and metastatic 
disease.  
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I wrote and developed the protocol for this study under the guidance of my supervisor 
during the production of this thesis, with input from Dr. Rebecca Roylance (Barts 
Cancer Institute, Queen Mary University of London). This study is currently awaiting 
R&D approval from University College London Hospital.  
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7.7 Conclusion 
The data presented in this thesis demonstrate the existence of a complex and 
heterogeneous genomic landscape in NSCLC. Furthermore, spatial and temporal 
heterogeneity has been demonstrated in pre-invasive lung adenocarcinoma in situ 
lesions, suggesting that heterogeneity in mutations and copy number aberrations may 
be a feature of the early stages of lung cancer development. Intratumour heterogeneity 
may have significant clinical implications for both cancer diagnosis and therapeutic 
intervention. The impact of such heterogeneity on therapeutic response and clinical 
outcome is yet to be determined. Taking multiple tissue biopsies and serial sampling of 
tumours to track progression, and to identify new targetable drivers of disease is 
practically challenging, and is currently not part of standard clinical practice. An 
alternative non-invasive approach may be the use of circulating biomarkers, such as 
cfDNA. In this thesis different approaches were taken to determine the use of cfDNA in 
early stage NSCLC to represent the underlying tumour landscape, consisting of both 
truncal and branch mutations. Although the data suggest that some branch mutations 
can be detected in cfDNA, the identification of low frequency branch mutations in 
cfDNA remains a difficult task, and studies are required to further develop effective 
strategies for mutation detection.  
  
Chromosomal instability (CIN), an initiator of intratumour heterogeneity, has been 
shown to be associated with poor prognosis in several tumour types (Carter et al. 
2006; Habermann et al. 2009; Walther et al. 2008). In this thesis data are presented 
from the largest breast cancer cohort study in which the association between CIN and 
clinical outcome is investigated. Having previously demonstrated a paradoxical 
relationship between extreme levels of CIN and improved long-term survival in ER-
negative breast cancers (Roylance et al. 2011; Birkbak et al. 2011), this relationship 
was further substantiated in this large prospective validation cohort study (Jamal-
Hanjani, A'Hern, et al. 2015). The association between extreme CIN and improved 
outcome may be related to increased tumour aneuploidy resulting in decreased cellular 
fitness. This suggests that in certain tumour types a threshold for CIN and intratumour 
heterogeneity may exist above which tumour growth and progression is limited, 
analogous to a mutational burden meltdown. Aside from the potential role of CIN as a 
prognostic biomarker in ER-negative cancers, the association between CIN and 
improved outcome may provide therapeutic opportunities whereby patients with 
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specific tumour types may benefit from certain drugs, such as DNA damaging agents, 
as a result of increased tumour CIN levels.  
 
Genomic studies involving longitudinal tissue and blood sampling, with the integration 
of genomic data with detailed clinical and phenotypic annotation of samples, have the 
potential to give us great insights into tumour biology. The realisation of precision 
medicine in the genomic era will rely on the collaborative efforts of multi-disciplinary 
teams, and the study of tumour evolution will require a multi-disciplinary approach 
combining studies in tumour microenvironment, the immune system, genetics, 
epigenetics, transcriptomics, and functional screening. Clinical studies, such as 
TRACERx and PEACE, will allow us to gain a deeper insight into the true extent of 
intratumour heterogeneity and CIN, how these evolve during the disease course, and 
their predictive and prognostic relevance.  
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8 Appendix 
8.1 Appendix 1: List of papers and abstracts published during 
this PhD 
8.1.1 Primary research articles 
Detection of Ubiquitous and Heterogeneous Mutations in Cell-Free DNA from 
Patients with Early-Stage Non‒Small-Cell Lung Cancer 
Jamal-Hanjani M, et al. (Submitted to Annals of Onoclogy) 
 
Clonal lung cancer neoantigens elicit T cell immunoreactivity and anti-PD-1 
response  
Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal, Sofie Ramskov, Rikke 
Lyngaa, Sunil Kumar Saini, Mariam Jamal-Hanjani et al. (Submitted to Science) 
 
TumorTracer: A method to identify the tissue of origin from the somatic 
mutations of a tumor specimen 
Andrea Marion Marquard, Nicolai Juul Birkbak, Cecilia Engel Thomas, Francesco 
Favero, Marcin Krzystanek, Celine Lefebvre, Charles Ferté, Mariam Jamal-Hanjani et 
al. BMC Med Genomics. 2015 Oct 1;8:58. doi: 10.1186/s12920-015-0130-0.  
 
Extreme chromosomal instability forecasts improved outcome in ER-negative 
breast cancer: a prospective validation cohort study from the TACT trial 
Jamal-Hanjani M, et al. Ann Oncol. 2015 Jul;26(7):1340-6. 
 
Spatial and temporal diversity in genomic instability processes defines lung 
cancer evolution 
de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L*, Jamal-Hanjani 
M*, et al. Science. 2014 Oct 10;346(6206):251-6.  
 
Expression of regulators of mitotic fidelity are associated with intercellular 
heterogeneity and chromosomal instability in primary breast cancer  
Roylance R*, Endesfelder D*, Jamal-Hanjani M*, et al. Breast Cancer Res Treat. 2014 
Nov;148(1):221-9.  
 
* Joint authors 
8.1.2 Review articles 
The value of patient and public involvement intrial design and development 
S. Gasson, J. Bliss, M. Jamal-Hanjani et al. Clin Oncol (R Coll Radiol). 2015 Dec 
27(12):747-9. 
 
Lung cancer 
Jamal-Hanjani and Siow-Ming Lee. Future Medicine, Lung Cancer Manag. Lung 
Cancer Manag. 2015 4(3), 117–123. 
 
Translational Implications of Tumor Heterogeneity 
Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Clin Cancer Res. 2015 Mar 
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15;21(6):1258-1266. 
 
Tracking genomic cancer evolution for precision medicine: the lung TRACERx 
study 
Jamal-Hanjani M, et al. PLoS Biol. 2014 Jul 8;12(7):e1001906.  
 
Implications of intratumour heterogeneity for treatment stratification 
Crockford A*, Jamal-Hanjani M*, Hicks J, Swanton C. J Pathol. 2014 Jan;232(2):264-
73.  
 
Tumour heterogeneity and immune-modulation  
Jamal-Hanjani M, Thanopoulou E, Peggs KS, Quezada SA, Swanton C. Curr Opin 
Pharmacol. 2013 Aug;13(4):497-503.  
 
Taxane benefit in breast cancer-a role for grade and chromosomal stability 
A'Hern RP*, Jamal-Hanjani M*, Szász AM, Johnston SR, Reis-Filho JS, Roylance R, 
Swanton C. Nat Rev Clin Oncol. 2013 Jun;10(6):357-64.  
 
* Joint authors 
8.1.3 Abstracts and presentations 
 
The TRACERx Study 
Cancer Research UK Lung Cancer Centre of Excellence Conference 2015 (poster 
presentation). 
 
Intratumour Heterogeneity and Clonal Evolution in Non-Small Cell Lung Cancer 
Cancer Research UK Lung Cancer Centre of Excellence Summer Conference, July 
2015 (oral presentation). 
 
Association between intratumour heterogeneity and genomic markers of 
chromosomal instability and chemotherapy response in the prospective lung 
cancer clinical trial TRACERx 
The British Association for Cancer Research, June 2015 (poster presentation). 
 
Intratumor heterogeneity and the detection of potential driver mutations in 
cfDNA in a NSCLC cohort using UltraSEEKTM 
The American Association for Cancer Research, April 2015 (poster presentation). 
 
The TRACERx Study  
The National Cancer Research Institute Conference, November 2014 (poster 
presentation, NCRI Prize Award). 
 
Evolution of the genomic landscape in non-small cell lung cancer 
The European Society of Medical Oncology, September 2014 (proffered paper - oral 
presentation). 
 
Intratumour Heterogeneity and Clonal Evolution in Non-Small Cell Lung Cancer 
The Royal Society of Medicine, Oncology Section Sylvia Lawler Prize Meeting, 
September 2014 (poster presentation). 
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8.2 Appendix 2: The lung TRACERx study protocol summary  
Title TRAcking non-small cell lung Cancer Evolution through 
therapy (Rx) 
Short Title/acronym TRACERx 
Sponsor name & reference UCL - UCL/12/0279 
Funder name Cancer Research UK 
Rosetrees Trust 
Academy for Medical Sciences  
UCL Biomedical Research Centre  
Clinicaltrials.gov no NCT01888601 
Design A prospective observational cohort study of patients with 
non-small cell lung cancer (NSCLC), in which 
translational research is the fundamental aspect of the 
study.  
Primary objectives 
• Define the relationship between intratumour 
heterogeneity and clinical outcome following surgery 
and adjuvant therapy (including relationships 
between intratumour heterogeneity and clinical 
disease stage and histological subtypes of NSCLC).  
• Establish the impact of adjuvant platinum-containing 
regimens upon intratumour heterogeneity in 
relapsed disease.  
Key secondary objectives • Development and validation of intratumour 
heterogeneity (ITH) ratio index (ITB) as a prognostic 
and predictive biomarker in relation to DFS and OS. 
Primary endpoints • Intratumour heterogeneity quantified by the ratio 
index ITB 
• Disease-free survival 
• Overall survival 
Target accrual 842 patients, of which 270 are expected to have a first 
recurrence and agree to provide a biopsy of the site of 
local recurrence/metastases 
Inclusion criteria • Written Informed consent 
• Patients ≥18 years of age, with early stage I-IIIA 
disease who are eligible for primary surgery  
• Histopathologically confirmed NSCLC, or a strong 
suspicion of cancer on lung imaging necessitating 
surgery (e.g. diagnosis determined from frozen 
section in theatre) 
• Primary surgery in keeping with NICE guidelines 
planned (see section 9.3)  
• Agreement to be followed up in a specialist centre 
• Performance status 0 or 1  
Exclusion criteria • Any other current malignancy or malignancy 
diagnosed or relapsed within the past 5 years (other 
than non-melanomatous skin cancer and in situ 
cervical cancer) 
• Psychological condition that would preclude 
informed consent 
Chapter 8 Appendix 
 198 
• Treatment with neo-adjuvant chemotherapy deemed 
necessary 
• Adjuvant chemotherapy regimen other than 
platinum-based chemotherapy (if a patient is 
deemed suitable for adjuvant chemotherapy) 
• Known Human Immunodeficiency Virus (HIV), 
Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or 
syphilis infection.  
• Sufficient tissue is unlikely to be obtained for the 
study based on pre-operative imaging 
 
Patients found to have in situ lesions rather than invasive 
cancer following surgery, such as adenocarcinoma in 
situ or minimally invasive lesions will be withdrawn. 
However, the surgical tissue already collected will be 
sent to the central laboratory, but these patients will not 
be followed-up in the study or required to provide any 
further blood samples. If these patients subsequently 
develop invasive cancer, the date of diagnosis and the 
tumour histology will be reported on the electronic data 
capture system. 
Planned number of sites 6 recruiting sites: UCLH, University Hospital of South 
Manchester, Heart of England, University Hospitals of 
Leicester, Cardiff & Vale and NHS Grampian. 
Treatment summary All recruited patients will be suitable for primary surgery, 
in accordance with NICE guidelines. Further treatments 
(e.g. chemotherapy) would be given according to 
standard of care. No treatments are specified as part of 
this observational study. 
Collection of tissue samples Baseline:  
• From the primary tumour and normal tissue from the 
resected specimen, surplus to diagnostic and 
pathological requirements. 
 
After first confirmed recurrence: 
• Biopsy (after consent) of local-regional and/or 
metastatic sites 
 
Following progression, after the first recurrence: 
• Biopsy (after consent) of local-regional and/or 
metastatic sites 
Collection of blood samples 
 
Baseline (before surgery):  
• 1 x 10mL for germ line DNA  
• 4 x 10mL for cfDNA 
• 2 x 10mL for cfDNA high sensitivity assay for 
approximately 100 patients initially 
• 2 x 10mL CellSave tube, for circulating tumour cells 
(pulmonary blood); for approximately 200 patients 
• 1 x 10mL for immunology 
• 1 x 40mL for immunology (only in 150 patients with 
larger tumours, >7cm after allowing for factors such 
as necrosis) 
• Leicester only – additional 1 x 10mL cfDNA 
• UCLH only – additional 1 x 10mL CellSave tube for 
30 patients 
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• Manchester only – additional 1 x 10mL CellSave 
tube. This may be omitted in patients who provide 
the 40mL immunology sample.  
 
48 hours after surgery: 
• 2 x 10mL for cfDNA high sensitivity assay for 
approximately 100 patients initially 
 
Follow-up after surgery: 
5 years of follow up in the adjuvant setting; every 3 
months in years 1-2, then every 6 months in years 3-5. 
For patients who receive adjuvant chemotherapy, the 
first post-surgery sample should be collected just before 
cycle 1 treatment and the next sample should be 
collected 6 months from the day of surgery 
• 2 x 10mL for cfDNA 
• 2 x 10mL for cfDNA high sensitivity assay for 
approximately 100 patients initially (for up to 3 years 
of follow-up only) 
• 2 x 10mL for cfDNA for patients identified with an 
EGFR or BRAF mutation 
• Leicester only – additional 1 x 10mL cfDNA 
 
At first confirmed recurrence: 
• 4 x 10mL for cfDNA 
• 2 x 10mL for cfDNA high sensitivity assay for 
approximately 100 patients initially (only if first 
recurrence is within 3 years of surgery) 
• 2 x 10mL for cfDNA for patients identified with an 
EGFR or BRAF mutation 
• 1 x 10mL CellSave tube (circulating tumour cells) 
• 1 x 10mL for immunology 
• 1 x 40mL (only in the patients with larger tumours 
who provided a 40mL blood sample for immunology 
before surgery) 
• Leicester only – additional 1 x 10mL cfDNA  
• UCLH only – additional 1 x 10mL CellSave tube for 
those of the 30 patient cohort whose disease recurs 
• UCLH only – additional 1 x 10ml CellSave tube for 
10 patients with EGFR, ALK, ROS, RET, KRAS or 
PD-L1 mutation 
 
Follow-up after first recurrence: 
At first CT on treatment for first recurrence 
• 2 x 10mL for cfDNA 
• 2 x 10mL for cfDNA for patients identified with an 
EGFR or BRAF mutation 
• 1 x 10mL CellSave tube 
• Leicester only – additional 1 x 10mL cfDNA  
• UCLH only – additional 1 x 10mL CellSave tube for 
those of the 30 patient cohort whose disease recurs  
• UCLH only – additional 1 x 10ml CellSave tube for 
the 10 patient cohort with EGFR, ALK, ROS, RET, 
KRAS or PD-L1 mutation 
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At progression, after the first recurrence: 
• 2 x 10mL for cfDNA 
• 2 x 10mL for cfDNA for patients identified with an 
EGFR or BRAF mutation 
• 1 x 10mL Cellsave tube 
• Leicester only – additional 1 x 10mL cfDNA  
• UCLH only – additional 1 x 10mL CellSave tube for 
those of the 30 patient cohort whose disease 
progresses  
• UCLH only – additional 1 x 10ml CellSave tube for 
the 10 patient cohort with EGFR, ALK, ROS, RET, 
KRAS or PD-L1 mutation 
 
Following progression: 
At up to 4 more timepoints, for example at the first CT 
scan whilst on treatment and at subsequent 
progressions 
• 2 x 10mL for cfDNA  
• 2 x 10mL for cfDNA for patients identified with an 
EGFR or BRAF mutation 
• Leicester only – additional 1 x 10mL cfDNA 
 
Completion of all treatment: 
• 4 x 10mL for cfDNA 
• 2 x 10mL for cfDNA for patients identified with an 
EGFR or BRAF mutation 
• 1 x 10mL Cellsave tube 
• Leicester only – additional 1 x 10mL cfDNA 
• UCLH only – additional 1 x 10mL CellSave tube 
where applicable to the 30 patients within the cohort  
• UCLH only – additional 1 x 10ml CellSave tube for 
the 10 patient cohort with EGFR, ALK, ROS, RET, 
KRAS or PD-L1 mutation 
Translational research • Multi-region tissue sampling (including DNA and 
RNA sequencing and immunological analyses) 
• Blood samples for germ line DNA 
• Blood samples for circulating free tumour DNA 
(cfDNA) 
• Blood samples for circulating tumour cells 
• Blood sample for immunology 
Duration of patient follow-up 5-years 
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8.3 Appendix 3: Number of regions sequenced and sequencing 
depth in the NSCLC and TRACERx cohort 
Table 29 shows the number of regions sequenced, and the mean and median 
sequencing depth for WES and/or Ion AmpliSeq sequencing for each sample. Where a 
recurrence sample was sequenced in addition to the primary tumour (L011 and L017), 
the mean sequencing depth is also shown.  
 
Patient Region Mean depth of WES 
Median depth of 
WES 
Mean depth of Ion 
AmpliSeq 
L011 
GL 99 78 1442 
R1 92 70 1542 
R2 95 73 1181 
R3 92 70 1695 
M1 117 105  
M2 118 106  
M3 123 112  
M4 120 110  
L012 
GL 279 130 1912 
R1 183 85 2148 
R2 237 97 2075 
R3 217 92 1291 
L013 
GL 124 116 868 
R1 107 100 844 
R2 114 104 902 
R3 102 90 821 
L015 
GL 411 380 415 
R1 335 302 446 
R2 373 339 459 
L016 
GL 415 383 2660 
R2 335 317 2516 
R3 250 231 2228 
L017 
GL 133 123 1415 
R1 156 140 1433 
R2 176 162 1284 
R3 162 149 1656 
M1 165 142  
L019 
GL 232 130 1028 
R1 145 75 1098 
LN1 161 94 995 
LN2 307 160 1326 
LN3 172 82 761 
L022 GL 71 65  
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R1 233 210  
R2 124 110  
LN1 238 215  
L023 
GL 143 133  
R1 154 135  
R2 212 182  
L029 
GL 98 686 688 
R1 145 785 781 
R2 149 1168 1180 
L030 
GL 102 1931 1914 
R1 166 2046 1967 
R2 170 2277 2221 
LTX001 
GL 478 431  
R1 384 346  
R2 432 383  
R3 534 478  
LTX012 
GL 420 381  
R1 424 371  
R2 436 380  
LTX015 
GL 330 299  
R1 355 310  
R2 405 349  
R3 366 325  
R4 418 365  
LTX016 
GL 384 351  
R1 411 372  
R2 502 456  
R3 450 408  
R4 432 395  
R5 400 362  
LTX019 
GL 436 400  
R3 465 422  
R4 422 379  
R5 473 423  
R6 495 449  
R7 415 377  
LTX022 
GL 381 350  
R1 431 393  
R5 280 253  
R6 481 438  
LTX028 
GL 414 370  
R1 510 445  
R2 478 428  
R3 633 500  
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R5 433 387  
R6 496 439  
R7 527 459  
LTX029 
GL 393 358  
R1 462 422  
R2 518 467  
LTX030 
GL 415 374  
R1 352 325  
R2 561 500  
LTX031 
GL 460 419  
R1 444 401  
R2 461 412  
LTX033 
GL 302 271  
R1 376 339  
R2 328 286  
R3 390 338  
R4 360 319  
LTX034 
GL 427 389  
R1 352 317  
R2 440 395  
LTX036 
GL 353 314  
R1 478 431  
R2 497 447  
R3 469 414  
R4 518 457  
R6 442 394  
LTX038 
GL 282 252  
R1 457 390  
R2 411 356  
R3 404 355  
R4 434 384  
R5 389 341  
R6 364 315  
R7 298 262  
LTX051 
GL 461 416  
R1 412 371  
R2 391 350  
LTX058 
GL 397 359  
R1 406 352  
R2 343 299  
R3 370 315  
R4 355 311  
R5 368 326  
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Table 29 Number of regions sequenced and sequencing depth 
Number of regions sequenced, mean and median depth of WES, and mean depth of Ion 
AmpliSeq sequencing for each tumour region in the NSCLC and TRACERx cohorts.   
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8.4 Appendix 4: Driver category 1 to 3 mutations in the NSCLC 
and TRACERx cohort 
Table 30 shows the genes in which driver mutations were predicted in the combined 
NSCLC and TRACERx cohort. The gene name, mutation type (SNV or indel), driver 
category, which region of the tumour the mutation was present in, and whether the 
mutation was on the trunk or branch of the evolutionary tree is included. 
 
Patient Gene Mutation type Driver category Truncal/Branch 
L011 BRAF SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 BCLAF1 SNV 2 Branch 
 FAT1 Indel 2 Truncal 
 FAT1 SNV 2 Truncal 
 FAT1 SNV 2 Truncal 
 MTOR Indel 2 Truncal 
 AKT1 SNV 3 Truncal 
 CACNA1D SNV 3 Branch 
 CDC73 SNV 3 Truncal 
 CLTCL1 SNV 3 Truncal 
 HOOK3 SNV 3 Truncal 
 JAK1 SNV 3 Truncal 
 MYCN SNV 3 Truncal 
 MYH9 SNV 3 Truncal 
 PIM1 SNV 3 Truncal 
 XPC SNV 3 Truncal 
L012 BRIP1 SNV 1 Truncal 
 CDKN2A SNV 1 Truncal 
 CIC SNV 1 Branch 
 KDM6A SNV 1 Branch 
 TP53 SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 CARS SNV 2 Truncal 
 NFE2L2 SNV 2 Truncal 
 RASA1 SNV 2 Branch 
 FANCA SNV 3 Branch 
 FAT1 SNV 3 Branch 
 MLLT4 SNV 3 Branch 
 TLX1 SNV 3 Branch 
L013 EGFR SNV 1 Truncal 
 EGFR SNV 1 Truncal 
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 MSH2 SNV 1 Branch 
 MLL3 SNV 2 Branch 
 MTOR SNV 2 Branch 
 PLCG2 SNV 2 Branch 
 TP53 SNV 2 Truncal 
 DNAH12 SNV 3 Truncal 
 JAK2 SNV 3 Branch 
 KIT SNV 3 Truncal 
 MED12 SNV 3 Truncal 
 SMO SNV 3 Truncal 
L015 KDM6A SNV 1 Truncal 
 KMT2D SNV 1 Branch 
 TP53 SNV 1 Truncal 
 ETV6 SNV 2 Truncal 
 ALK SNV 3 Truncal 
 GOLGA5 SNV 3 Truncal 
 ROS1 SNV 3 Truncal 
 TFRC SNV 3 Truncal 
L016 BRCA1 SNV 1 Branch 
 TP53 SNV 1 Truncal 
 GAS7 SNV 2 Truncal 
 NOTCH1 SNV 2 Truncal 
 FLT3 SNV 3 Truncal 
L017 ARID1A SNV 1 Truncal 
 ATRX SNV 1 Truncal 
 ATRX SNV 1 Truncal 
 ATRX SNV 1 Truncal 
 ATRX SNV 1 Truncal 
 BCOR SNV 1 Branch 
 FBXW7 SNV 1 Truncal 
 KRAS SNV 1 Truncal 
 NF1 SNV 1 Truncal 
 PMS1 SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 WT1 SNV 1 Truncal 
 ALK SNV 2 Truncal 
 ALK SNV 2 Truncal 
 AMER1 SNV 2 Truncal 
 AMER1 SNV 2 Truncal 
 ATP2B3 SNV 2 Truncal 
 BRCA2 SNV 2 Truncal 
 CCND1 SNV 2 Truncal 
 CHD4 SNV 2 Truncal 
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 ETV5 SNV 2 Truncal 
 FOXP1 SNV 2 Truncal 
 GNPTAB SNV 2 Truncal 
 GPC3 SNV 2 Truncal 
 KEAP1 SNV 2 Truncal 
 MGA SNV 2 Truncal 
 NCOA1 SNV 2 Truncal 
 NF1 SNV 2 Truncal 
 POLE SNV 2 Truncal 
 RBM10 SNV 2 Truncal 
 STAG2 SNV 2 Truncal 
 ASPSCR1 SNV 3 Truncal 
 ATP2B3 SNV 3 Truncal 
 BRAF SNV 3 Truncal 
 BRD4 SNV 3 Truncal 
 CDC73 SNV 3 Truncal 
 CNKSR1 SNV 3 Truncal 
 FAT1 SNV 3 Truncal 
 FGFR1OP SNV 3 Truncal 
 HIST1H3B SNV 3 Branch 
 HOOK3 SNV 3 Truncal 
 HOXD13 SNV 3 Branch 
 KDM5A SNV 3 Truncal 
 MTOR SNV 3 Truncal 
 NOTCH1 SNV 3 Truncal 
 NTRK1 SNV 3 Truncal 
 PAX8 SNV 3 Branch 
 PRDM16 SNV 3 Truncal 
 RANBP17 SNV 3 Branch 
 TPR SNV 3 Branch 
 TRAF7 SNV 3 Truncal 
 TRIP11 SNV 3 Branch 
 WAS SNV 3 Truncal 
 WWTR1 SNV 3 Truncal 
 ZRSR2 SNV 3 Truncal 
L019 EML4-ALK Translocation 1 Truncal 
 AKAP9 SNV 3 Truncal 
 MYCN SNV 3 Branch 
 POU2AF1 SNV 3 Branch 
L022 STAG2 SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 WT1 SNV 1 Truncal 
 FAT1 SNV 2 Truncal 
 MGA SNV 2 Truncal 
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 SETBP1 SNV 2 Truncal 
 ABL2 SNV 3 Branch 
 CALR SNV 3 Branch 
 CNBD1 SNV 3 Truncal 
 JAK1 SNV 3 Truncal 
L023 CASP8 SNV 1 Branch 
 FANCA SNV 1 Branch 
 KRAS SNV 1 Truncal 
 WT1 SNV 1 Truncal 
 GOLGA5 SNV 2 Truncal 
 PIK3CA SNV 2 Truncal 
 ARID1A SNV 3 Branch 
 CCNB1IP1 SNV 3 Branch 
 GMPS SNV 3 Branch 
 GNAS SNV 3 Branch 
 HLF SNV 3 Truncal 
 HNRNPA2B1 SNV 3 Branch 
 MAP2K1 SNV 3 Branch 
 PIM1 SNV 3 Branch 
 SETBP1 SNV 3 Branch 
 SMO SNV 3 Truncal 
 TET2 SNV 3 Branch 
L029 KRAS SNV 1 Truncal 
 MSH6 SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 AMER1 SNV 2 Truncal 
 CHD8 SNV 2 Truncal 
 KIT SNV 2 Truncal 
 PICALM SNV 2 Truncal 
L030 EGFR Indel 1 Truncal 
 ATM Indel 2 Truncal 
LTX001 ATM SNV 1 Truncal 
 ATM SNV 1 Truncal 
 CIC SNV 1 Branch 
 KRAS SNV 1 Truncal 
 EGFR SNV 2 Truncal 
 HERPUD1 SNV 2 Branch 
 MBD1 SNV 2 Truncal 
 MGA SNV 2 Branch 
 EBF1 SNV 3 Truncal 
 ELF4 SNV 3 Truncal 
 JAK2 SNV 3 Branch 
 PDE4DIP SNV 3 Branch 
 RANBP17 SNV 3 Truncal 
Chapter 8 Appendix 
 209 
 SUZ12 SNV 3 Branch 
 SYK SNV 3 Truncal 
 TPR SNV 3 Truncal 
LTX012 CDKN2A Indel 1 Truncal 
 NRAS SNV 1 Truncal 
 BCL11B SNV 2 Truncal 
 DDX3X SNV 2 Truncal 
 EBF1 SNV 2 Truncal 
 KDR SNV 2 Truncal 
 MTOR SNV 2 Truncal 
 MTOR SNV 2 Truncal 
 PAX5 SNV 2 Truncal 
 PLCG2 SNV 2 Truncal 
 SOCS1 SNV 2 Truncal 
 CDH11 SNV 3 Truncal 
 GAS7 SNV 3 Truncal 
 NSD1 SNV 3 Truncal 
 PIK3R1 Indel 3 Truncal 
 PRDM16 SNV 3 Truncal 
 PTPRC SNV 3 Truncal 
 SLC45A3 SNV 3 Truncal 
 SRGAP3 SNV 3 Branch 
LTX015 ATM SNV 1 Branch 
 TP53 SNV 1 Truncal 
 ZRSR2 SNV 1 Truncal 
 SEPT12 SNV 2 Truncal 
 EIF4A2 SNV 2 Truncal 
 PIK3CA SNV 2 Truncal 
 RB1 SNV 2 Branch 
 RPS2 SNV 2 Truncal 
 SERPINB13 SNV 2 Truncal 
 CD274 SNV 3 Branch 
 CLTCL1 SNV 3 Branch 
 CREB3L1 SNV 3 Truncal 
 CSF3R SNV 3 Truncal 
 HOOK3 SNV 3 Branch 
 IRF4 SNV 3 Truncal 
 KMT2D SNV 3 Truncal 
 MGA SNV 3 Truncal 
 MPL SNV 3 Branch 
 NUP214 SNV 3 Truncal 
 ODAM SNV 3 Branch 
LTX016 PIK3CA SNV 1 Truncal 
 ATM SNV 3 Branch 
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 MED12 SNV 3 Branch 
 MYH9 SNV 3 Branch 
 PIK3CA SNV 3 Branch 
 PRF1 SNV 3 Branch 
LTX019 CDKN2A Indel 1 Truncal 
 CDKN2A SNV 1 Truncal 
 CYLD SNV 1 Truncal 
 DAXX SNV 1 Branch 
 EP300 SNV 1 Branch 
 FBXW7 SNV 1 Branch 
 MSH2 SNV 1 Truncal 
 NF1 SNV 1 Branch 
 PIK3CA SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 EZH1 SNV 2 Truncal 
 GNPTAB SNV 2 Branch 
 HOOK3 SNV 2 Truncal 
 CDKN2A SNV 3 Truncal 
 EGFR SNV 3 Branch 
LTX022 CYLD SNV 1 Branch 
 FANCC SNV 1 Branch 
 TP53 SNV 1 Truncal 
 BCLAF1 SNV 2 Truncal 
 BCLAF1 SNV 2 Truncal 
 CNBD1 SNV 2 Truncal 
 ERCC4 SNV 2 Branch 
 FAT1 SNV 2 Truncal 
 MBD1 SNV 2 Truncal 
 MBD1 SNV 2 Truncal 
 NSD1 SNV 2 Branch 
 ZNF521 SNV 2 Truncal 
 CREBBP SNV 3 Truncal 
 DDX10 SNV 3 Branch 
 GNA11 SNV 3 Truncal 
 LCK SNV 3 Truncal 
 NOTCH1 SNV 3 Truncal 
 SETBP1 SNV 3 Truncal 
LTX028 TP53 Indel 1 Truncal 
 CIITA SNV 2 Truncal 
 IL21R SNV 2 Truncal 
 MLLT10 SNV 2 Truncal 
 MLLT10 SNV 2 Truncal 
 PIK3CA SNV 2 Truncal 
 ROS1 SNV 2 Truncal 
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 TRIP11 SNV 2 Truncal 
 ZNF521 SNV 2 Truncal 
 ACSL3 SNV 3 Truncal 
 ETV1 SNV 3 Truncal 
 HIST1H3B SNV 3 Branch 
 MUC1 SNV 3 Truncal 
 TAL1 SNV 3 Truncal 
LTX029 APC Indel 1 Truncal 
 PIK3CA SNV 1 Branch 
 TP53 SNV 1 Truncal 
 ERBB2 SNV 2 Truncal 
LTX030 CBLB SNV 1 Truncal 
 PIK3CA SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 RASA1 SNV 2 Truncal 
 SMAD4 SNV 2 Truncal 
 TRIM33 SNV 2 Truncal 
 TCF3 SNV 3 Branch 
LTX031 CDKN2A SNV 1 Truncal 
 SMARCA4 SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 KTN1 SNV 2 Truncal 
 MTOR SNV 2 Truncal 
 NTRK1 SNV 2 Truncal 
 FAT1 SNV 3 Truncal 
 GNAS SNV 3 Truncal 
 MLLT10 SNV 3 Truncal 
 MYB SNV 3 Truncal 
 TOP1 SNV 3 Truncal 
LTX033 TP53 SNV 1 Truncal 
 ERBB3 SNV 2 Truncal 
 KEAP1 SNV 2 Truncal 
 WAS SNV 2 Branch 
 ASXL1 SNV 3 Truncal 
 BRIP1 SNV 3 Truncal 
 HOXD11 SNV 3 Truncal 
 MTOR SNV 3 Truncal 
 NSD1 SNV 3 Truncal 
 ZNF521 SNV 3 Truncal 
LTX034 BAP1 SNV 1 Truncal 
 RB1 SNV 1 Branch 
 TP53 SNV 1 Branch 
 EZH2 SNV 2 Truncal 
 MED12 SNV 3 Truncal 
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LTX036 ATM SNV 1 Branch 
 STK11 SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 MYC SNV 2 Branch 
 PAX7 SNV 2 Branch 
 POLE SNV 2 Truncal 
 ZNF521 SNV 2 Truncal 
 ATP2B3 SNV 3 Branch 
 BCL2 SNV 3 Branch 
 FLI1 SNV 3 Branch 
 IL7R SNV 3 Truncal 
 JAK3 SNV 3 Truncal 
 MAP3K1 SNV 3 Branch 
 MYH9 Indel 3 Branch 
 RALGDS SNV 3 Branch 
 USP6 SNV 3 Truncal 
LTX038 ARID1A SNV 1 Branch 
 CDKN2A SNV 1 Truncal 
 MLH1 SNV 1 Branch 
 NFE2L2 SNV 1 Truncal 
 NIN SNV 1 Truncal 
 PIK3CA SNV 1 Branch 
 TP53 SNV 1 Truncal 
 SEPT12 SNV 2 Branch 
 ATRX SNV 2 Branch 
 CCND1 SNV 2 Branch 
 FAM166A SNV 2 Branch 
 JAK1 SNV 2 Branch 
 KDM5A SNV 2 Branch 
 KDR SNV 2 Branch 
 NOTCH1 SNV 2 Branch 
 NUP214 SNV 2 Truncal 
 PTPRC SNV 2 Branch 
 SMC3 SNV 2 Branch 
 STX2 SNV 2 Branch 
 ACVR1B SNV 3 Branch 
 ARHGEF12 SNV 3 Branch 
 CACNA1D SNV 3 Truncal 
 CHD8 SNV 3 Truncal 
 CRTC3 SNV 3 Branch 
 FANCF SNV 3 Branch 
 FAT1 SNV 3 Branch 
 GNAS SNV 3 Truncal 
 KCNJ5 SNV 3 Truncal 
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 KIAA1549 SNV 3 Branch 
 MSN SNV 3 Branch 
 NCOA1 SNV 3 Branch 
 RBM10 SNV 3 Truncal 
LTX051 EGFR SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 EGFR SNV 2 Truncal 
 INTS12 Indel 2 Truncal 
 NSD1 SNV 2 Truncal 
 SERPINB13 SNV 2 Branch 
LTX058 AMER1 SNV 1 Branch 
 KRAS SNV 1 Truncal 
 TP53 SNV 1 Truncal 
 BCLAF1 SNV 2 Branch 
 FAT1 SNV 2 Truncal 
 LIFR SNV 2 Branch 
 MYH11 SNV 2 Truncal 
 NTRK3 SNV 2 Truncal 
 PAX5 SNV 2 Truncal 
 ARHGEF12 SNV 3 Branch 
 FCGR2B SNV 3 Branch 
 JAK2 SNV 3 Branch 
 MN1 SNV 3 Truncal 
 NFKB2 SNV 3 Branch 
 ROS1 SNV 3 Truncal 
 TRIP11 SNV 3 Truncal 
Table 30 Driver category 1 to 3 mutations in the NSCLC pilot and TRACERx 
cohorts 
 
Predicted category 1 to 3 driver mutations identified in each tumour for the NSCLC and 
TRACERx cohorts. The gene name, type of variant (SNV or indel), and whether the mutation is 
truncal or branch is shown.  
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8.5 Appendix 5: Number of regions sequenced and sequencing 
depth in the lung adenocarcinoma in situ lesions 
Table 31 shows the number of regions sequenced, and the mean and median 
sequencing depth for WES for each sample from the adenocarcinoma in situ lesions.  
Patient Region Mean depth of WES Median depth of WES 
LTX013 
GL 363.5 331 
R1 387.3 351 
R2 386.6 348 
R3 369.6 348 
LTX021 
GL 534 483 
R1 444.7 402 
R2 515.3 452 
R3 482.5 438 
R4 441.2 396 
LTX041 
GL 339.6 308 
R2 328 295 
R3 451.4 403 
R4 564.9 500 
LTX049 
GL 441.5 406 
R1 342.8 309 
R2 480.3 423 
LTX055 
GL 547.5 500 
R1 573.7 500 
R2 381.1 341 
R3 370 331 
Table 31 Number of regions sequence and sequencing depth 
Number of regions sequenced, mean and median depth of WES for each tumour region in the 
AIS tumours. 
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